

AUTHOR INDEX

VOLUME 36

Abou-Shala, Nabil, 1553
 Abruzzo, G., 1648
 Ackerman, Bruce H., 1766
 Aerts, Frans, 417
 Afrime, M. B., 1832
 Agger, William A., 1788
 Agrawal, Krishna C., 2370
 Akaniro, Joseph C., 255
 Alahuusua, S., 1241
 Albritton, William L., 467
 Alcantara, Joel, 2054
 Aldridge, Kenneth E., 851, 854
 Al-Hokail, Abdullah A., 172
 Al Khayat, R., 1519
 Allaman, Jane A., 2037
 Allard, Sylvie, 2085
 Allegra, Carmen, 1935
 Allen, Lois B., 206
 Allendoerfer, R., 217
 Almadany, Rady, 997
 Al-Obeid, S., 77
 Alós, J. I., 1794
 Alpert, Gershon, 2275
 Alpert, Nathaniel M., 2286
 Al-Sibai, M. Badawi, 150
 Amicosante, Gianfranco, 1068
 Amor, E., 1794
 Ancelin, Marie L., 50
 Anders, E.-M., 942
 Anderson, B. D., 2156
 Anderson, J., 1964
 Anderson, M. D., 2552
 Anderson, R., 1236
 Anderson, Ronald, 2729
 Andrade, A. B., 277
 Andremont, A., 2009
 Andremont, Antoine, 502
 Andrews, J., 2360
 Andrews, J. M., 1002, 1928, 2444
 Andries, K., 100
 Andries, Koen, 417, 727
 Andriole, Vincent T., 2681
 Andry, G., 2014
 Angehrn, Peter, 2825
 Antonacci, Barry, 64, 498
 Antony, Kelly K., 115
 Anwar, Hosmin, 890, 1208, 1347
 Aoki, Hiroyuki, 2270
 Aoun, M., 2014
 Aoyama, Hiroshi, 2108
 Appelbaum, Peter C., 856, 1140
 Arai, Sumio, 1322
 Arakawa, Soichi, 188
 Arakawa, Yoshichika, 1460
 Araki, Kimi, 2042
 Araki, Ryouko, 1198
 Araujo, Fausto G., 326, 2454
 Arguedas, Adriano G., 255
 Arika, Tadashi, 2523
 Arima, Yasushi, 2589
 Armstrong, Donald, 808
 Arnett, Gussie, 206
 Arnow, Paul M., 2125
 Arrowood, Michael J., 220
 Arruda, Eurico, 1186
 Artal, A., 2816
 Arthur, Michel, 867, 1514
 Arvin, Ann M., 1991
 Ashida, Noriyuki, 214
 Ashton, Wallace T., 2020
 Asikainen, S., 1241
 Asin, Henk R. G., 1456
 Asselbergs, Fred A. M., 1782
 Atkins, Loretta T., 2346
 Au, Jessie L.-S., 665
 Aubier, M., 2099
 Auge, Annie, 2804
 Auger, François, 2085
 Authors, No, 1584
 Averett, Devon R., 2686
 Aweeka, Francesca T., 1773
 Awni, W. M., 1832
 Ayoub, Rihab, 1404
 Azoulay-Dupuis, Esther, 1412, 2698
 Baba, Masanori, 214, 435, 1432
 Babbar, Sunita, 299
 Babich, John, 2286
 Bacchi, Cyrus J., 2736
 Bäckstrand, B., 2766
 Bacon, Teresa H., 2747
 Bailey, Elaine M., 1109, 1192, 1204, 2709, 2741
 Bains, M., 1057
 Bains, Manjeet, 2566
 Baker, Carolyn N., 717
 Baldwin, D. R., 1171, 1176
 Balkovec, J., 1648, 1964
 Ballesta, Juan P. G., 639
 Balzarini, Jan, 1073
 Bancal, C., 2099
 Bannam, Trudi L., 2548
 Baquero, F., 662
 Baquero, Fernando, 639, 2536
 Baranowski, John, 2778
 Barbhaiya, R. H., 938, 962
 Barbhaiya, Rashmi H., 552, 687, 1181, 1382, 1387, 2075
 Barc, M. C., 1332
 Barclay, M. L., 1951
 Bar-David, Yair, 287
 Bards, Thomas J., 108
 Baron, Denis, 744
 Barón, M. González, 2816
 Barrett, J. F., 860
 Barrett, M. S., 2049
 Barriere, Steven L., 453, 2233
 Barry, A. L., 137
 Barth, Robert H., 1424
 Bartizal, K., 1648
 Bartlett, M. S., 779
 Barrett, M. S., 2049
 Barriere, Steven L., 453, 2233
 Barry, A. L., 137
 Barth, Robert H., 1424
 Bastian, Tracey L., 1553
 Bate, B. Jane, 2037
 Batteiger, Byron E., 1144
 Bauchet, Jacqueline, 470, 2698
 Bayer, Arnold S., 1665, 1864
 Bazile, S., 2622
 Beach, J. Warren, 672
 Beam, Thomas R., Jr., 2639
 Beauchamp, D., 1504, 2147
 Beauchamp, Denis, 2204
 Bebear, Christiane, 870
 Beckman, Barbara S., 2370
 Bedos, Jean Pierre, 2698
 Begg, E. J., 1951
 Behre, Gerhard, 2139
 Bell, Angus, 2566
 Bellido, F., 1057
 Benedetti, Margherita Strolin, 1958
 Ben-Nathan, David, 2275
 Bennett, P., 1447
 Bennett, W. M., 2556
 Bentorcha, Fairouze, 59
 Berger, Bradley J., 1825
 Berger-Bächi, Brigitte, 25, 566, 1367, 2617
 Bergeron, M. G., 1504
 Bergeron, Michel G., 2204, 2211
 Bergman, L., 2766
 Bergogne-Berezin, E., 2099
 Bergogne-Bérezin, Eugenia, 1412
 Bergogne-Berezin, Eugenie, 669
 Berman, J. D., 1978
 Bernard, Alfred, 1525
 Bernareggi, Alberto, 1744
 Berrocal, A., 2816
 Berry, Alison J., 690
 Berry, Valerie, 1427
 Bertasso, A., 1601, 1779
 Berti, Marisa, 446
 Bertino, Joseph S., Jr., 679
 Bessalle, Roberto, 313
 Bhagavathula, Purushothama R., 2487
 Bhuripanyo, Kiertichai, 158
 Biavasco, Francesca, 331
 Biele, Jon, 2039
 Billot-Klein, D., 77, 1487
 Binczewski, Brian, 1392
 Biollaz, Jérôme, 1013
 Bisson, Chantal, 2085
 Biswas, Anita N., 92
 Bitonti, Alan J., 2736
 Black, Henry R., 318
 Blacky, Albert R., 2542
 Blanco, Javier, 898
 Blanco, María Teresa, 898
 Blanchard, Christine, 1821
 Blaschke, Terrence F., 1230
 Blaszczak, Larry C., 533
 Blouin, Robert A., 632
 Blumenkopf, Todd A., 934
 Blumenthal, Robert M., 2118
 Bodey, Gerald P., 879
 Bodily, Howard L., 2398
 Boehme, Richard E., 1688
 Boissel, P., 2331
 Bolard, Jacques, 262, 1799, 2518
 Bolger, Michael, 1062
 Bologne, D. P., 982
 Bonnet, M., 1302
 Bonnez, William, 2245
 Boobis, Alan, 1958
 Boonma, Paithoon, 158
 Borcherding, Shawn M., 1553
 Borghi, Angelo, 1744
 Borgonovi, Monica, 446, 1744
 Borin, Marie T., 126
 Borner, Klaus, 144, 796
 Borotz, Susan E., 1091
 Borsa Lebas, F., 1519, 2794
 Boslego, J. W., 1682
 Böttiger, D., 1770, 2418
 Boudinot, F. Douglas, 2432
 Bourgault, Anne-Marie, 343
 Bourlioux, P., 1332
 Bourne, Nigel, 2020
 Bourneix, C., 2009
 Bouting, Anne, 2462
 Bouvet, Anne, 2216
 Bouzard, D., 2622
 Bowler, William A., 2542
 Boyce, John M., 1032
 Boyer, Kenneth, 1040
 Bozza, Mary A., 1151
 Brackman, Marcia A., 115
 Bradford, Patricia A., 394
 Bradley, Suzanne F., 2533
 Branch, R. A., 2670
 Brandimarte, Camillo, 723
 Branger, T., 801
 Branger, Tine, 1456
 Bratoeva, Momka, 2346
 Bravo, Fernando J., 2020
 Bresler, L., 2331
 Bressolle, Françoise, 1404
 Brewer, Thomas G., 1825
 Brier, Gordon L., 318
 Brismar, B., 1997, 2766
 Brivio, Luca, 1499
 Brochu, A., 1504, 2166
 Brochu, N., 2166
 Brodaty, O., 2539
 Brouqui, Philippe, 2799
 Brown, Barbara A., 180, 1987
 Brown, James F., 68
 Brown, Wallace D., 1614
 Brown, William J., 1635
 Bruguerolle, Bernard, 1115
 Brummer, Elmer, 2487
 Brune, K. H., 2670
 Brun-Pascaud, Monique, 470, 2328
 Bryan, Charles S., 2639
 Bryan, Joe P., 949
 Bryskier, A., 1756
 Bugelski, P. J., 982
 Bugg, Timothy D. H., 867
 Bugnon, Denis, 744
 Bunnell, S. T., 2447
 Bure, Anne, 1883
 Burger, Roger, 473
 Burke, Amy, 2392
 Burman, Lars G., 989
 Burnett, D., 1545
 Burnham, Jeffrey C., 2118
 Burns, Jane L., 2280
 Burtin, P., 2493
 Bush, Karen, 1155, 1991
 Byers, Carol, 545
 Caccamo, Francesco, 1567
 Cacciapuoti, Anthony, 64, 498
 Caillou, Jocelyne, 744
 Calandra, Thierry, 1256
 Callahan, Ronald J., 2286
 Callister, Steven M., 1788
 Camarasa, Marià-José, 1073
 Cameron, Janet M., 202, 733, 1688

Cammack, Nicholas, 202
 Cammack, Nick, 733
 Campbell, D. A., 938
 Campbell, I., 1619
 Campos, José, 1028
 Candiani, Giampaolo, 446
 Cannon, Deborah, 672, 2423
 Cantón, E., 558
 Canton, Rafael, 2536
 Carbon, Claude, 262, 833, 907, 1883, 2069, 2216, 2403, 2462, 2611, 2722
 Cardoso, Marisa, 580
 Carlier, Cecile, 463
 Caroff, Bruno, 2852
 Caron, François, 2611
 Carpenter, Pierre, 378
 Carper, Holliday T., 39, 408, 2584
 Carroll, M. L., 1971
 Cars, Otto, 1852
 Carson, Dennis A., 2025
 Catchpole, Christopher R., 1928
 Catherall, Elaine J., 458
 Cauwenbergh, Geert F. M. J., 2661
 Cavalieri, Stephen J., 2039
 Cavanaugh, J., 1147
 Cavenaghi, Luigi, 446, 1744
 Caya, Martine, 2093
 Cercenado, E., 2201, 2526
 Chachaty, E., 2009
 Chacón, I., 2816
 Chambers, Henry F., 656
 Chambers, S. T., 1951
 Chams, Vida, 267
 Chan, C. Y., 2057
 Chanal, Catherine, 1817
 Chance, Michael L., 2228
 Chandy, M., 2468
 Chang, Frank N., 2645
 Chantot, J. F., 1756
 Chantrain, G., 2014
 Chapman, Stanley W., 977
 Chapman, Trevor, 1909
 Chapman, W. L., 1978
 Chappel, Larry R., 2080
 Chartrand, Stephen, 1614
 Chatis, Pamela A., 1589
 Chatterjee, Anadi N., 788
 Chatton, Jean-Yves, 1013
 Chau, Françoise, 997, 2852
 Chaudhuri, Keya, 788
 Chauveau, P., 1519
 Chauvin, Jean Pierre, 833
 Chavalitshewinkoon, Porntip, 1644
 Chave, Jean-Philippe, 1013
 Chen, Karen, 1208
 Chen, Thomas J. H., 603
 Cheng, A. F. B., 2057
 Chi, S.-C., 2156
 Chiang, Jamie, 1472
 Chin, Nai-Xun, 1310, 1336, 1418, 1699
 Choi, Woo-Baeg, 672, 2423
 Chong, Yunsop, 195
 Chopra, Ian, 876, 913, 1068
 Chou, Ting-Chao, 808, 1472, 1559
 Christensson, B. A., 1532
 Christensson, Bengt A., 2512
 Christian, Sylvie, 2310
 Chu, Chung K., 672
 Chu, Daniel T. W., 81
 Chu, S.-Y., 1147, 2447
 Chu, Sou-yie, 2478
 Citron, Diane M., 1158
 Clairoux, N., 1504
 Clark, Dana K., 2280
 Clark, Julie C., 2037
 Clark, Rebecca A., 647
 Clarke, Alison M., 2197
 Cleare, W. J., 607
 Cleary, John D., 977
 Cleeland, Roy, 2286
 Clemons, Karl V., 2656
 Clendennen, T. E., 1682
 Clendennen, T. E., III, 277
 Clermont, Dominique, 59
 Clewell, Don B., 769
 Clink, Hugh M., 172
 Clumeck, Nathan, 2661
 Cluzel, Roger, 1817
 Coates, Jonathan A. V., 202, 733
 Coene, Marie-Claire, 2602
 Cogollos, R., 1794
 Cohen, B. Eleazar, 2518
 Cohen, Guy M., 1296
 Cohen, Yves, 2104, 2408
 Cole, P. J., 1236
 Coleman, Robert W., 1230
 Collatz, E., 77, 1487
 Collette, F., 1756
 Collignon, A., 1332
 Colonno, Richard J., 1441
 Comstock, R. Dawn, 1695
 Condra, Jon H., 1441
 Condreay, Lynn, 2686
 Connolly, Kevin J., 245, 509
 Connor, James D., 886
 Conti, Cinzia, 95
 Cooley, Timothy P., 1280
 Cooper, M. A., 2444
 Corkill, John E., 1870
 Cornaglia, Giuseppe, 1902
 Cornelissen, J. J., 801
 Correia, John A., 2286
 Cortier, G., 1332, 2009
 Costerton, J. William, 890, 1208, 1347, 2054
 Coudron, Philip E., 1125
 Courtie, A. L., 1677
 Courval, Jeanne M., 2392
 Curvalin, Patrice, 463, 502, 867, 1514, 2005
 Craft, J. Carl, 2478
 Craig, William A., 2577
 Cremieux, Anne-Claude, 2069, 2216, 2403, 2611
 Crist, Arthur E., Jr., 1635
 Crokaert, F., 46
 Crongvist, J., 2676
 Crooke, Rosanne M., 527
 Cross, J. H., 611
 Crump, Carolyn E., 1186
 Crumpacker, Clyde S., 1589
 Cuchural, George J., Jr., 540
 Cuencu, Rafaela, 198
 Cummings, Marinella, 1131
 Cundliffe, Eric, 348
 Cynamon, M. H., 1611, 2413
 Czuprynski, Charles J., 68
 Dagan, Ron, 287
 Daifuku, Richard, 2349
 Dalton, M. T., 343
 Dan, M., 677
 Daneau, D., 2014
 Daneels, Guy, 417
 Danenberg, Haim D., 2275
 Darden, Paul, 1614
 Dargis, M., 2147
 Darlison, Sarah J., 2747
 Das, Jyotirmoy, 788
 Daviau, Nathalie, 2085
 Davidson, Ross J., 1136
 de Cespédes, Gilda, 59
 De Clercq, Erik, 435, 1073, 2628
 de Graaff, J., 2634
 de Graeff, A., 801
 DeJoy, S. Q., 1971
 Dekker, A. W., 801
 De Kruif, A., 1606, 1859
 Delabre, I., 191
 de la Coussaye,
 Jean-Emmanuel, 1404
 de Lalla, Fausto, 1567, 2192
 De Leenheer, A. P., 1606, 1859
 de Lentdecker, P., 2539
 Del Valle, Robert, 2497
 De Micco, Philippe, 1115
 Denaro, Maurizio, 446
 Denny, William, 1644
 de Paredes, M. L. García, 2816
 Depitre, C., 1332, 2009
 Depperman, Karl M., 796
 Deraemaeker, R., 2014
 De Raeymaeker, Marc, 417
 Deringer, James R., 626
 De Rosas, Victoria, 180
 Derouin, Francis, 997, 2852
 Deshusses, Jacques, 2506
 Desideri, Nicoletta, 95
 Deslandes, Antoine, 2462
 Desmyter, Jan, 2628
 DeStefano, M. S., 2413
 DeVincenzo, Nicholas, 1424
 Devine, Catherine, 2216, 2403
 Dewindt, B., 100
 De Wit, Stéphane, 2661
 Dillon, William I., 2533
 Dittrich, W., 1119
 Dixon, Russell M., 2075
 Dohin, Elisabeth, 1821
 Doi, Ryuichiro, 1483
 Dolence, E. K., 2166
 Dolence, E. Kurt, 840
 Dolin, Raphael, 1280
 Dombret, M. C., 2099
 Dopff, C., 2331, 2493
 Dor, P., 2014
 Dornson, Ronna E., 2686
 Doucet-Populaire, Florence, 502
 Downey, P., 1447
 Drapeau, Chantal, 2085
 Drapeau, Guy, 955
 Drehabl, Margaret A., 1614
 Dreyer, G. B., 982
 Drugeon, Henri, 744
 Drusano, George L., 1280
 Dubin, Donald T., 153
 Dubois, C., 2539
 Dukes, George M., 1387
 Dulworth, Jacqueline K., 115
 Dupont, Bertrand, 1805
 DuPont, Herbert L., 87, 2821
 DuPont, Margaret W., 87
 Dureux, J. B., 2331, 2493
 Durkin, M. M., 779
 Dutka-Malen, Sylvie, 2005
 Duval, Jean, 2005
 Duverne, Chantal, 2462
 Dux-Guyot, Anne, 470
 Düzgüneş, Nejat, 2808
 Earnshaw, David L., 2747
 Ebert, Steven C., 2577
 Echeverria, P., 1682
 Echols, Roger M., 993
 Edelstein, Martha A. C., 2387, 2559
 Edelstein, Paul H., 2387, 2559
 Edlind, T. D., 779
 Edmonds, Kay, 2747
 Edwards, John E., Jr., 2239
 Edwards, Richard, 223
 Efthymiopoulos, Constantin, 1958
 Eibl, Hansjörg, 1630
 Eklund, A. E., 2766
 Elabbadi, Noureddine, 50
 Eledjam, Jean-Jacques, 1404
 Eliopoulos, G. M., 2201, 2526
 Eliopoulos, George M., 121, 1329, 1864
 Ellerstad, George, 913
 Ellis, M. Nixon, 934
 Ellis, Michael E., 172
 El-Shaker, Mohammed M., 150
 Emini, Emilio A., 1019, 1441
 Engel, Joanne N., 2304
 Entenza, José M., 1256
 Erickson, John, 926
 Erickson, S., 2253
 Ericsson, Charles D., 87, 2821
 Erkkola, Risto, 2652
 Ernst, Peter, 172
 Eron, Joseph J., Jr., 1559
 Erwin, M. E., 2049
 Erwin, Meridith E., 233
 Espinol-Ingroff, Ana, 1805
 Espinosa, E., 2816
 Espinosa, G. E., 277
 Essink, Monika, 2139
 Essiz, M., 2622
 Etienne, I., 2794
 Etter, Laura, 1392
 Etzel, Joseph V., 679
 Eudy, Elizabeth B., 1766
 Ewalenko, P., 2014
 Fabre, David, 1404
 Facklam, Richard, 2176
 Fang, Wei, 1310, 1336, 1418
 Fantini, Bruno, 907
 Farber, Bruce, 2639
 Farinotti, R., 2539
 Farinotti, Robert, 2462
 Fasching, Claudine E., 1166

Fattorini, Lanfranco, 1068
 Fay, Michel, 470
 Feistauer, S. M., 505
 Feliu, J., 2816
 Fennell, Cynthia L., 712
 Fernández, M. Carmen, 639
 Fernandez-Rodriguez,
 Amparo, 2536
 Ferrari, Pietro, 1744
 Ferrieri, Patricia, 1215
 Fielding, Robert M., 299
 Figgitt, David, 1644
 Figueiredo, Agnes M. S., 886
 Figueiredo, Hermia T., 1688
 File, Thomas M., 1400
 Fillastre, J. P., 1519, 2794
 Filler, Scott G., 2239
 Finegold, Sydney M., 239,
 1658
 Fischler, M., 2539
 Fischman, Alan J., 2286
 Fitzgerald, Thomas J., 598
 Fitzgibbon, Joseph E., 153
 Flaherty, John P., 2125
 Flasher, Diana, 2808
 Fleck, R. Peter, 2542
 Flor, Soledad, 308
 Foleno, Barbara, 860
 Fontana, Roberta, 1902
 Forgue, S. Thomas, 552
 Foss, Robert, 1040
 Fostel, Jennifer, 2778
 Fostel, Jennifer M., 2131
 Foster, Thomas S., 632
 Foulds, George, 603
 Foy, Jilanna, 1935, 1943
 Fraimow, Henry S., 1563
 Frame, George M., 2080
 Franceschini, Nicola, 1068
 Francia, M. Victoria, 1049
 Francoual, S., 77
 Frank, Michael O., 2584
 Franklin, Anders, 2704
 Franzblau, Scott G., 92
 French, G. L., 2057
 Frick, Lloyd W., 2686
 Fridkin, Mati, 313
 Friedland, Ian R., 1596
 Friend, Daniel S., 2808
 Frosolono, Mira, 230
 Frost, R. Wayne, 830
 Frostegard, Cecilia, 1821
 Fu, K. P., 860
 Fu, Yue, 2239
 Fuchs, N., 2316, 2322
 Fuchs, P. C., 137
 Fuhr, U., 942
 Fujii, Akira, 188
 Fujii, K., 387
 Fujii, Noboru, 2589
 Fujii, Nobutaka, 1249
 Fukasawa, Masatomo, 1577
 Fukuda, Hideyuki, 2108, 2562
 Funk, Evelyn, 1596
 Furet, Yves Xavier, 894, 2506
 Furmaga, Kevin, 2125
 Furman, Phillip A., 2423, 2686
 Furtado, Gary, 1032
 Furukawa, Yasuo, 481
 Furuya, Nobuhiko, 1198, 1922
 Fyfe, James A., 2686
 Gallegos, Jesse, 603
 Galtier, Marc, 1404
 Gambertoglio, John G., 1773
 Gan, Vanthaya N., 2478
 Garcia, Isabel, 1053
 Gatenbeck, L., 2766
 Gaydos, Charlotte A., 291
 Gazzard, Brian G., 1821
 Gelber, R. H., 2544
 Gelfusa, Vincenzo, 723
 Genovese, Domenico, 95
 George, David, 2125, 2681
 George, William J., 647
 Georgopapadakou, N. H.,
 1601, 1779
 Georgopoulos, A., 505
 Georgopoulos, M., 505
 Gerding, Dale N., 2639
 Gerena, Lucia, 1538, 2761
 Gerlach, E. H., 137
 Ghannoum, Mahmoud A.,
 2239
 Gilbert, Brian E., 1466
 Gilbert, D. N., 2556
 Gilbert, Huguette, 343
 Gilbert, John, 473
 Gill, Maura, 540
 Gilliom, Mercedes, 1062
 Gillon, Valerie, 458
 Gilmore, Michael S., 902
 Ginsburg, Hagai, 1102
 Girard, Dennis, 1671
 Girard, Pierre-Marie, 2328
 Giwercman, B., 71
 Glatt, Aaron E., 1131
 Glauzer, Michel P., 1013, 1256
 Glazer, Edward A., 368, 2080
 Gleason, Carol R., 552
 Gierum, Jan H., 2458
 Gloff, Carol A., 1472
 Gobernado, M., 558
 Gocke, David J., 153
 Gogu, Sudhir R., 2370
 Goh, Khye Seng, 2841, 2843
 Gohara, Yukiko, 1322
 Goldberg, Burt, 2736
 Goldman, Mark E., 1019
 Goldstein, Beth P., 446
 Goldstein, Ellis J. C., 1158
 Goldstein, F. W., 1677
 Golub, Lorne M., 227
 Gomeni, Roberto, 1404
 Gómez-Garcés, J. L., 1794
 Gómez-García, Antonio C.,
 898
 Gonzalez, Patricia C., 1163
 Gooding, B. Briggs, 2049
 Gootz, Thomas D., 751, 1671
 Gordon, Gloria, 913
 Gordon, Ronald E., 2497
 Goria, Alfred, 313
 Goswitz, Joseph J., 1166
 Gotlib, Leah, 1441
 Goto, Sachiko, 17, 573
 Gouin, François, 1115, 2804
 Gourde, P., 1504, 2147
 Gourde, Pierrette, 2204
 Graham, Donald J., 1441
 Graninger, W., 505
 Granneman, G. Richard, 378
 Graves, Donna, 1991
 Gray, Norman M., 1688
 Graybill, J. R., 217
 Graybill, John R., 690, 2790
 Grayson, M. Lindsay, 1864
 Graziano, Frank M., 2075
 Green, Michael, 545
 Greenwood, David, 223
 Griess, Rhonda S., 1296
 Griffith, Marguerite E., 2398
 Grigoriew, G. A., 1619
 Grosset, J., 548
 Grosset, Jacques, 2104, 2408,
 2839
 Groves, Eric S., 2349
 Gruda, Ilona, 2310
 Gu, Jian-Wei, 1310, 1336,
 1418
 Guan, Liming, 1902
 Guan, Linong, 2118
 Guay, David R. P., 308
 Guerra, Nancy, 545
 Guillen, Jean-Claude, 2804
 Guo, Luke S. S., 299
 Gustafson, John E., 566, 1367
 Gutmann, L., 77, 1487
 Gutmann, Laurent, 2611
 Gutteridge, Winston E., 326
 Guzenda, E., 2418
 Guzman, M. Carmen, 1053
 Haak-Frendscho, Mary, 68
 Haas, Hava, 313
 Haberzettl, Cecilia A., 153
 Hadley, W. Keith, 1163, 2808
 Haegeman, Sara, 989
 Haenftling, Katherine, 2349
 Hajdu, R., 607
 Hak, Lawrence J., 1387
 Hakenbeck, Regine, 783
 Hakusui, Hideo, 2270
 Halim, Magid A., 150
 Hall, James Edwin, 1825
 Hall, M. C., 1057
 Halstenson, C. E., 1832
 Halstenson, Charles E., 126
 Hamelin, Bettina A., 632
 Hames, C. S., 277
 Hamill, R. J., 1785
 Hammer, Scott M., 245, 509,
 920
 Hammerschlag, Margaret R.,
 682, 1573
 Hammond, M., 1648, 1964
 Hamzeh, F. M., 2061, 2473
 Hanboula, Salem Y., 2228
 Hancock, R. E. W., 1057
 Hancock, Robert E. W., 2365,
 2566
 Handwerger, Sandra, 1570
 Hanks, D., 2253
 Hanson, Linda H., 477, 486,
 2487, 2656
 Hanson, W. L., 1978
 Hara, Keibun, 1483
 Harabe, Eiko T., 1577
 Hardin, Thomas C., 2790
 Harding, Godfrey, 343
 Hardy, D. J., 137
 Hare, R. S., 64, 498, 1447
 Hare, Roberta S., 2222
 Harris, Eugene B., 92
 Harris, Steven C., 603
 Hart, Graham J., 1688
 Hart, T. K., 982
 Hashimoto, Hajime, 2562
 Hata, Katsura, 1894
 Hawkey, Peter M., 1981
 Haworth, S. J., 1532
 Hayakawa, Isao, 1491
 Hayashi, Kyoko, 1890
 Hayashi, Toshimitsu, 1890
 Hayden, Frederick G., 727,
 1186
 Hayes, Kathleen A., 2715
 Hazebroucq, Jean, 833
 He, Ping, 769
 Healey, Mark C., 220
 Hector, R. F., 1284
 Heidemann, H. T., 2670
 Heidenreich, Amy C., 283
 Heider, Arvela R., 108
 Heifets, Leonid B., 1695
 Heikkilä, Anne, 2652
 Heim-Duthoy, K. L., 1832
 Heller, Allen H., 993
 Hellinger, Walter C., 1272
 Henry, Nancy K., 56, 1272
 Heritage, John, 1981
 Herman, C. S., 1832
 Hermans, Philippe, 2661
 Hermus, Ad R. M. M., 2785
 Herrmann, J. L., 1081
 Hidaka, T., 387
 Hidemann, Wolfgang, 2139
 Hikida, Muneo, 481
 Hill, Bertha C., 2176
 Hill, David A., 1575
 Hill, Hal E., 2542
 Hill, S. L., 1545
 Hillier, Valerie F., 172
 Hirai, Keiji, 2108, 2562
 Hirakata, Yoichi, 1198, 1922
 Hiramatsu, Keiichi, 429
 Hirsch, Martin S., 1559
 Hiruma, Ryoichi, 589
 Hisaoka, Masafumi, 1810
 Hjelte, Lena, 2512
 Ho, Dai H., 879
 Hoban, Daryl J., 343, 1136
 Hodel-Christian, Susan L.,
 2259
 Hodge, R. Anthony Vere,
 2747
 Hodges, Teri L., 121
 Hoepelman, Andy I. M.,
 1456, 2458
 Hoffman, Jacob M., 1019
 Hoffmeister, Karen A., 2542
 Hohl, Peter, 2825, 2835
 Hsiby, N., 71
 Hoke, Glenn D., 527
 Holder, Ian Alan, 643
 Hollingshead, Melinda G., 206
 Holy, Antonin, 1837
 Holzknecht, Barbara, 2387
 Hommel, Marcel, 2228
 Honeybourne, D., 1171, 1176
 Honzumi, Ken, 435
 Hooper, David C., 1151
 Hooton, Thomas M., 1144
 Hopkins, Philip, 1097
 Horaud, Thea, 59, 1215
 Horn, Ruth, 2051
 Hosaka, Masaki, 2108
 Hoshino, Kazuhi, 1491
 Hoskins, JoAnn, 533
 Hosoe, K., 387
 Hosoya, Mitsuaki, 1432

Hostetler, John S., 477, 2656
 Hostetler, Karl Y., 2025
 Houston, John, 1909
 Howell, Renee M., 153
 Hoyle, Brian D., 2054
 Hsiung, G. D., 1127
 Hsu, Mei-Chich, 1276
 Hsu, Pei-Wen, 1276
 Hubbell, James, 1040
 Hubschwerlen, Christian, 2825
 Huffman, John H., 473
 Huggins, Andrea S., 2548
 Hughes, George S., 126
 Hughes-Fulford, M., 2253
 Humbert, G., 1519, 2794
 Hunter, Susan, 2176
 Huovinen, Pentti, 989
 Hürliemann-Dale, Rocio L., 2617
 Hurn, Sarah, 458
 Hurtado, Cipriano, 898
 Huskinson-Mark, Jayne, 326
 Husson, M. O., 1677
 Hutchison, M., 1532
 Hyman, Charles L., 682
 Hyslop, Newton E., Jr., 647
 Ibrahim, Ashraf S., 2239
 Ibrahim, Safaa S., 2432
 Ikeda, Takao, 214
 Imada, Akira, 1358, 2481
 Imada, Takuma, 573
 Imbimbo, Bruno P., 1296
 Inoue, Eiko, 684
 Inoue, Kazutomo, 1483
 Inoue, Matsuhisa, 883, 2293
 Inoue, Shigeharu, 492
 Inoue, Yoshimasa, 883
 Inukai, Masatoshi, 1024
 Iranmanesh, A., 2544
 Irie, Kenji, 1290
 Irwin, Raymond, 458
 Isaacson, D. M., 860
 Ishida, Kazuo, 1922
 Islam, Khalid, 1374
 Isono, Fujio, 1024
 Ito, Hideo, 1460
 Ito, Keizo, 883
 Ito, Masahiko, 435
 Ito, Tatsuya, 1708
 Itoh, Yuko, 2030
 Iwagaki, Akitaka, 1352
 Iwahashi, Tomoyuki, 1358
 Iyobe, Shizuko, 684, 2562
 Jabarit-Alidighieri, N., 2529
 Jacob, L. S., 1263
 Jacobs, Michael R., 856, 1140
 Jacobs, Richard F., 1614
 Jacobson, Mark A., 1773
 Jacques, Mario, 2093
 Jagannathan, V., 938
 Jakics, Eva B., 2562
 Janc, M., 2850
 Jang, In Ho, 195
 Janssen, Cor, 417
 Janssen, P. A. J., 100
 Janssen, Paul A. J., 727
 Jansson, Catarina, 2704
 Jaresko, George S., 2233
 Jehl, F., 2493
 Jehl, Francois, 1883
 Jenkinson, Helen J., 202, 733
 Jeong, Lak-Shin, 672
 Ji, B., 548
 Ji, Baohong, 2839
 Jimenez, M. T., 558
 Jin, Shao Hong, 1068
 Jobe, Dean A., 1788
 John, Joseph F., Jr., 2346
 John, William J., 632
 Johnson, B. Lamar, Jr., 453, 2233
 Johnson, Caroline C., 2342
 Johnson, D. M., 2049
 Johnson, J., 1002
 Johnson, J. H., 2444
 Johnson, Susan, 2715
 Johnson, Victoria A., 1559
 Johnston, Linda, 1097
 Joly, Véronique, 262, 1799, 2722
 Jones, R. N., 2049
 Jones, Ronald N., 233, 873
 Joone, G., 1236
 Jooné, Gisela K., 2729
 Jousimies-Somer, H., 1241
 Jowett, Amanda J., 733
 Jowett, Michael I., 733
 Joye, Steve M., 2381
 Judson, Franklyn N., 1144
 Juteau, Jean-Marc, 467
 Kaatz, Glenn W., 1109, 1192, 2709
 Kabrerra, G., 277
 Kageyama, Seiji, 926
 Kajiser, B., 2847
 Kaiser, Lee, 993
 Kaku, Mitsu, 1198, 1922
 Kalman, Debra, 453
 Kamidono, Sadao, 188
 Kamimura, Toshiaki, 17
 Kanaani, JAMIL, 1102
 Kaplan, Sheldon L., 1703
 Karkas, John D., 2020
 Karle, Isabella L., 1538
 Karle, Jean M., 1538
 Karlovsky, James A., 1136
 Kashholm-Tengve, B., 2766
 Katlama, Christine, 1821
 Kato, Masuhiro, 1290
 Kato, Nobuo, 1460
 Katsu, Kanemasa, 589, 684
 Kauffman, Carol A., 2533
 Kaufhold, Achim, 1215
 Kawahara, Yukinori, 1810
 Kawashima, Kousuke, 481
 Kawashima, Takanori, 1322
 Kayser, Fritz H., 25, 1367, 2617
 Keane, W. F., 1832
 Keck, C. W., 1764
 Kees, E. S., 277, 1682
 Kelloway, J. H., 1832
 Kelloway, Judy S., 126
 Kempf, Dale J., 926
 Kenny, Michael T., 115
 Kerestedjian, Jean-Jacques, 1244
 Kernodle, Douglas S., 440
 Kerwar, S. S., 1971
 Khan, Bashir A., 150
 Khoosal, Manikant, 1596
 Kibsey, Patricia C., 343
 Kiehbauch, Julia A., 717
 Kihlström, E., 2766
 Kim, C. Kurtis, 1935
 Kim, Michael H., 626
 Kim, Young Jin, 195
 Kimura, Makoto, 2774
 Kinsman, Oonagh, 1909
 Kinzig, M., 1997
 Kisicki, James C., 1296
 Kita, Yasuo, 2481
 Kitagawa, Takayasu, 1219
 Kitzis, Marie-Dominique, 2611
 Kivistö, Kari T., 489
 Klare, I., 77
 Klare, Ingo, 783
 Klatzmann, David, 267
 Klein, Robert S., 1935
 Klemens, S. P., 1611, 2413
 Klich, M., 1756
 Klostermann, Heidrun, 1230
 Klotz, Stephen A., 132
 Klugman, Keith P., 1596
 Knapp, Joan S., 1639
 Knapp, Catherine A., 552, 1181, 1382, 1387, 2075
 Ko, T. C., 2057
 Kobashi, Yoshihiro, 2774
 Kobayashi, George S., 1805
 Kobayashi, Shinobu, 1352
 Kociba, Gary J., 2715
 Kodama, Kentaro, 1024
 Koeppe, Peter, 144, 796
 Kohlbrenner, William E., 81
 Kohler, C. A., 1971
 Kohlhepp, S. J., 2556
 Kohnen, P. W., 2556
 Kohzuki, Tsuneo, 1290, 1577
 Kojima, Kana, 1715
 Kondo, Masahiro, 1358
 Kong, Xiang-Bin, 808, 1472
 Konishi, Masaharu, 757
 Kontinen, Yrjö T., 227
 Koornhof, H. J., 1236
 Kornhauser, D. M., 2473
 Korvick, Joyce A., 620, 2639
 Kosunen, Timo U., 163
 Koszalka, George W., 353
 Kotera, Yasuo, 883
 Kovarik, John M., 2458
 Koyanagi, Yoshio, 1249
 Krajden, M., 1619
 Kramer, Barnett S., 1062
 Kropp, H., 607
 Krupa, D., 1648
 Ksionski, G., 1978
 Kuhlencord, Armin, 1630
 Kuistila, Maud, 989
 Kullberg, Bart-Jan, 1225
 Kulmala, Henrik K., 115
 Kunimoto, Setsuko, 492
 Kunz, Samuel, 2693
 Kuo, Cho-Chou, 1478
 Kurihara, Atsushi, 1810
 Kusmiesz, Helen T., 2478
 Kuwahara, S. K., 2473
 Kuwano, Koichi, 1322
 Kuwano, Sadahito, 481
 Kyle, Dennis E., 2761
 Labia, Roger, 1817
 Labrousse, Valérie, 2843
 Lacave, Charlotte, 1316
 Lacroix, C., 548
 Lacroix, Jean-Michel, 740
 Ladd, Elizabeth A., 920
 LaForge, Robert G., 1032
 Lafredo, Stephen C., 860
 Lagrange, P. H., 1081
 Lai, C. W., 2057
 Lalonde, Richard L., 1553
 Lam, Y. F. Francis, 2790
 Lambe, Catherine U., 353
 Lambert, D. M., 982
 Lambert, Dominique, 1115
 Lambert, John S., 1280
 Lambert, P. A., 71
 Lambeth, Linda B., 1703
 Lamotte, François, 343
 Lamp, Kenneth C., 1109, 1192, 2709, 2741
 Landini, Paolo, 446
 Lanéelle, Gilbert, 1316
 Lang, R., 973
 Lang, Stanley A., Jr., 808
 Larder, Brendan A., 2664
 Larson, Tom A., 2334
 Lartey, Paul A., 2778
 Lasseter, K. C., 830
 Lavallée, Jocelyne, 2051
 Lavoie, M. C., 2166
 Leary, J. J., 982
 LeBel, Marc, 2085
 LeBlanc, Barbara, 879
 LeBlanc, Donald J., 712
 Le Bras, Jacques, 209
 Lebrun, Annie, 2093
 Leclercq, Roland, 2005
 Le Conte, Philippe, 744
 Lescos-Bornet, Marilyn, 669
 LeDuc, Barbara W., 1553
 Lee, Hsi-Ming, 227
 Lee, Kyungwon, 195
 Lee, Linda, 712
 Leffers, Nilima Pai, 704
 Le Gallou, Florence, 744
 Leggett, J. E., 2556
 Legrand, Philippe, 2518
 Lehnert, Erich K., 495
 Le Jeune, Ludo, 2602
 Lejko-Zupanc, T., 2850
 Lemeland, Jean-François, 2611
 Lemozy, J., 1677
 Lenert, Leslie A., 1230
 Leonhardt, Judy A., 1837
 Léophonte, Paul, 833
 Lepage, Jean-Yves, 744
 Leroy, A., 2794
 Lertora, Juan J. L., 647
 Lettieri, J. T., 830
 Lettieri, John T., 993
 Leung, J. W. C., 2057
 Levesque, Roger C., 467
 Levin, Myron J., 2037
 Levin, Samuel, 1040
 Levison, Matthew E., 2342
 Levitz, Robert E., 1575
 Levy, Stuart B., 695
 Lewis, Eric W., 115
 Lewis, Ian J., 1981
 Lewis, L. D., 2061, 2473
 Li, Karl I., 545
 Li, Shixiong, 206
 Li, Su-Ling, 1770
 Liberator, P., 1964
 Liebman, Howard A., 1280
 Lietman, P. S., 2061, 2473
 Ligvoet, Eric, 1456

Lin, Teri, 2454
 Lindblad, Anders, 2512
 Lindholm-Levy, Pamela J., 1695
 Ling, Kah-Hieng John, 108
 Liotta, Dennis C., 672, 2423, 2432, 2686
 Liu, Yu-Ying, 2286
 Livermore, David M., 1870, 2046
 Livni, E., 2286
 Ljungberg, B., 1437
 Ljungberg, Bengt, 2512
 Ljungdahl-Stähle, E., 2418
 Lloyd, Robert M., 2423
 Lobe, David C., 934
 Lobo, Juan M. García, 1049
 Lockhart, Brian Paul, 1750
 Lode, Hartmut, 144, 796
 Loebenberg, David, 64, 217, 498
 Lohia, Anuradha, 788
 Lokiec, F., 2331
 Lokiec, François, 2804
 Loo, Vivian G., 1133
 Lopardo, Horacio A., 230
 Lounis, Nacer, 2839
 Lovering, A. L., 1545
 Low, Donald E., 343
 Löwdin, Elisabeth, 1852
 Lubera, Sylviane, 669
 Lubowski, Teresa J., 651, 2758
 Lucain, Christine, 894
 Ludlam, Hugo, 1097
 Lumish, Robert, 2639
 Lupidi, Remo, 331
 Lurie, Jon, 1230
 Lustig, Shlomo, 2275

Macdonald, Timothy L., 495
 MacGowan, Alasdair, 463
 Machida, Haruhiko, 214
 Mack, Doug, 1040
 Maclean, Ian W., 467
 Maddon, Paul J., 267
 Madu, Assumpta, 32
 Madu, Christian N., 32
 Maeda, Hiroshi, 188
 Mahr, G., 942
 Majumdar, Sabita, 788
 Majumdar, Sadhana, 2808
 Malanowski, Gregory J., 1329
 Malinverni, Raffaele, 1256
 Malmborg, A. S., 2766
 Malmborg, Anna-Stina, 2512
 Malone, John D., 1062
 Malouin, F., 1504, 2147, 2166, 2569
 Mandell, Carol P., 2381
 Mandell, Gerald L., 39, 408, 2584
 Manfrin, Vinicio, 2192
 Maniera, Titus, 1630
 Mann, P., 1447
 Manning, Carolina, 2432
 Maple, P. A. H., 2346
 Marceau, François, 955
 Marder, Victor, 2245
 Marichal, Patrick, 2602
 Mario, N., 2009
 Markowitz, Sheldon M., 1125
 Markus, A., 1756

Marlin, Steven D., 1186
 Marone, Piero, 1567
 Maroushek, Nancy, 68
 Marquis, A. J., 217
 Marshall, Steven H., 1843
 Marthas, Marta L., 2381
 Martin, Barbara Anne, 751
 Martin, Claude, 1115, 2804
 Martin, R. Russell, 552
 Martin, Rodger K., 2761
 Martinez-Beltran, Jesus, 2536
 Martino, Pietro, 723
 Martinson, Bernt, 1738
 Maserati, Renato, 1567
 Mason, Edward O., Jr., 1703
 Massias, L., 2539
 Masters, Helen B., 2037
 Masuda, Koji, 1460
 Masuda, Masao, 1249
 Masuda, Nobuhisa, 966
 Mathes, Lawrence E., 2715
 Mathewson, John J., 87, 2821
 Mathis, Rodney, 672, 2423
 Mathisson, Kevin, 32
 Matlow, Anne G., 1133
 Matsubara, Kenichi, 2042
 Matsubara, Shuzo, 1715
 Matsubayashi, Kyuichi, 966
 Matsuda, Akira, 435
 Matsumoto, Akiyoshi, 1249
 Matsumoto, Keizo, 1352
 Matsumoto, Masahiko, 1715
 Matsumoto, Satoru, 17
 Matsumoto, Tetsuya, 1198, 1922
 Matsumura, Haruki, 1577
 Matsuno, S., 762
 Matsushima, Toshiharu, 2774
 Matsuyama, Shinichi, 1432
 Mattern, William, 1387
 Mattheeuws, D., 1606
 Matthews, T. J., 982
 Mattie, Herman, 2375, 2439
 Matzke, Gary R., 308
 May, Phyllis, 2342
 Mayer, Roger M., 2228
 Mayers, Martin, 32
 Maziere, Bernard, 2216, 2611
 McKoy, Judith, 2497
 McCaffrey, C., 1601
 McCann, Peter P., 2736
 McClure, Harold M., 2432
 McCormack, Robert J., 1296
 McCormack, William, 1131
 McDanah, C. E., 982
 McDermott, Laura, 540
 McDonald, Peter J., 10
 McDougal, Linda K., 2176
 McFadden, D. C., 1964
 McFarland, James W., 368, 372
 McGowan, Ellen K., 2381
 McGrath, Betty J., 2741
 McGrath, Jacqueline M., 920
 McGrath, M. S., 2253
 McGuirk, Paul R., 751, 1671
 McKee, J. A., 2166
 McKee, Julia A., 840
 McLauchlin, James, 463
 McLaughlin, J. C., 137
 McLeod, Gavin X., 920
 McLeod, Rima, 1040
 McMahon, F. Gilbert, 308

McMillan, Angela, 672, 2423
 McNicholas, Paul, 913
 Mead, Jan R., 1837
 Medeiros, Antone A., 1032
 Medina, D. J., 1127
 Meek, T. D., 982
 Mellors, J. W., 1127
 Mentec, Hervé, 1883
 Mentzing, L. O., 2766
 Menzel, Fred, Jr., 64
 Menzel, Frederick, Jr., 498
 Merle-Melet, M., 2331
 Merluzzi, Vincent J., 1186
 Merrill, Debra P., 1559
 Mertens, Jacqueline C. C., 1456
 Mertes, P. M., 2493
 Metcalf, B. W., 982
 Meulemans, A., 295
 Meunier, F., 2014
 Meurer, Laura C., 2020
 Meyer, Christian, 71
 Meyers, Fred J., 2349
 Meyran, M., 1677
 Micozzi, Alessandra, 723
 Mierzwa, R., 1447
 Mierzwa, Ronald, 2222
 Migaki, Thomas T., 2080
 Mignon, F., 1519
 Miick, Cathleen, 656
 Mildvan, Donna, 1570
 Milhous, Wilbur K., 1538, 2761
 Millar, Michael Ronald, 185
 Miller, G. H., 64, 498, 1447
 Miller, George H., 2222
 Miller, M. J., 2166
 Miller, Marvin J., 840
 Miller, Michael H., 32
 Miller, Wayne H., 2686
 Miniter, Peggy, 2681
 Minkler, Paul, 1392
 Minnick, A. A., Jr., 2166
 Minnick, Albert A., 840
 Miranda, Abraham G., 1325
 Mitsuhashi, Susumu, 684, 2185, 2293
 Mitsuya, H., 2156
 Mitsuya, Hiroaki, 926
 Mitsuyama, Jun-Ichi, 2030
 Mitsuyama, Masao, 361
 Miwa, Hideaki, 1219
 Miyake, Akio, 1358
 Miyashiro, Deborah, 1991
 Miyazaki, Shuichi, 573
 Mizen, Linda, 458, 1427
 Mizojiri, K., 762
 Mizukane, Ryusuke, 1922
 Moellering, R. C., Jr., 2201, 2526
 Moellering, Robert C., Jr., 121
 Moeremans, Marc, 417
 Molinas, Catherine, 867, 1514
 Molitoris, Eric, 239
 Monosov, M., 2316
 Monsigny, Michel, 2228
 Monteil, H., 2493
 Montero, J. M., 2816
 Montgomery, Debra A., 2131, 2778
 Moore, Carol Wood, 2497
 Moosmann, Yves, 1256

Morán, Francisco J., 898
 Moreau, N., 2622
 Morel, C., 1677
 Moreno, A., 662
 Morgan, M. E., 2156
 Mori, Shuichi, 435
 Morita, Naokata, 1890
 Morris, Janis L. B., 1837
 Morrison, Paul J., 378
 Morse, Gene, 1280
 Morse, Gene D., 2245
 Moscon, Bret, 473
 Moss, Eugene L., Jr., 64, 498
 Motley, Milwood, 1639
 Motomiya, Masakichi, 6
 Movahhed, Hassan, 552
 Muchmore, Elizabeth, 808
 Muder, Robert R., 620, 2639
 Muffat-Joly, Martine, 2216, 2403
 Müller, Christine, 144
 Müller, Johannes, 1805
 Müller-Serries, C., 2099
 Munafó, Alain, 1013
 Munakata, Kei-Ichi, 1580
 Munayyeri, H., 1447
 Murakami, K., 2156
 Murakami, Tsutomu, 1249
 Muratani, Tetsuro, 2293
 Murciano, G., 2099
 Murray, Barbara E., 230, 273, 1325, 1720, 2259, 2265, 2355
 Murray, L., 2544
 Musher, D. M., 1785
 Mutton, Ian M., 202
 Myhr, Egil, 1738

Nafziger, Anne N., 679
 Naganawa, Takehito, 2042
 Naganawa, Hiroshi, 492
 Nagano, Hiroyuki, 1715
 Naganuma, Hideo, 1810
 Nagaraj, R., 2468
 Nagashima, Minoru, 2589
 Nagatake, Tsuyoshi, 1352
 Naiman, Noreen A., 1825
 Nakae, Taiji, 1791
 Nakahama, Chikara, 167
 Nakamura, Junichi, 2774
 Nakamura, Kiyoto, 435
 Nakamura, Mariko, 492
 Nakano, Hirofumi, 2589
 Nakashima, Hideki, 1249
 Nakashima, M., 762
 Nakata, Katsuhisa, 188
 Nakayama, Hiroaki, 1626
 Nassos, Patricia, 2808
 Nassos, Patricia S., 1163
 Nathan, Henry C., 2736
 Naumovski, Louie, 1991
 Neely, Alice N., 643
 Négre, Éric, 2228
 Neider, Katharina, 796
 Nelis, H. J., 1606, 1859
 Nelson, Donald J., 353, 2686
 Nentwig, Birgit, 2139
 Neu, Harold C., 1310, 1336, 1418, 1699
 Neuvonen, Pertti J., 489, 1086
 Newcomb, Deborah M., 368, 372
 Neyfakh, Alexander A., 484
 Ng, Eva Y., 1151

Nguyen, Hieu T., 879
 Nicas, T. I., 2166
 Nicholls-Vasquez, Ines, 2821
 Nicolin, Roberto, 1567, 2192
 Nielsen, Eva Møller, 401
 Nightingale, Charles, 651
 Nightingale, Charles H., 1575, 2758
 Niki, Yoshihito, 167
 Nikolich, Mikkeljon P., 1005
 Nilsson-Ehle, I., 1437, 1532, 2676
 Nilsson-Ehle, Ingrid, 2512
 Nishida, Minoru, 573
 Nishikawa, Takashi, 1219
 Nishiki, Katsuyuki, 481
 Nishino, Takeshi, 1708, 1894, 2595
 Nishizawa, Kazuaki, 481
 Noe, A. J., 830
 Noguchi, Hiroshi, 1290
 Nolan, Rathel L., 977
 Nollstadt, K., 1648
 Nomoto, Kikuo, 361
 Nomoto, Koji, 361
 Norbeck, Daniel W., 926
 Nord, C. E., 1997, 2766
 Nord, Carl-Eric, 144
 Nordmann, Patrice, 1244
 Norman, Dean C., 1665
 Norrby, S. R., 1532, 2676
 Norris, Christine, 64, 498
 Nothnagel, Robert F., 1091
 Nouda, Hiroshi, 1577
 Novak, E., 1764
 Novick, Richard P., 626
 Numazaki, Yoshio, 435
 Nunberg, Jack H., 1019
 Nyhart, Eldon H., Jr., 318
 Nyström, P. O., 2766

Obara, Takumi, 435
 Öberg, B., 1770, 2418
 Öberg, Bo, 339
 Oblon, David J., 1062
 O'Brien, Julie A., 1019
 Ochi, Hiroshi, 1290
 Odds, Frank C., 1727, 2602
 Odenholt-Tornqvist, Inga, 1852
 O'Doherty, Elizabeth, 2661
 Oduolu, Ayoade M. J., 2761
 Oguma, T., 762
 Oguma, Takayoshi, 1219
 O'Halloran, James J., 1424
 O'Hara, Caroline, 1785
 Ohashi, Masami, 883
 Ohno, Tsuneyuki, 492
 Ohta, Michio, 1460
 Ohya, Satoshi, 1847
 Oishi, Kazunori, 1352
 Ojala-Karlsson, Pirjo, 489
 Okabayashi, Yoshito, 1219
 Okamoto, Seiki, 2030
 Okazaki, Osamu, 2270
 Okonogi, Kenji, 1358
 Okuda, Takao, 1577
 Oldfield, Edward C., III, 2542
 Oliva, Brunello, 876, 913
 Olson, John, 2245
 Olson, Julie A., 372, 2080, 2338
 Olsson-Liljequist, B., 2766

Onishi, J., 607
 Onyi, Grace O., 180, 1987
 Opal, Steven M., 1032
 Oppegård, Hanne, 1738
 Opsahl, John A., 308
 Öqvist, B., 1532, 2676
 Ordóñez, A., 2816
 Orefici, Graziella, 1068
 O'Reilly, Terry, 2693
 Oronsky, A. L., 1971
 Orr, David C., 1688
 Orsi, Nicola, 95
 Osada, Yasuaki, 1491
 Osheroff, Neil, 751
 Oshitani, Hitoshi, 435
 Ossi, Michael J., 1614
 Ostrander, Michael, 808
 O'Sullivan, John F., 2729
 O'Sullivan, N., 1002
 Otsuki, Masako, 1708, 1894, 2595
 Ott, Christopher L., 1296
 Otter, Brian A., 1935
 Outman, William R., 1575

Pace, J., 1601
 Padmos, M. Andrew, 172
 Paff, Melanie, 2686
 Page, Malcolm, 2825
 Painter, George, 2423
 Painter, George R., 2686
 Pajukanta, R., 1241
 Palzkill, Tim, 1991
 Paradis, Dominique, 2085
 Parent de Curzon, O., 1519
 Parker, Richard, 1329
 Parmegiani, Raulo, 64, 498
 Parr, T. R., Jr., 1504, 2166
 Pascual, Alvaro, 1053
 Patel, Marlynn, 1991
 Patterson, Thomas F., 2681
 Patton, Dorothy L., 1478
 Pauwels, Rudi, 2628
 Pavčić, M. J. A. M. P., 2634
 Paxton, L. M., 1764
 Peacock, James E., Jr., 620
 Pearson, Bridget A., 202, 733
 Pearson, Richard D., 495
 Pechère, Jean-Claude, 894, 2506
 Peck, Annette, 672, 2423
 Pecking, Michèle, 2804
 Pedersen, Gordon, 473
 Pedersen, Niels C., 2381
 Peggins, James, 1825
 Peltola, Heikki, 1086
 Pemán, J., 558
 Penn, Charles R., 202, 733, 1688
 Perea, Evelio J., 1053
 Perez, R., 1677
 Perez-Diaz, Jose C., 2536
 Pérez-Giraldo, Ciro, 898
 Perez-Perez, María-Jesús, 1073
 Pérez-Rivilla, A., 1794
 Perkins, B. A., 1785
 Perkins, Robert M., 2747
 Pernet, Andre G., 378
 Perronne, Christian, 2104, 2408
 Petavy, A. F., 191
 Peterson, Lance R., 1166

Petitclerc, Eric, 955
 Petitpretz, Patrick, 833
 Petrikos, G. L., 1447
 Petteway, S. R., Jr., 982
 Pfaller, M. A., 137
 Pfaller, Michael A., 1805
 Pfeffer, Morris, 1382, 1387
 Pfefferkorn, E. R., 1091
 Pfleger, S., 505
 Phan, M., 2014
 Picard, M., 1504, 2569
 Picazo, Juan J., 2536
 Pickering, Larry K., 1720
 Pickett, W. C., 1971
 Piddock, L. J. V., 1057
 Piddock, Laura J. V., 819
 Pierre, Josiane, 669
 Pike, Jane, 185
 Pillai, V. N. R., 2468
 Pinelli, G., 2493
 Piriz, Segundo, 198
 Pitsakis, Peter, 2342
 Pittarelli, L., 1964
 Pittman, K. A., 938, 962
 Pittman, Kenneth A., 552, 687, 1181, 1382, 1387
 Plank, Carol, 2245
 Plattner, Jacob J., 926
 Pleterski-Rigler, D., 2850
 Pocidalo, Jean-Jacques, 470, 997, 1412, 2104, 2216, 2328, 2408, 2698, 2852
 Podbielski, Andreas, 1215
 Poell, Robertt J. M., 1225
 Poignet, J. L., 1519
 Polas, Phyllis J., 2715
 Polsky, Bruce, 808
 Portet, Cécile, 1115
 Portmore, Amy C., 2245
 Potel, Gilles, 744
 Potter-Bynoe, Gail, 1032
 Poupart, Marie-Christine, 1817
 Powles, M. A., 1964
 Poyart-Salmeron, Claire, 463
 Pramanik, Ajay, 2497
 Preat, Veronique, 1525
 Preston, David A., 533
 Price, F. C., 277
 Principi, Nicola, 1499
 Projan, Steven J., 626
 Prokocimer, Philippe, 2852
 Prokocimer, Philippe, 2454
 Prosser, Barbara L., 2286
 Prus, Karen L., 283
 Prul, Hendrik, 10
 Pulliam, L., 2253
 Punyagupta, Sompone, 158

Qadri, S. M. Hussain, 150
 Quale, John M., 1424
 Quassem, C., 677
 Queener, S. F., 779
 Quémard, Annaik, 1316
 Quentin-Noury, C., 1677
 Quinn, John P., 1991
 Quinn, Thomas C., 291
 Quintero, Julio C., 1019
 Quintiliani, Richard, 651, 2758
 Qumei, Khaldoon K., 1573

Raabach, Ralph, 1773
 Rabadian, Pablo M., 1272
 Ragni, Jacques, 2804
 Ralph, Ray, 1644

Ramamurthy, Nungavaram, 227
 Ramón, M. S., 558
 Ramos, Marcelo C., 1864
 Ramos, Ross A., 2381
 Ramphal, Reuben, 1062
 Ranaldi, Giulia, 1374
 Rand, Kenneth H., 1062
 Raoult, D., 2529
 Raoult, Didier, 2799
 Ras, G. J., 1236
 Rasmussen, Beth A., 1155
 Rasmussen, Kathleen R., 220
 Rastogi, Nalin, 2841, 2843
 Rather, P. N., 1447
 Rather, Philip N., 2222
 Rathod, Pradipsinh K., 704
 Rautelin, Hilpi, 163
 Raynaud, G., 191
 Raza, Jocelyne, 744
 Reeves, Michael, 2176
 Rege, Arvind B., 647
 Reichman, Richard C., 2245
 Reig, M., 662
 Reig, Milagro, 639
 Reinert, C., 71
 Remington, Jack S., 326, 2454
 Renaudin, Helene, 870
 Renkonen, Olli-Veikko, 163, 1086, 2652
 Resetar, Andrea, 353
 Reverdy, M. E., 1677
 Reves, Randall R., 1720
 Reymen, Diane, 2628
 Rezvani, Y., 1677
 Rice, John R., 372, 2338
 Rice, Louis B., 1843
 Richman, Douglas D., 2025
 Ricketts, Anthony P., 368, 372, 2080, 2338
 Riess, G., 2360
 Rigoli, Roberto, 1567, 2192
 Rinaldi, Enrico, 2192
 Rinaldi, M. G., 217
 Rinaldi, Michael G., 603, 690, 1805, 2790
 Ripamonti, Franca, 446
 Roberts, M. C., 611
 Robinson, Kristin A., 2533
 Robinson, Megan J., 751
 Roblin, Patricia M., 682, 1573
 Robson, Hugh G., 2051
 Roche, Annie-Claude, 2228
 Rodloff, Arne C., 783
 Rodriguez, Ana, 1028
 Rodriguez, Carlos A., 616
 Rogge, Mark C., 993
 Roland, Michel, 1525
 Rolston, Kenneth V. I., 879
 Romero, Eneida A., 2518
 Ronald, Allan R., 467
 Ronco, Esthel, 1244
 Rood, Julian I., 2548
 Roscoe, Diane L., 2197
 Rosembaum, M., 1677
 Rosenberg, E., 2316, 2322
 Rosenthal, M. E., 860
 Rotmensch, H. H., 677
 Rotschafer, John C., 2334
 Rouse, Mark S., 56, 1272
 Rouse, Philippa L., 733
 Rousseau, N., 1504, 2147
 Rouveix, Bernard, 997

Rozenberg-Arsk, M., 801
 Rozenberg-Arsk, Maja, 2458
 Rubeglio, Etelvina A., 230
 Ruberg, Stephen J., 115
 Rubin, Robert H., 2286
 Rubinstein, E., 973
 Rueppel, W. J., 277
 Ruffing, Thomas L., 1019
 Rush, Dawn, 32
 Rybak, Michael J., 1109, 1192, 1204, 2709, 2741
 Ryffel, Cristina, 25, 2617

Saarela, M., 1241
 Saari, Herkko, 227
 Saathoff, Nina, 796
 Sabatelli, F. J., 1447
 Sabra, R., 2670
 Saenger, S., 1682
 Sahm, Daniel F., 902
 Saint-Julien, Line, 262, 2722
 Saissi, Gilbert, 1404
 Saito, H., 387
 Saito, Isao, 481
 Sakai, Osamu, 2270
 Sakata, Shinji, 214
 Sakau, Morito, 492
 Saldivar, Ayda, 81
 Saleh-Mghir, Azzam, 1883, 2216, 2403, 2611
 Salstrom, Sara-Jane, 1400
 Salyers, Abigail A., 1005
 Samathanam, Glory, 32
 Sambuy, Yula, 1374
 Samuelson, John C., 2392
 Sanchez, Martha L., 873
 Sande, Eric, 2693
 Sande, Merle A., 2693
 Sanders, Christine C., 394, 1877
 Sanders, Cynthia A., 1163
 San-Felix, Ana, 1073
 Sarafian, Samuel K., 1639
 Sarciron, M. E., 191
 Sardana, Vinod V., 1441
 Sarkis-Karam, Dolla, 669
 Sassella, Daniela, 1958
 Sastre, Bernard, 1115
 Sato, K., 387
 Sato, Kenichi, 1491
 Satoh, Ken, 6
 Satoh, Masaru, 1580
 Satta, Giuseppe, 1902
 Saulnier, P., 2009
 Saunders, J., 1236
 Sautter, Robert L., 1635
 Savage, J. E., 1236
 Scardaci, Giovanna, 1068
 Scarpellini, Paolo, 1567, 2192
 Schaberg, Dennis R., 2533
 Schaller, K., 1284
 Schaub, R. E., 1971
 Schedel, Ingolf, 2139
 Scheftel, J. M., 1677
 Scheld, W. Michael, 949
 Schenfeld, Louis, 2639
 Schinazi, Raymond F., 108, 672, 2423, 2432, 2686
 Schiro, Denise D., 854
 Schlabbach, Abner J., 1441
 Schleif, William A., 1019
 Schlievert, Patrick M., 626
 Schlundt, Jørgen, 401

Schmatz, D., 1648
 Schmatz, D. M., 1964
 Schmid, George, 1639
 Schneider, Sheila A., 2037
 Schols, Dominique, 2628
 Schrempp, H., 1119
 Schuster, F. L., 1263
 Schwartz, R., 1648
 Schwarz, Stefan, 580
 Scotti, Roberto, 446
 See, Darryl M., 425
 Seibert, G., 1756
 Seidlín, Mindell, 1280
 Sekh, Beata Razab, 2375
 Sekh, Beata A. Razab, 2439
 Self, Timothy H., 1553
 Seman, Michel, 2722
 Sengupta, Tapas K., 788
 Sennello, L. T., 2447
 Seo, Susan M., 1192
 Seoane, Asunción, 1049
 Seppälä, Kari, 163
 Serra, Pietro, 723
 Seuba, Teresa, 1028
 Severin, Anatoly, 886
 Shadomy, Smith, 1805
 Shah, V. R., 938
 Shalit, Itamar, 313
 Shamblen, E. C., 830
 Shands, Joseph W., Jr., 1062
 Shannon, William M., 206
 Shapiro, Bruce E., 126
 Sharkey, Patricia K., 2790
 Shasha, B., 973
 Shaw, K. J., 1447
 Shaw, Karen J., 2222
 Shaw, M. M., 779
 Shen, Linus L., 2131, 2778
 Sherertz, Robert J., 1062
 Sherman, Philip, 1133
 Shiba, Kohya, 1219, 2270
 Shigeta, Shiro, 214, 435, 1432
 Shiki, Shikiko, 1358
 Shimada, Jingoro, 1219, 2270
 Shimam, Ross, 1140
 Shimizu, Kihachiro, 757
 Shimokawa, Osamu, 1626
 Shintani, Shozo, 966
 Shirasaka, Takuma, 926
 Shively, Jesse E., 368
 Shlaes, David M., 1392
 Shoemaker, Jo Ellen E., 527
 Shoemaker, Nadja B., 1005
 Shoji, Satoru, 6
 Shonekan, Dokun, 1570
 Shuto, Satoshi, 435
 Shyu, W. C., 938, 962
 Shyu, Wen Chyi, 687
 Sidwell, Robert W., 473, 1837
 Siegl, Peter K. S., 1019
 Signs, Steven A., 1400
 Simard, Marie, 2204
 Singer, Allen W., 299
 Singer, Susan B., 1991
 Singh, Kavindra V., 230, 1325, 1720
 Singlas, E., 1519
 Singlas, Eric, 1821
 Sips, Peter A., 2458
 Sirot, D. L., 1677
 Sirot, Danielle, 1817
 Sirot, Jacques, 1817
 Sitaram, N., 2468

Siu, P., 2544
 Sjöberg, L., 2766
 Sjoerdsma, Albert, 2736
 Sjögren, E., 2847
 Skatrud, Paul L., 533
 Skau, T., 2766
 Sköld, Ola, 2704
 Slaney, Leslie, 467
 Slusher, J. T., 2473
 Smee, Donald F., 1837
 Smit, Jan M., 2458
 Smith, Anthony M., 1019
 Smith, David E., 616
 Smith, Deborah A., 632
 Smith, J. W., 779
 Smith, John A., 343
 Smith, Monica C., 273, 2265
 Smith, Robert L., 132
 Smithers, Jacqueline A., 115
 Snoeks, J., 100
 Snydman, David R., 540
 Sobel, A., 1519
 Soler, P., 2099
 Sommadossi, Jean-Pierre, 2423
 Sommereijns, Bernadette, 2661
 Sonders, R. C., 2447
 Sonoda, Fuminari, 1352
 Sookprane, Mondej, 158
 Sörgel, F., 942, 1997
 Soriano, Francisco, 223
 Sorsa, Timo, 227
 Sörum, H., 611
 Soussy, C. J., 1677
 Spangler, Sheila K., 856, 1140
 Spector, Thomas, 353, 934
 Spence, David G., 172
 Sperber, Steven J., 153
 Spruance, Spotswood L., 1144
 St. Clair, Marty, 2423
 St. Peter, John V., 126
 Stähle, L., 1770, 2418
 Stähle, Lars, 339
 Staib, A. H., 942
 Stamm, Walter E., 1144
 Stanberry, Lawrence R., 2020
 Stasi, Patrizia, 1499
 Steckelberg, James M., 56, 1272
 Steele, Paul, 1935, 1943
 Stein, Maria Luisa, 95
 Stevens, David A., 477, 486, 2487, 2656
 Stewart, Brian W., 132
 Stockley, R. A., 1545
 Stokbroekx, R., 100
 Storer, Richard, 202
 Strandvik, Birgitta, 2512
 Strap, Janice L., 890, 1208, 1347
 Strässle, Anni, 566, 1367
 Stratton, Charles W., 440
 Strauss, H. William, 2286
 Strie, F., 2850
 Stuhmiller, Louise M., 2025
 Stutman, Harris R., 255
 Su, W. J., 1332
 Su, Yan A., 769
 Sullivan, Gail W., 39, 408, 2584
 Sumita, Yoshihiro, 1577
 Summanen, Paula, 1658

Sunagawa, Makoto, 1577
 Sundar, Latha, 2645
 Sundelof, J. G., 607
 Suomalainen, Kimmo, 227
 Susaengrat, Watanachai, 158
 Suzuki, Eiko, 429
 Suzuki, Hitoshi, 1432
 Swan, S. K., 2556
 Sweeney, Kevin, 651, 2758
 Sweep, C. G. J. (Fred), 2785
 Swenson, Cheryl L., 2715
 Swenson, Jana M., 2176
 Szczecz, George M., 934

Taburet, A. M., 1519
 Taburet, Anne-Marie, 1821
 Tachizawa, Haruo, 966
 Takahashi, Yoshikazu, 492
 Takahata, Masahiro, 2030
 Takeuchi, Hideo, 1580
 Takeuchi, Tomio, 492
 Tallan, Barbara M., 56
 Tally, F. P., 2766
 Tan, James S., 1400
 Tanaka, Mayumi, 1491, 2595
 Tanaka, Shigenori, 1460
 Tanio, Tomoharu, 1577
 Tasset, Chantal, 1525
 Tatara, Osamu, 167
 Tateda, Kazuhiro, 1198, 1922
 Täuber, Martin G., 2693
 Tawara, Shuichi, 17
 Taylor, Charlene, 2245
 Taylor, G. W., 1236
 Taylor, Shirley, 2342
 Teal, M. A., 1832
 Tellier, R., 1619
 Tenney, James, 552
 Tenover, Fred C., 712, 2176
 Terashima, Masazumi, 1290
 Terpenning, Margaret S., 2533
 Teutsch, G., 1756
 Tharpe, William N., 172
 Then, Rudolf, 2825
 Thom, Edna, 2286
 Thompson, Gary A., 115
 Thomson, Kenneth S., 1877
 Thornber, D., 1928, 2360
 Thornber, Dawn, 2197
 Tidwell, Richard R., 1825
 Tilles, Jeremiah G., 425
 Tillman, Jill, 1703
 Tobe, Takayoshi, 1483
 Tobia, A. J., 860
 Todd, Neil, 1981
 Tokiwa, Hiroshi, 1810
 Tokue, Yutaka, 6
 Tolchinsky, S., 2316, 2322
 Tolman, Richard L., 2020
 Tomao, Paola, 95
 Tomasz, Alexander, 886
 Tomioka, H., 387
 Tomizawa, Hiroshi, 2108
 Tommasi, Paola, 1499
 Tomono, Kazunori, 1198
 Tong, William P., 1472
 Tordo, Noel, 1750
 Torley, L. W., 1971
 Torres, H., 2529
 Toscano, John P., 2334
 Totsuka, Kyōichi, 757
 Toulouse, André, 955
 Toyer, Barbara, 206

Trainor, C., 1648
 Tramarin, Andrea, 2192
 Trieu-Cuot, Patrick, 463, 502
 Troetel, William M., 1296
 Troke, Peter F., 1805
 Trouvin, Jean-Hugues, 2462
 Truffot-Pernot, C., 548
 Truffot-Pernot, Chantal, 2104, 2408, 2839
 Trujillo, Gloria, 1028
 Tsang, M., 2544
 Tsiang, Henri, 1750
 Tubbs, H. J., 1764
 Tullus, Kjell, 989
 Tully, Joseph G., 870
 Tuneyall, G., 2766
 Turcotte, André, 2211
 Turner, L. F., 1764
 Turrell, Corrine, 2349
 Tuttle, Joel V., 2686

Uematsu, T., 762
 Uezumi, Ikuko, 1290
 Uitto, Veli-Jukka, 227
 Umezawa, Keiichi, 188
 Unger, Clemens, 1630

Vaara, Martti, 826
 Väärälä, Marita, 1086
 Vadillo, Santiago, 198
 Vainio, Unto, 163
 Valentine, Fred T., 1280
 Valle, Jorge, 198
 Vallee, Eric, 2698
 Vallée, Éric, 1412
 Vallée, François, 2085
 Vallois, Jean-Marie, 1883, 2216, 2403, 2611
 van Barneveld, Peter W. C., 1456
 Vance-Bryan, Kyle, 2334
 Vandamme, Anne-Mieke, 2628
 van den Bosch, Henk, 2025
 Vanden Bossche, Hugo, 2602
 Vandenbunder, J., 1606, 1859
 Van der Auwera, P., 521, 1302, 2014
 van der Horst, Charles, 1773
 Van der Linden, M. P., 46
 van der Meer, Jos W. M., 1, 2785
 Van de Velde, Vera, 2661
 Van Eemeren, K., 100
 van Furth, Ralph, 1225, 2375
 van Heijenoort, J., 77, 1487
 Vanmiddlesworth, F., 1648
 van Nickerk, E., 1236
 Vannier, Ann M., 1766
 van Ogtrop, Marc L., 2375, 2439
 Van Rensburg, Constance E. J., 2729
 Van Rompay, Koen K. A., 2381
 van Someren, Petri, 1782

van Strijen, Elisabeth, 2375, 2439
 Van't Wout, Jan W., 1225
 van Wijk, Gijsbert M. T., 2025
 van Winkelhoff, A. J., 2634
 Varaldo, Pietro E., 331
 Varga, L. L., 2447
 Vargas, Ofelia M., 255
 Vargas, Ramon, 308
 Varner, Laura M., 854
 Varon, M., 2316, 2322
 Vaz Pato, Maria Vitoria, 886
 Veber, Benoit, 2698
 Vékey, Karoly, 1744
 Velazquez, Sonsoles, 1073
 Venditti, Mario, 723
 Venitz, J., 938
 Venuti, Elaine, 1563
 Verdonck, L. F., 801
 Verhaeghe, B., 1606
 Verhoeft, J., 801
 Verhoeft, Jan, 2458
 Vial, Henri J., 50
 Victor, Gary, 1032
 Vidal, Pedro, 1472
 Vidal, Pedro M., 808
 Viganò, Alessandra, 1499
 Vilde, Jean-Louis, 2104
 Vilde, Jean-Louis, 2408
 Villa, Anna Dalla, 1499
 Villemot, J. P., 2493
 Vincent, Sophie, 1392
 Viner, K. Claire, 733
 Viron, B., 1519
 Visser, Maarten R., 1456
 Vogels, Maria T. E. I., 2785
 von Graevenitz, Alexander, 2835
 Vuorio, Riitta, 826

Wacharatayankun, Rochaporn, 1460
 Wachsmuth, I. Kaye, 717
 Wagener, Marilyn M., 2639
 Wagle, N., 2552
 Wagner, Jutta, 783
 Wahren, B., 2418
 Waits, V. B., 1978
 Wakebe, Hirokazu, 2185
 Walbaum, S., 191
 Wald, Ellen R., 545
 Walker, Clay B., 740
 Walker-Cador, Janice Y., 647
 Wallace, Jack E., 603, 2790
 Wallace, Richard J., III, 180
 Wallace, Richard J., Jr., 180, 1987
 Walsh, Christopher T., 867, 1514
 Walsh, Thomas J., 1805
 Walters, Ruth N., 819
 Walzer, Peter D., 1935, 1943
 Wang, Laurene H., 299
 Wang, Lotte, 687
 Wang, Sha-ke, 1478

Wanger, Audrey R., 1325
 Warbasse, Lawrence H., 1204
 Warnock, David W., 1805
 Warren, M. M., 2552
 Warren, Reed P., 473
 Watanabe, Akira, 6
 Watanabe, Kyoichi A., 808
 Watanabe, Masato, 684
 Watanabe, Nao-Aki, 589
 Wegener, Henrik C., 580
 Weidler, Donald J., 552
 Weigl, Debra, 81
 Weinbaum, David, 2639
 Weinberg, Adriana, 2037
 Weinstein, John N., 926
 Weiss, Peter J., 2542
 Welker, Horst A., 632
 Welsh, Laura E., 291
 Wennersten, C. B., 2201, 2526
 Wennersten, Christine, 121
 Wenzel, Richard P., 873
 Werbovetz, Karl A., 495
 Werner, M., 2847
 Westenborghs, Robert, 2661
 Westphal, Jean-Frédéric, 2462
 Wexler, Hannah M., 239, 1658
 Wheeler, Rebecca R., 620
 White, Michael, 1935, 1943
 Wichstrøm, Reidun, 1738
 Wideburg, Norman, 81
 Wiedemann, Bernd, 1915
 Wientjes, M. Guillaume, 665
 Wignall, F. S., 277, 1682
 Wilairat, Prapon, 1644
 Wilber, R. B., 938, 962
 Wilkinson, Brian J., 566
 Willard, Keith E., 1166
 Willebrods, R., 100
 Wilson, D. S., 2447
 Wilson, Jeanne, 2423
 Wilson, Lawrence J., 2686
 Wilson, R., 1236
 Wilson, Samuel Z., 1466
 Wilson, Walter R., 56, 1272
 Wise, R., 1002, 1171, 1176, 1928, 2360, 2444
 Wise, Richard, 2197
 Wissner, A., 1971
 Withers, Shawn, 1040
 Witte, Wolfgang, 783
 Witvrouw, Myriam, 2628
 Wolfgang, Jill A., 1441
 Wolfson, John S., 1151
 Wolny, James D., 318
 Wong, Edward S., 1125
 Wong, M. O., 1832
 Woodnutt, Gary, 1427
 Woodworth, James R., 318
 Wörmann, Bernhard, 2139
 Wren, Cathie G., 2037
 Wretlind, B., 2766
 Wright, Gerard D., 867, 1514
 Wu, C. Y. Ernie, 533
 Wurster, J. A., 2686
 Wyde, Philip R., 1466

Yajko, David, 2808
 Yajko, David M., 1163
 Yamaguchi, Hideyo, 2523
 Yamaguchi, Keizo, 573, 1198, 1922
 Yamamoto, Naohiko, 2628
 Yamamoto, Naoki, 1249
 Yamamoto, S., 762
 Yamamoto, Sadao, 757, 1219
 Yamamura, Ken-Ichi, 2042
 Yamane, T., 387
 Yamashita, K., 387
 Yamashita, Yoshinori, 2589
 Yamazaki, Toshiyuki, 1358, 2481
 Yang, Youjun, 1155
 Yarlett, Nigel, 2736
 Yarosh-Tomaine, Taisa, 64, 498
 Yasuda, Takashi, 2030
 Yasue, Tokutaro, 2108
 Yates, R. R., 217
 Yatsu, J., 1764
 Yeaman, Michael R., 1665
 Yeni, Patrick, 262, 1799, 2722
 Yeola, Suresh, 672
 Yetman, Robert, 1614
 Yokokura, Teruo, 361
 Yokoo, Mamoru, 2523
 Yokota, Takeshi, 429, 1715
 Yoneyama, Hiroshi, 1791
 Yoshida, Osamu, 1580
 Yoshida, T., 762
 Yoshihara, Eisaku, 1791
 Yoshikai, Yasunobu, 361
 Yoshimura, Yohko, 1219
 Yoshioka, Mariko, 966
 Young, John, 2349
 Young, Michele, 2365
 Young, Michele L., 2566
 Young, Robert D., 704
 Yourassowsky, E., 46
 Yu, Victor L., 620, 2639
 Yuen, Geoffrey J., 1280

Zaccardelli, David, 1387
 Zaidi, Akbar A., 1639
 Zak, Oto, 2693
 Žakelj, J., 2850
 Zambias, R., 1964
 Zamora, P., 2816
 Zanol, Margherita, 1744
 Zarlenga, Liana J., 902
 Zemcov, S. Janet V., 2197
 Zerilli, Luigi F., 1744
 Zervos, Marcus J., 1032
 Zhanell, George G., 1136
 Zhong, Min, 470
 Zhu, Qing-Yu, 808
 Zighelboim-Daum, Sonia, 121
 Zimmerman, Thomas P., 283
 Zollinger-Itten, Jacqueline, 2835
 Zorza, Grégoire, 1821
 Zuabi, T., 677
 Zühsdorf, Michael T., 1915
 Zygmunt, Deborah J., 440

SUBJECT INDEX

VOLUME 36

aac(6')-Ic
S. marcescens
aminoglycoside resistance, 1447
characterization of, 1447

aac(3)-Vb
S. marcescens
cloning and sequence analysis, 2222

Acanthamoeba polyphaga
magainins
ameba and cyst stages, effects on, 1256

Acridines
antiparasitic agents, 1644
P. falciparum, 1644
T. lewisi, 1644

Actinobacillus actinomycetemcomitans
aztreomycin
comparative evaluation, 1241

erythromycin
comparative evaluation, 1241
in vitro susceptibilities
antibiotic combinations, 2634

Active efflux mechanisms
minireview, 695

Acyclovir
combinations
herpes simplex virus, 934
inactivators of herpes simplex virus
ribonucleotide reductase, 934

herpes simplex virus
type 1, 2037
type 2, 2037

pharmacokinetics
distribution over blood-brain barrier, 339
rats, 339

Aeromonas salmonicida
oxytetracycline
temperature-dependent activity, 1738

4-quinolones
temperature-dependent activity, 1738

Agar dilution
B. fragilis group
antimicrobial susceptibilities, 195

foot rot
antimicrobial susceptibilities, 198

AM-1155
in vitro and in vivo activities
comparative evaluation, 2108

Amikacin
cefepime
pharmacokinetic interaction, lack of, 1382

combinations
aztreonam, 2741
cefepime, 2741
ceftazidime, 2741, 2808
clarithromycin and ciprofloxacin, 1567
clindamycin, 2014
comparative evaluation, 2808
febrile neutropenic patients with cancer, 2808

M. avium-*M. intracellulare* complex, 1567
major head and neck surgery in cancer patients, prophylaxis, 2014

P. aeruginosa, 2741
piperacillin, 2808

E. coli
postantibiotic sub-MIC effects, 1852

P. aeruginosa

postantibiotic sub-MIC effects, 1852

pharmacokinetics
cefepime, lack of interaction with, 1382

R. equi, 1244
resistance in a neonatal unit, 1596

Amino acids
Enterococcus resistance to vancomycin
effects on expression, 902

9-Aminoacridines
Leishmania spp.
cytotoxicity for promastigotes, 495

Aminoglycosides
computer-assisted dosing, 1230

E. cloacae
factors affecting in vivo activity, 744

E. faecium resistance
β-lactamase-producing strain, 1125

endocarditis
factors affecting in vivo activity, 744

Enterococcus resistance
ampicillin, continuous intravenous versus intermittent therapy, 1263

modifying enzymes
β-lactamase-harboring isolates, 2536

S. marcescens
factors affecting in vivo activity, 744

S. marcescens resistance
aac(6')-Ic, characterization of, 1447
aac(3)-Vb, cloning and sequence analysis, 2222

synergy
endocarditis, 2403
optimal dosing regimen, 2403

penicillin, 2403

S. adjacens, 2403

transfected prokaryotic and eukaryotic cells
increased susceptibility, 1782

Amoxicillin
bronchitis
5-day course, 1456
acute exacerbations of, 1456
comparative evaluation, 1456

combinations
BRL 42715, 1140
clavulanate, 1140, 1785
clavulanic acid, 1794
gram-negative organisms, 1140

H. pylori, metronidazole resistant, 163

K. rhinoscleromatis, 1785
metronidazole and bismuth subcitrate, 163

salmonellae, ampicillin resistant, 1794

comparative evaluation
erythromycin, minocycline, ampicillin, cefixime, metronidazole, and bismuth subcitrate, 185

gram-negative organisms, 1140

H. pylori
slowly growing, 185

high-performance liquid chromatography
bovine plasma, determination in, 1859
potency determination, 1272
tandem solid-phase extraction method, 1859

pharmacokinetics
enzyme-linked immunosorbent assay, use to assess, 1545
penetration into lung secretions, 1545

pneumonia

community acquired, 833
comparative evaluation, 833
efficacy and safety, 833

Amphotericin B
aggregation state
toxicity, effect on, 2310

C. albicans
endothelial cells, interaction with, modulation of, 2239

cholesterol dispersion
leishmaniasis, visceral, 1978

colloidal dispersion
deoxycholate suspension, comparative evaluation, 486, 2656
distribution in tissue, relationship to safety, 299

murine cryptococcosis, 2656
pharmacokinetics, relationship to safety, 299

deoxycholate suspension
colloidal dispersion, comparative evaluation, 486, 2656

effect on neutrophil function, 39

murine cryptococcosis, 2656

derivatives
MS-8209, activity against systemic mycoses, 2722

flucytosine
nephrotoxicity, effects on, 2670

human mononuclear cells
interleukin-1 expression, pharmacologic modulation, 977

immunoglobulin G
C. albicans infection in burned mice, 643

lipid complex
effect on neutrophil function, 39

liposomal
C. neofmans, 1466
pulmonary and systemic infections, 1466

nephrotoxicity
different formulations, comparative evaluation, 1525

flucytosine, acute and chronic effects of, 2670

neutrophils, activation of
modulation by pentoxifylline, 408

phospholipid type
influence on renal cell toxicity and fungicidal activity, 262

phospholipid/amphotericin B ratio
influence on renal cell toxicity and fungicidal activity, 262

toxicity
aggregation and solvent, effects on, 2518

effect of aggregation state on, 2310

infusion rates, effect of, 172, 2573

letter to the editor, 2573

ventricular dysrhythmias
1-hour infusions in patients with preserved renal function, 2542

Ampicillin
B. fragilis group, 2051

combinations
B. fragilis group, 2051
E. faecium, vancomycin and ampicillin resistant, 1563

endocarditis, 1864

Enterococcus spp., penicillin resistant,

1864
 gentamicin, 1864
 major head and neck surgery in cancer patients, prophylaxis, 2014
 pharmacokinetics, 2233
 subbactam, 2014, 2051, 2233
 vancomycin and gentamicin, 1563
 comparative evaluation
 erythromycin, minocycline, amoxicillin, cefixime, metronidazole, and bismuth subcitrate, 185
 endocarditis
 continuous intravenous versus intermittent therapy, 1263
Enterococcus resistance
 emergence and nosocomial transmission, 1032
Enterococcus spp.
 aminoglycoside resistant, 1263
Enterococcus spp., highly vancomycin resistant
 vancomycin, absence of synergy, 2201
Enterococcus susceptibility
 gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
H. pylori, 1133
 slowly growing, 185
 high-performance liquid chromatography
 improved determination, 1606
 tandem solid-phase extraction method, 1606
L. monocytogenes
 comparative evaluation, 2375
 hydrocortisone-treated mice, 2375
N. meningitidis susceptibility
 discrimination between moderately and fully susceptible isolates, 1028
 pharmacokinetics
 2085P, after oral administration of, 1002
 liver transplant patients, 2125
 prophylaxis
 liver transplant patients, 2125
 Anaerobic organisms
 antimicrobial susceptibilities, 198
 CI-960
 comparative evaluation, 1158
 CI-990
 comparative evaluation, 1158
 ciprofloxacin
 comparative evaluation, 1158
 foot rot, ovine
 antimicrobial susceptibilities, 198
 ofloxacin
 comparative evaluation, 1158
 sparfloxacin, 239
 comparative evaluation, 1158
 temafloxacin, 239
 comparative evaluation, 1158
 WIN 57273, 239
 comparative evaluation, 1158
 Angiotensin II
 cefonidic
 effect on clearance in rat kidneys, 616
 Animal models
 synergy, *in vivo*
 minireview, 907
 Antacids
 DR-3355
 pharmacokinetics, effect on, 2270
 lomefloxacin
 effect of antacid on, 1219
 pharmacokinetics
 DR-3355, effect on, 2270
 Antibodies
P. aeruginosa
 monoclonal, antiflagellar, in combination with antibiotics, 1290
 sparfloxacin, combination with, 1352
 Anticancer agents
 acridines
 possible antiparasitic agents, 1644
 Anticoccidial agents
in vivo expression of *in vitro* activity, 2338
 Antifolate agents
P. carinii
 rat model, 1935
 pneumonia
P. carinii, 1935
 Antifungal agents
C. albicans
 turbidimetric method, 898
Candida spp.
 susceptibility testing, 1727
 L-646,991, 1648
 L-671,329, 1648
 L-687,781, 1648
 susceptibility testing
Candida spp., 1727
 endpoint determination system, 1619
 tetrahydroechinocandin B, 1648
 toxicity
in vitro models, 1799
 minireview, 1799
 Antileishmanial agents
 drug targeting
 polymers internalized by macrophages, 2228
 Antimycobacterial agents
 susceptibility testing
 stability in, 2398
 Antipyrine
 pharmacokinetics
 rifampin, 2- and 4-day regimens, effect of, 1553
 Antiviral agents
 cytomegalovirus
 novel method for evaluation, 206
 ginkgetin
 herpes simplex virus, 1890
 mechanism of action, 1890
 hepatitis B virus
 inhibition of replication, 2042
 mouse model, novel transgenic, 2042
 herpesvirus resistance
 minireview, 1589
 human immunodeficiency virus
 protease inhibitors, 982
P. carinii
 rat model, 1935
 pneumonia
P. carinii, 1935
 retroviruses
 minireview, 509
aphA-7
 kanamycin resistance
C. jejuni, 712
 characterization of plasmid, 712
 1- β -D-Arabinofuranosyl-E-5-(2-bromovinyl)luracil
 combinations
 anticancer nucleosides, 214
 anti-human immunodeficiency virus agents, 214
 azidothymidine, 214
 human immunodeficiency virus, 214
Aspergillus
 pulmonary
 MS-8209, 2722
 saperconazole
 comparative evaluation, 2681
 oral and intravenous, 2681
Aspergillus fumigatus
 saperconazole
 comparative evaluation, 2681
 oral and intravenous, 2681
Aspergillus niger
 topoisomerase
 targets for discovery of antifungal agents, 2778
 Autolysis
S. aureus
 methicillin resistant, 566
 methicillin susceptible, 566
 3'-Azido-3'-deoxythymidine
 cellular transport
 comparative evaluation, 808
 2',3'-dideoxyinosine
 pharmacokinetic interaction, lack of, 665
 high-pressure liquid chromatography-radioimmunoassay
 intracellular concentrations, measurement of, 2473
 human immunodeficiency virus
 comparative evaluation, 808
 human immunodeficiency virus resistance
 suppression by mutation conferring resistance to reverse transcriptase inhibitors, 2664
 pharmacokinetics
 comparative evaluation, 808
S. typhimurium
 intracellular activity, 1081
 simian immunodeficiency virus
 rhesus macaques, 2381
 3'-Azido-3'-dideoxythymidine
 feline leukemia virus
 pre- and postexposure chemoprophylaxis, 2715
 3'-Azidothymidine
 simian immunodeficiency virus
 long-term tolerance and efficacy, 1770
 Azithromycin
A. actinomycetemcomitans
 comparative evaluation, 1241
 AIDS patients
 tolerability, pharmacokinetics, and effect on zidovudine disposition, 1013
 bronchitis
 3-day course, 1456
 acute exacerbations of, 1456
 comparative evaluation, 1456
C. pneumoniae, 291, 1573
C. trachomatis, 291
 elementary body formation, block of, 2304
 combinations
 clarithromycin, 1611
 comparative evaluation, 1611
 rifampin, 2693
 staphylococcal osteomyelitis, 2693
 comparative evaluation
 erythromycin, clarithromycin, and roxithromycin, 180

H. influenzae
lung infection, 1412

H. pylori, 1133

inhibitory activity in presence of human serum, 10

intraleukocytic accumulation
in vitro and in vivo, 1302

M. avium
comparative evaluation, 1611

M. chelonae, 180

M. chelonae-like organisms, 180

M. fortuitum, 180

osteomyelitis
comparative evaluation, 2693
concentration in bone and efficacy,
relationship between, 2693
staphylococcal, 2693

pharmacokinetics
AIDS patients, 1013
lung, 1412
uptake by phagocytes, 1412

serum protein binding, 10

synergy
pyrimethamine, 997
sulfadiazine, 997
toxoplasmosis, 997

T. gondii, 997

tolerability
AIDS patients, 1013
toxoplasmosis, 997

U.S. FDA approval, 1584

zidovudine
effect on disposition, 1013

Azoles
C. glabrata resistance
characterization of isolate, 2602

combinations
C. albicans, 1284
nukomycins, 1284

pharmacokinetics
effect of cyclodextrin, 477

synergy
C. albicans, 1284
nukomycins, 1284

Aztreonam
combinations
amikacin, 2741
P. aeruginosa, 2741

salmonellae
ampicillin resistant, 1794

B669
lysophospholipids
mediators of antimicrobial activity,
2729

Bacillus subtilis
multidrug efflux transporter Bmr
homolog of *Staphylococcus* NorA, 484

Bacitracin
renovascular effects, 955

Bacteremia
daptomycin, 1109
erythromycin, 1198

Klebsiella spp.
combination versus monotherapy,
2639

P. aeruginosa
erythromycin, 1198
rifampin-beta-lactam-aminoglycoside
therapy, 620

vancomycin, 1109

Bacteroides fragilis
antimicrobial susceptibilities, in vitro
agar dilution method, 195

beta-lactamases
CcrA, biochemical characterization,
1155

Bacteroides fragilis group
cefoxitin
correlation of in vitro testing with clin-
ical outcome, 540

in vitro susceptibilities, 2051

susceptibility patterns
Canada, 343

Bacteroides spp.
tetracycline resistance
ribosome protection gene, 1005

Bacteroides vulgaris
clindamycin resistance, ribosomal
inducible expression, 639

BCH-189
human immunodeficiency virus type 1
activities of the four optical isomers,
672

inhibition of replication, 202

Benzimidazoles
P. carinii
antimicrotubule activity, 779

Benzoxazinorifamycins
KRM-1648
M. avium complex, 387

Benzylamines
butenafine
interdigital tinea pedis, reduction of
relapse rate, 2523

B-Lactamase inhibitors
sulfones
CO₂ and pH, effect on inhibition, 1870

B-Lactamases
B. fragilis
CcrA, biochemical characterization,
1155

Capnocytophaga spp.
characterization, 2197

CAZ-2
nucleotide sequence, 1817

CAZ-6
nucleotide sequence, 1817

CAZ-7
nucleotide sequence, 1817

ceftazidime resistance
outbreak in cancer patients, 1991

E1077
affinity for, 589

susceptibility to hydrolysis, 589

E. coli
epidemiology, 989

relation to antimicrobial therapy, 989

E. corrodens
partial Tn3 transposon, 740

E. faecalis
incorporation into a transposon de-
rived from staphylococci, 1843

E. faecalis, gentamicin resistant
intrahospital spread, 230

E. faecium
aminoglycoside resistant, 1125

Enterobacter spp.
epidemiology, 989

relation to antimicrobial therapy, 989

Enterobacteriaceae
three-dimensional versus double-disk
tests, 1877

Enterococcus spp.
minireview, 2355

Staphylococcus spp., comparison, 273

extended spectrum
aminoglycoside-modifying enzymes in
isolates harboring, 2536

H. ducreyi, 467

plasmid content, correlation with anti-
microbial susceptibility, 1639

Klebsiella spp.
epidemiology, 989

relation to antimicrobial therapy, 989

LJC 10,627
stability of, 1418

M. fortuitum, 1068

P. aeruginosa
activity in sputum samples from cystic
fibrosis patients, 71

imipenem resistant, 2046

impermeability, association with, 2046

ROB-1

H. ducreyi, 467

S. aureus
characterization, 440

WIN 57273, inhibitory activity, 894

S. aureus repressor gene
homology with enterococci, 2265

sequence analysis, 2265

Staphylococcus spp.
Enterococcus spp., comparison, 273

sulfones
CO₂ and pH, effect on inhibition, 1870

TEM-12
transposition of gene encoding, 1981

Y. enterocolitica
ampC-ampR nucleotide sequence,
1049

B-Lactams
combinations
E. coli, 2166

siderophores, 2166

continuous infusion
minireview, 2577

E1040
P. aeruginosa, imipenem resistant,
684

E. coli
effect of inoculum size on bacteriolytic
activity, 223

siderophore conjugates, mechanism of
action, 2166

Enterobacteriaceae resistance, 1677

H. influenzae
peptidoglycan metabolism, effect on,
2147

H. influenzae resistance
molecular basis, 1504

non-beta-lactamase mediated, 1504

M. fortuitum resistance
beta-lactamases, 1068

penicillin-binding proteins, 1068

Methylobacterium spp.
susceptibility testing, 1635

pharmacokinetics
continuous infusion, 2577

minireview, 2577

RU44790
in vitro activity, 1756

V. cholerae
interaction, novel features of, 788

V. cholerae resistance, 788

Biflavones
ginkgetin
herpes simplex virus, 1890

mechanism of action, 1890
Bilophila wadsworthia
 susceptibility testing
 triphenyltetrazolium chloride, end-point determination, 1658
Bioavailability
 cefixime
 nifedipine, effect on, 2462
 ceftazidime
 patients with pneumonia, 1404
 ciprofloxacin
 aluminum hydroxide, effect on, 830
 calcium carbonate, effect on, 830
 cystic fibrosis patients, 2512
 clarithromycin
 oral administration in humans, 1147
epithelial cells
 intestinal transport of antimicrobial agents, use as a model for, 1374
 rifampin
 letter to the editor, 2066
 murine tuberculosis, 2066
Biofilms
 mechanisms of bacterial resistance
 minireview, 1347
P. aeruginosa
 piperacillin, barrier to diffusion, 2054
Biologics
 U.S. FDA approvals, 1584
Bismuth
 subcitrate
 combinations
H. pylori, metronidazole resistant, 163
 metronidazole and amoxicillin, 163
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, cefixime, and metronidazole, 185
H. pylori
 slowly growing, 185
Blastomyces dermatitidis
 itraconazole-macrophages
 synergy, 2487
[*S*-methyl-³H]Bleomycin A₂
S. cerevisiae
 lesions and preferential initial localization on cell walls, 2497
Borrelia burgdorferi
 cefaclor
 comparative evaluation, 1788
 cefadroxil
 comparative evaluation, 1788
 cefixime
 comparative evaluation, 1788
 ceftriaxone
 comparative evaluation, 1788
 cefuroxime
 comparative evaluation, 1788
 cephalexin
 comparative evaluation, 1788
BRL 42715
 combinations
 amoxicillin, 1140
 cefazolin, 1427
E. coli, 1427
 gram-negative organisms, 1140
 piperacillin, 1427
S. marcescens, 1427
pharmacokinetics
 rats, 1427
Brobactam
pharmacokinetics
 2085P, after oral administration of, 1002

7-Bromo-*N*-(2-imidazolidinylidene)-1*H*-indazol-6-amine
 anticoccidial activity, 368, 372
E. tenella
 chickens, 368, 372
Bronchitis
 amoxicillin
 5-day course, 1456
 comparative evaluation, 1456
 azithromycin
 3-day course, 1456
 comparative evaluation, 1456
Broprimine
 cytomegalovirus
 severe combined immunodeficient mice, 1837
Brucella melitensis
 ciprofloxacin, 150, 973
 co-trimoxazole, 973
 doxycycline, 973
 ofloxacin, 973
 pefloxacin, 973
 rifampin, 973
 streptomycin, 973
Brucellosis
 ciprofloxacin, 973
 co-trimoxazole, 973
 doxycycline, 973
 ofloxacin, 973
 pefloxacin, 973
 rifampin, 973
 streptomycin, 973
Butenafine
 tinea pedis, interdigital relapse rate reduction, 2523
Campylobacter butzleri
 susceptibilities, in vitro, 717
Campylobacter coli
 antimicrobial susceptibility
 10-year follow-up report, 2847
Campylobacter cryaerophila
 susceptibilities, in vitro, 717
Campylobacter jejuni
 antimicrobial susceptibility
 10-year follow-up report, 2847
R plasmids
aphA-7 kanamycin resistance determinant, 712
 characterization, 712
Campylobacter spp.
 aerotolerant
 antimicrobial susceptibilities, in vitro, 717
Candida albicans
 adherence
 arginine-glycine-aspartic acid containing, effect of, 132
 amphotericin B
 endothelial cells, interaction with, modulation of, 2239
 antifungal agents
 turbidimetric method, 898
 chitin biosynthesis, 1909
 nikkomycin Z, inhibition by, 1909
 cilofungin
 rabbits, 56
 fluconazole, 64
 endothelial cells, interaction with, modulation of, 2239
 fluconazole-interleukin-1, 1225
 hydrogen peroxide
 increased sensitivity after growth with sub-MIC concentrations of clotrimazole, 1626
 immunoglobulin G-amphotericin B
 burned mice, 643
 ketoconazole, 64
 L-646,991, 1648
 L-671,329, 1648
 L-687,781, 1648
 MS-8209, 2722
 naftifene, 1779
 nikkomycin Z
 chitin biosynthesis, inhibition of, 1909
 nikkomycin-azole combinations
 synergistic activity, 1284
 SCH 39304, 64
 SCH 42427, 498
 SDZ 87-469, 1779
 squalene epoxidase inhibitors, 1779
 terbinafine, 1779
 tetrahydroechinocandin B, 1648
 tolciclate, 1779
 tolnaftate, 1779
 topoisomerase I
 drug discovery, target for, 2131
 topoisomerasomes
 targets for discovery of antifungal agents, 2778
Candida glabrata
 azole resistant
 characterization of, 2602
Candida spp.
 susceptibility testing
 relative growth measurement, 1727
Candidiasis
 cilofungin
 rabbits, 56
 fluconazole-interleukin-1, 1225
 MS-8209, 2722
 nikkomycin-azole combinations
 synergistic activity, 1284
Capnocytophaga spp.
 antimicrobial susceptibilities, 2197
β-lactamases
 characterization, 2197
Carbapenems
 L-627
 in vitro activity, 1928
P. aeruginosa, 1928
 LJC 10,627
β-lactamase stability, 1418
 comparative evaluation, 1418
 gram-negative organisms, 1418
 gram-positive organisms, 1418
 renal dehydropeptidase-I stability, 481
 panipenem-betamipron
 pharmacokinetics, prediction from animal data, 1810
Carboxypeptidases
Enterococcus spp., activity in vancomycin inducible, 77
Cefaclor
B. burgdorferi
 comparative evaluation, 1788
 comparative evaluation
 cefdinir, 46
H. influenzae
 kill and growth rates, 46
 molecular basis of efficacy, 2569
S. pneumoniae
 kill and growth rates, 46

Cefadroxil
B. burgdorferi
 comparative evaluation, 1788
 skin infections
 children, 1614
S. aureus, 1614
S. pyogenes, 1614

Cefazolin
 combinations
BRL, 42715, 1427
E. coli, 1427
S. marcescens, 1427
 pharmacokinetics
 rats, 1427

Cefdinir
 comparative evaluation
 cefaclor, 46
H. influenzae
 kill and growth rates, 46
S. pneumoniae
 kill and growth rates, 46

Cefepime
 amikacin
 pharmacokinetic interaction, lack of, 1382
 bactericidal activity, 453
 combinations
 amikacin, 2741
P. aeruginosa, 2741
E. coli
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 pharmacokinetics
 age and gender, effects of, 1181
 amikacin, lack of interaction with, 1382
 patients on continuous ambulatory peritoneal dialysis, 1387
 serum and blister fluid, 453
 single and multiple intravenous administrations, 552
 subjects with renal impairment, 2676

Cefetamet pivoxil
 syphilis
 rabbits, 598
T. pallidum, 598

Cefixime
B. burgdorferi
 comparative evaluation, 1788
 bioavailability
 nefedipine, effect on, 2462
C. difficile
 correlation of presence in feces, 2009
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, metronidazole, and bismuth subcitrate, 185
H. pylori, 1133
 slowly growing, 185
 pharmacokinetics
 bioavailability, effect of nifedipine on, 2462

Cefmenoxime
 combinations
K. pneumoniae, 167
 romurtide, synergy, 167
 pharmacokinetics
 concentrations in sera and peritoneal tissues, 1483
 patients undergoing gastrointestinal surgery, 1483

Cefminox
E. coli
 effect of inoculum size on bacteriolytic activity, 223

Cefonicid
 clearance in rat kidneys
 angiotensin II-induced alterations in renal flow, 616

Cefoperazone
 bactericidal activity, 453
 cancer patients, bacterial isolates from comparative evaluation, 879
 pharmacokinetics
 serum and blister fluid, 453
 tissue penetration model, 295

Cefoperazone-sulbactam
 disk diffusion tests
 new disk, development of, 394

Cefotaxime
E. coli
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
Enterobacteriaceae resistance, 1677
 pharmacokinetics
 liver transplant patients, 2125
 prophylaxis
 liver transplant patients, 2125
S. pneumoniae resistance, high level characterization of isolate, 886
salmonellae
 ampicillin resistant, 1794

Cefotetan
B. fragilis group, 2051
 pharmacokinetics
 patients undergoing colorectal surgery, 1115
 serum and blister fluid, 2233
 single dose, 1115

Cefoxitin
B. fragilis group, 2051
 correlation of in vitro testing with clinical outcome, 540
 pharmacokinetics
 serum and blister fluid, 2233

Cespirome
 bactericidal activity, serum
 comparative evaluation, 2085
 pharmacokinetics
 comparative evaluation, 2085

Cefpodoxime
K. rhinoscleromatis, 1785

Cefpodoxime proxetil
C. difficile
 correlation of presence in feces, 2009
N. gonorrhoeae
 urethritis, 1764
 pharmacokinetics, 796
 effect of antacid and H₂-receptor antagonist on absorption, 796
 healthy volunteers, 126
 patients with impaired renal function, 126
 penetration into lung parenchyma and epithelial lining fluid, 2099
 urethritis, 1764

Cefprozil
 absolute bioavailability
 beagles, 687
 bioavailability
 antacid, effect of, 962
 excretion in human breast milk, 938
 intestinal flora, effect on, 144
 pharmacokinetics, 938

antacid, effect of, 962
 beagles, 687
 multiple dosing, 144

Ceftazidime
 bactericidal activity, 453
 bactericidal activity, serum
 comparative evaluation, 2085
 bioavailability
 patients with pneumonia, 1404
 cancer patients, bacterial isolates from comparative evaluation, 879
 combinations
 amikacin, 2741, 2808
 chloramphenicol-doxycline-co-trimoxazole, comparative evaluation, 158
 comparative evaluation, 2808
 co-trimoxazole, 158
 febrile neutropenic patients with cancer, 2808
 melioidosis, severe, 158
P. aeruginosa, 2741
E. coli
 comparative evaluation, 2439
 in vitro and in vivo, 2439

E. coli resistance
 β-lactamase, extended spectrum, 1991
 cancer patients, 1991
 febrile neutropenic patients
 vancomycin, not necessary for initial treatment, 1062

K. pneumoniae resistance
 β-lactamase, extended spectrum, 1991
 cancer patients, 1991
P. aeruginosa, 1580
P. mirabilis, 1580
 pharmacokinetics
 comparative evaluation, 2085
 patients with pneumonia, 1404
 serum and blister fluid, 453
 resistance, outbreak of
 β-lactamase, extended spectrum, 1991
 urinary tract infections, 1580

Ceftizoxime
B. fragilis group, 2051
 pharmacokinetics
 serum and blister fluid, 2233

Ceftriaxone
B. burgdorferi
 comparative evaluation, 1788
 bactericidal activity, serum
 comparative evaluation, 2085
C. difficile
 emergence, influence on, 2850
 comparative evaluation
 imipenem, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole, 949
 meningitis, 949
N. gonorrhoeae resistance, 1682
 pharmacokinetics
 1,000 mg intravenously, 2804
 comparative evaluation, 2085
 diclofenac, effects on, 2331
 prophylaxis in thoracic surgery, 2804
 tissue penetration, 2804
 transudative and exudative pleural effusion, penetration, 2774
S. enteritidis, 949
S. pneumoniae resistance, high level characterization of isolate, 886
salmonellae
 ampicillin resistant, 1794

Cefuroxime
B. burgdorferi
 comparative evaluation, 1788
 combinations
 comparative evaluation, 801
 febrile neutropenic patients, 801
 gentamicin, 801
K. rhinoscleromatis, 1785

Cefuroxime axetil
 skin infections
 children, 1614
S. aureus, 1614
S. pyogenes, 1614

Cephalexin
B. burgdorferi
 comparative evaluation, 1788
K. rhinoscleromatis, 1785
S. aureus biofilm cells
 interaction in a chemostat system, 890

Cephalosporinases
Y. enterocolitica
ampC-ampR nucleotide sequence, 1049

Cephalosporins
 DQ-2556
 in vitro and in vivo activities, 2595
 mode of action, 2595
 pharmacokinetics, 966

E1077
 β -lactamases, susceptibility to hydrolysis by, 589
 comparative evaluation, 589
 in vitro activity, 589
 in vitro and in vivo activities, 1894

Ro 09-1227
Enterobacteriaceae, 233

RU 29246
 comparative evaluation, 2360
 in vitro activity, 2360

S-1006
 in vitro activity, 1336
 susceptibility to hydrolysis, 1336

SCE-2787
 comparative evaluation, 1358
 in vitro and in vivo activities, 1358

Cephalothin
 combinations
 comparative evaluation, 801
 febrile neutropenic patients, 801
 gentamicin, 801

Cephem antibiotics
 serum protein binding
 effect on therapeutic efficacy, 17

Cephems
P. aeruginosa resistance
 meropenem and quinolone cross-resistance, 1847
 outer membrane protein overproduction, association with, 1847

Cervical infections
 doxycycline
 comparative evaluation, 1144
 ofloxacin
 comparative evaluation, 1144

Checkerboard titration technique
A. actinomycetemcomitans
 susceptibility to antibiotic combinations, 2634

Chlamydia pneumoniae
 azithromycin, 291, 1573
 ciprofloxacin
 comparative evaluation, 682
 clarithromycin, 1573

doxycycline, 1573
 erythromycin, 291, 1573
 fleroxacin
 comparative evaluation, 682
 ofloxacin
 comparative evaluation, 682
 L-ofloxacin, 1573
 sparfloxacin
 comparative evaluation, 682
 temafloxacin
 comparative evaluation, 682
 tetracycline, 291

Chlamydia trachomatis
 azithromycin, 291
 elementary body formation, block of, 2304
 doxycycline
 cervical infection, 1144
 comparative evaluation, 1144
 erythromycin, 291
 noxynol 9
 infected HeLa 229 cells, 1478
 infected primary monkey cervical epithelial cells, 1478
 ofloxacin
 cervical infection, 1144
 comparative evaluation, 1144
 quinolones
 comparative evaluation, 188
 sparfloxacin
 comparative evaluation, 188
 in vivo and in vitro activity, 188
 tetracyclines, 291
 comparative evaluation, 188

Chloramphenicol
 combinations
ceftazidime-co-trimoxazole, comparative evaluation, 158
doxycycline-co-trimoxazole, 158
 melioidosis, severe, 158
K. rhinoscleromatis, 1785
 salmonellae
 ampicillin resistant, 1794

Chloramphenicol acetyltransferases
C. butyricum
 sequence analysis, comparative, 2548

Chloroquine
 combinations
 chlorpromazine, 209
P. falciparum, 209
 prochlorperazine, 209
P. falciparum resistance
 fluoxetine hydrochloride, enhancement of susceptibility, 2761

Chlorpromazine
 combinations
 chloroquine, 209
P. falciparum, 209

CI-960
 anaerobic bacteria
 comparative evaluation, 1158
 endocarditis, 1192
Legionella spp., 2049
S. aureus
 ciprofloxacin susceptible and resistant, 1192
 endocarditis, 1192
Staphylococcus spp.
 comparative evaluation, 851

CI-990
 anaerobic bacteria
 comparative evaluation, 1158

Clastatin
 combinations
 comparative evaluation, 2766
 effect of biliary obstruction on hepatic excretion, 2057
 imipenem, 2057, 2766
 intra-abdominal infections, 2766
 pharmacokinetics, 2057

Clofungin
C. albicans
 rabbits, 56
 candidiasis
 rabbits, 56

Cinchona alkaloids
P. falciparum
 stereochemical evaluation, 1538

Cinnamic acid
 malaria-infected cells
 permeability, effect on, 1102

P. falciparum, 1102

Ciprofloxacin
 anaerobic bacteria
 comparative evaluation, 1158
B. melitensis, 150, 973
 bactericidal activity, serum
 comparative evaluation, 2085
 bioavailability
 aluminum hydroxide, effect on, 830
 calcium carbonate, effect on, 830
 cystic fibrosis patients, 2512
 brucellosis, 973
C. burnetii, 2529
C. pneumoniae, 682
 cancer patients, bacterial isolates from comparative evaluation, 879
 combinations
 clarithromycin and amikacin, 1567
M. avium-M. intracellulare complex, 1567
 comparative evaluation
 ofloxacin, fleroxacin, temafloxacin, sparfloxacin, 682

E. coli
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 SOS-response and cell-division mutants, 819

Enterococcus resistance
 increasing occurrence of, 2533

H. pylori, 1133

K. rhinoscleromatis, 1785

L. monocytogenes
 comparative evaluation, 2375
 hydrocortisone-treated mice, 2375

M. avium-M. intracellulare complex
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816

methicillin-resistant *S. aureus* resistance
gyrA mutations, analysis of, 1166
 penetration into ascitic fluid
 single 750-mg dose, 677
 penetration into blister fluid
 fleroxacin, comparative evaluation, 651

pharmacokinetics
 bioavailability in cystic fibrosis patients, 2512
 comparative evaluation, 2085
 infants and small children, 1086
 single 750-mg dose, 677
 single intravenous and oral doses, 993

R. conorii, 2529

R. equi, 1244
R. rickettsii, 2529
 salmonellae
 ampicillin resistant, 1794
 CL 184, 005
 sepsis, bacterial
 animal models, evaluation in, 1971
 Clarithromycin
 bioavailability
 oral administration in humans, 1147
C. pneumoniae, 1573
 combinations
 ciprofloxacin and amikacin, 1567
 gentamicin, 1695
M. avium, 1695
M. avium complex, 2413
M. avium-M. intracellulare complex, 1567
 pyrimethamine, 2454
 rifabutin, 2413
 sulfadiazine, 2454
T. gondii, 2454
 comparative evaluation
 erythromycin, azithromycin, and roxithromycin, 180
M. avium complex
 beige mice, 2413
 comparative evaluation, 1163
 human macrophages, 2104
J774 cells and alveolar macrophages, 1163
M. avium resistance
 selection of mutants by monotherapy, 2839
M. chelonae, 180
M. chelonae-like organisms, 180
M. fortuitum, 180
M. kansasii
 in vitro susceptibility, 2039
M. paratuberculosis
 comparative evaluation, 2843
 ethambutol, enhancement of activity, 2843
 metabolites
 pharmacokinetics, 2478
Mycobacterium spp.
 pH, effect on MICs, 2841
 slowly growing, nontuberculous, 1987
 pharmacokinetics
 infants and children, 2478
 metabolite, 14-(R) hydroxylated, 2478
 oral administration in humans, 1147
 single ascending oral doses, 2447
 synergy
 minocycline, 2852
T. gondii, 2852
T. gondii, 2454
 U.S. FDA approval, 1584
 Clavulanic acid
 combinations
 amoxicillin, 1140, 1785
 gram-negative organisms, 1140
K. rhinoscleromatis, 1785
 pharmacokinetics, 2233
 ticarcillin, 2233
 Clavulanic acid
 combinations
 amoxicillin, 1794
 letter to the editor, 2352
S. aureus endocarditis, 458
 salmonellae, ampicillin resistant, 1794
 susceptibility tests, error rates, 137
 ticarcillin, 137, 458, 2352
 zone size criteria, 2352
 Clindamycin
B. fragilis group, 2051
B. vulgaris resistance, ribosomal inducible expression, 639
 combinations
 amikacin, 2014
 major head and neck surgery in cancer patients, prophylaxis, 2014
 gram-negative organisms, 1140
P. aeruginosa
 proinflammatory interactions, inhibition of, 1236
T. gondii
 infected human fibroblasts, 1091
 resistant mutant, selection of, 1091
 Clofazamine
 B669
 lysophospholipids, mediators of antimicrobial activity, 2729
 lysophospholipids
 mediators of antimicrobial activity, 2729
Clostridium butyricum
 chloramphenicol acetyltransferase sequence analysis, comparative, 2548
Clostridium difficile
 cefixime
 correlation of presence in feces, 2009
 cefpodoxime proxetil
 correlation of presence in feces, 2009
 ceftriaxone
 emergence, influence on, 2850
 diarrhea
 teicoplanin, oral, 2192
 vancomycin, oral, 2192
 teicoplanin
 comparative evaluation, 2192
 oral, 2192
 toxin production
 effects of antibiotics, 1332
 vancomycin
 comparative evaluation, 2192
 oral, 2192
 Clotrimazole
C. albicans
 sub-MIC concentrations, increased sensitivity to hydrogen peroxide after growth in, 1626
Coccidioides immitis
 meningitis
 RR 42427, 217
 SCH 39304, 217
 SS 42426, 217
 Coccidioides
 CP-72, 2588, 2080
 Collagenase
 tetracyclines
 relevance of specificity to anti-inflammatory potential, 227
Corynebacterium spp.
 CDC group II
 antimicrobial susceptibilities, 1325
 penicillin, vancomycin, and gentamicin susceptibility, 1325
 penicillin-gentamicin synergy, 1325
 vancomycin-gentamicin, 1325
 Co-trimoxazole
B. melitensis, 973
 brucellosis, 973
 combinations
 ceftazidime, 158
 chloramphenicol-doxycycline, 158
 melioidosis, severe, 158
 salmonellae
 ampicillin resistant, 1794
Coxiella burnetii
 ciprofloxacin, 2529
 ofloxacin, 2529
 PD 127, 391, 2529
 PD 131, 628, 2529
 pefloxacin, 2529
Coxsackievirus
 WIN 54954
 mice, 425
 CP-72, 2588
 coccidioides, 2080
Eimeria spp., 2080
 pharmacokinetics, 2080
 CP-74, 667
 pharmacokinetics
 laboratory animals, 1671
Cryptococcosis
 amphotericin B
 colloidal dispersion, 2656
 deoxycholate suspension, 2656
 MS-8209, 2722
Cryptococcus neoformans
 amphotericin B
 colloidal dispersion, 2656
 deoxycholate suspension, 2656
 liposomal, aerosolized, 1466
 meningitis
 RR 42427, 217
 SCH 39304, 217
 SS 42426, 217
 MS-8209, 2722
Cryptococcus spp.
 meningitis
 fluconazole, 690
Cryptosporidiosis
 dehydroepiandrosterone
 immunosuppressed rats, 220
Cryptosporidium parvum
 dehydroepiandrosterone
 immunosuppressed rats, 220
Cyclodextrin
 azole, oral
 effect on pharmacokinetics, 477
Cytochromes
 P450IA2
 quinolones, inhibitory potency of, 942
Cytokines
 minireview, 1
 nonspecific resistance to infection, 1
Cytomegalovirus
 antiviral agents
 novel method for evaluation, 206
 bropirimine, 1837
 ganciclovir, 1837
 (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine, 1837
 interferon
 recombinant alpha, 1837
 Daptomycin
 bacteremia, 1109
 combinations
E. faecium, glycopeptide resistant, 2611
 endocarditis, 2611
 gentamicin, 2611
E. faecium
 glycopeptide resistant, 2611
 endocarditis, 1109, 2611

comparative evaluation, 1854
enterococci, penicillin resistant, 1864
Enterococcus sp., 318
Enterococcus spp.
comparative evaluation, 1864
endocarditis, 1864
penicillin resistant, 1864
gram-positive organisms
blood isolates, 1570
comparative evaluation, 1570
pharmacokinetics
healthy volunteers, 318
intravenous drug abusers, 1109
S. aureus, 318
S. aureus early killing
in vitro pharmacodynamic model, investigation by, 2334
serum bactericidal activity
concentration, pH, and growth phase, effects on, 2709
Decaplanin
gram-positive organisms, 873
Dehydroepiandrosterone
C. parvum
immunosuppressed rats, 220
cryptosporidiosis
immunosuppressed rats, 220
endotoxin toxicity
protection from in mice, 2275
tumor necrosis factor
reduction of production of in mice, 2275
2'-Deoxy-3'-thiacytidine
human immunodeficiency virus
inhibition of replication, 202
(-)-2'-Deoxy-3'-thiacytidine
human immunodeficiency virus
inhibition of replication, 733
type 1, 733
type 2, 733
(-)-2'-Deoxy-3'-thiacytidine 5'-triphosphate
human immunodeficiency virus
DNA polymerases alpha, beta, and gamma, 1688
reverse transcriptase inhibition, 1688
3'-Deoxythymidine
lipid prodrug
human immunodeficiency virus,
greatly enhanced inhibition, 2025
3'-Deoxythymidine diphosphate dimyristoylglycerol
human immunodeficiency virus type 1
greatly enhanced inhibition, 2025
dhfrIX
trimethoprim resistance
spread among human and porcine pathogens, 2704
Diarrhea
bacterial
ofloxacin, three versus five days of therapy, 87
C. difficile associated
teicoplanin, oral, 2192
vancomycin, oral, 2192
ofloxacin
three versus five days of therapy, 87
teicoplanin
comparative evaluation, 2192
oral, 2192
vancomycin
comparative evaluation, 2192
oral, 2192

Diclofenac
ceftriaxone
pharmacokinetics, effects on, 2331
4',6-Dicyanoflavan
rhinovirus
mechanism of action, 95
Didanosine
human immunodeficiency virus type 1
ganciclovir antagonism, 1127
human immunodeficiency virus type 1
resistance
replication endpoint concentration assay, 920
pharmacokinetics
influence of hemodialysis, 1519
patients with normal and impaired renal function, 1519
ranitidine, interaction with, 2075
U.S. FDA approval, 1584
2',3'-Dideoxy-3'-thiacytidine
human immunodeficiency virus type 1
activities of the four optical isomers, 672
2',3'-Dideoxycytidine
combinations
human immunodeficiency virus type 1, 1559
zidovudine, 1559
human immunodeficiency virus type 1
pol gene mutations, decreased susceptibility, 153
mitochondrial function
impairment of, 2061
Molt-4 cells, 2061
Molt-4 cells
impaired mitochondrial function, 2061
ultrastructural changes, 2061
ultrastructural changes
Molt-4 cells, 2061
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
metabolism
racemic, 2432
rhesus monkeys, 2432
pharmacokinetics
racemic, 2432
rhesus monkeys, 2432
2',3'-Dideoxyinosine
3'-azido-3'-deoxythymidine
pharmacokinetic interaction, lack of, 665
bioavailability
maximal tolerated dose, impact on determination, 1280
3,5-Dihydroxy-4-ethyl-trans-stilbene
in vitro activity
guanosine-3',5'-bis-pyrophosphate, role in, 2645
mechanism of action, 2645
Dimethyl prostaglandin A₁
herpes simplex virus
replication, effect on, 2253
human immunodeficiency virus type 1
replication, effect on, 2253
6-Dimethylaminopurine arabinoside
pharmacokinetics and metabolism, 353
Disk diffusion tests
cefoperazone-sulbactam
new disk, development of, 394
DNA gyrases
fluoroquinolones
inhibition of, relationship among antibacterial activity and intracellular accumulation, 2622

Doxycycline
B. melitensis, 973
brucellosis, 973
C. pneumoniae, 1573
C. trachomatis
cervical infection, 1144
comparative evaluation, 1144
combinations
ceftazidime-co-trimoxazole, comparative evaluation, 158
chloramphenicol-co-trimoxazole, 158
melioidosis severe, 158
H. pylori, 1133
DQ-2556
in vitro and in vivo activities, 2595
mode of action, 2595
pharmacokinetics
rats, rabbits, dogs, and monkeys, 966
DR-3355
pharmacokinetics
antacids, effect of, 2270
ferrous sulfate, effect of, 2270
ranitidine, effect of, 2270
DU-6859
antimicrobial activity
comparative evaluation, 1491
inoculum size, media, pH, serum, and urine
effects on activity, 1491
E1040
P. aeruginosa, 1580
imipenem resistant, 684
P. mirabilis, 1580
urinary tract infections, 1580
E1077
β-lactamase
affinity for, 589
susceptibility to hydrolysis by, 589
comparative evaluation
cefpirome, ceftazidime, cefuzonam, cefoperazone, and cefotaxime, 589
in vitro and in vivo activities
comparative evaluation, 1894
P. aeruginosa
morphological changes, 1894
S. aureus
morphological changes, 1894
E4695
Legionella spp., 2049
Echinococcus multilocularis
isoprinosine
effect of multiple doses on metacercodes, 191
Ehrlichia chaffeensis
in vitro antibiotic susceptibilities, 2799
Ehrlichiosis
E. chaffeensis
in vitro antibiotic susceptibilities, 2799
Eikenella corrodens
β-lactamase, 740
streptomycin resistance gene, 740
Eimeria spp.
CP-72,588, 2080
Eimeria tenella
7-bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine, 368, 372
Emetine
E. histolytica resistance mutants
channel blockers, susceptibility to, 2392

susceptibilities, in vitro, 2392

Endocarditis
aminoglycosides
factors affecting in vivo activity, 744

ampicillin
continuous intravenous versus intermittent therapy, 1263

Corynebacterium CDC group II
penicillin, vancomycin, and gentamicin susceptibility, 1325

penicillin-gentamicin synergy, 1325

vancomycin-gentamicin, 1325

E. faecalis
teicoplanin, comparative evaluation, 1276

vancomycin, comparative evaluation, 1276

E. faecium, glycopeptide resistant
daptomycin, 2611

daptomycin-gentamicin, 2611

teicoplanin, high versus low dose, 2611

Enterococcus spp.
ampicillin-gentamicin, 1864

daptomycin, 1864

penicillin resistant, 1864

vancomycin, 1864

gram positive
daptomycin, 1109

vancomycin, 1109

penicillin-tobramycin
optimal tobramycin dosing regimen, 2403

synergy, 2403

pharmacokinetic and pharmacodynamic requirements
minireview, 2069

S. aureus
CI-960, 1192

ciprofloxacin susceptible and resistant, 1192

ticarcillin-clavulanic acid, 458

streptococcal
teicoplanin, 723

teicoplanin
4-week treatment, 723

streptococcal, 723

temafloxacin
S. adjacens, 2216

ticarcillin-clavulanic acid, 458

Endotoxin
neutropenic patients
anti-endotoxin core antibodies, 2139

correlation with clinical outcome, 2139

E. coli
SOS-response and cell-division mutants, 819

P. aeruginosa resistance
mechanism of resistance, 1057

pleiotropic, posttherapy mutant, 1057

U.S. FDA approval, 1584

Entamoeba histolytica
emetine-resistant mutants
channel blockers, susceptibility to, 2392

susceptibilities, in vitro, 2392

Enterobacter cloacae
aminoglycosides
factors affecting in vivo activity, 744

Enterobacter spp.
β-lactamases
epidemiology, 989

relation to antimicrobial therapy, 989

Enterobacteriaceae
β-lactam resistance, 1677

β-lactamases
three-dimensional versus double-disk tests, 1877

cefotaxime resistance, 1677

OPC-17116
assay conditions, effect on activity, 1310

comparative evaluation, 1310

Ro 23-9424
cancer patients, isolates from, 879

Ro 40-6890
intestinal species, 2835

ticarcillin
susceptibility tests, error rates, 137

ticarcillin-clavulanic acid
susceptibility tests, error rates, 137

Enterococcus faecalis
β-lactamase
incorporation into a transposon derived from staphylococci, 1843

gentamicin resistance
comparison of regions encoding, isolates from diverse geographic locations, 2259

structural gene, identical to those for *E. faecium* and *S. agalactiae*, 1215

gentamicin resistant, β-lactamase producing
intrahospital spread, 230

kanamycin resistance plasmid
conjugal transfer to *E. coli*, 502

penicillin
effect of exposure on antimicrobial susceptibility, 121

teicoplanin
comparative evaluation, 1276

Tn5281
comparison in isolates from diverse geographic locations, 2259

vancomycin
comparative evaluation, 1276

Enterococcus faecium
aminoglycoside resistant
β-lactamase-producing strain, 1125

gentamicin resistance
structural gene, identical to those of *E. faecalis* and *S. agalactiae*, 1215

glycopeptide resistant
daptomycin, 2611

daptomycin-gentamicin, 2611

teicoplanin, high versus low dose, 2611

penicillin resistance
mechanisms of, 783

vancomycin and ampicillin resistant
vancomycin-ampicillin-gentamicin, 1563

vancomycin resistant
VanY, characterization of, 1514

Enterococcus gallinarum
vancomycin resistance
vanC, species specificity, 2005

vancomycin resistant, 1392

penicillin-binding protein 6, possible role, 1392

Enterococcus spp.
aminoglycoside resistant
ampicillin, continuous intravenous versus intermittent therapy, 1263

ampicillin resistant
emergence and nosocomial transmission, 1032

ampicillin susceptibility
gentamicin resistance, high level, and beta-hemolysis, influence on, 2526

β-lactamase-encoding fragments
comparison with those from *Staphylococcus* spp., 273

β-lactamases
minireview, 2355

ciprofloxacin resistance
increasing occurrence of, 2533

daptomycin, 318

gentamicin resistant
ramoplanin, 2342

penicillin G resistant
ramoplanin, 2342

penicillin resistant
ampicillin-gentamicin, 1864

daptomycin, 1864

vancomycin, 1864

ramoplanin
antibiotic-resistant isolates, 2342

tetracycline resistant
occurrence of structures with homology to Tn916, 59

vancomycin resistance
effects of amino acids on expression, 902

vancomycin resistant
carboxypeptidase activity, inducible, 77

D-lactate, incorporation into peptidoglycan precursors, 867

peptidoglycan precursors, analysis of, 1487

ramoplanin, 2342

vancomycin resistant, highly
ampicillin-vancomycin, absence of synergy, 2201

vancomycin susceptibility
gentamicin resistance, high level, and beta-hemolysis, influence on, 2526

Enterovirus
piroavir, 100

R 61837, 100

Enzyme-linked immunosorbent assays
human immunodeficiency virus
inhibitors of gp120-CD4 binding, detection of, 267

Erythromycin
A. actinomycetemcomitans
comparative evaluation, 1241

bacteremia, 1198

C. pneumoniae, 291, 1573

C. trachomatis, 291

comparative evaluation
azithromycin, clarithromycin, roxithromycin, 180

minocycline, ampicillin, amoxicillin, cefixime, metronidazole, and bis-muth subcitrate, 185

H. pylori, 1133
slowly growing, 185

host defense systems, 1922

impetigo
comparison with mupirocin, 287

erythromycin-resistant *S. aureus*, 287

inhibitory activity in presence of human serum, 10

M. avium complex

comparative evaluation, 1163
J774 cells and alveolar macrophages, 1163
M. chelonae, 180
M. chelonae-like organisms, 180
M. fortuitum, 180
P. aeruginosa, 1198
 proinflammatory interactions, inhibition of, 1236
 virulence effect on, 1922
R. equi, 1244
 serum protein binding, 10
Escherichia coli
 amikacin
 postantibiotic sub-MIC effects, 1852
 β -lactam hypersusceptible siderophores, antibacterial activity, 840
 β -lactam-siderophore conjugates mechanism of action, 2166
 β -lactamases
 epidemiology, 989
 relation to antimicrobial therapy, 989
 BRL-42715-cefazolin, 1427
 BRL-42715-piperacillin, 1427
 ceftazime
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 cefminox
 effect of inoculum size on bacteriolytic activity, 223
 cefotaxime
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 ceftazidime
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 ceftazidime resistance
 β -lactamase, extended spectrum, 1991
 cancer patients, 1991
 ciprofloxacin
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 colonization ability
 norfloxacin, use to study, 401
 gentamicin
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 imipenem
 diffusion through outer membrane, correlation with activity, 1902
 kanamycin resistance plasmid
 conjugal transfer from *E. coli*, 502
lpxA2
 antibiotic supersusceptibility, 826
 meropenem
 diffusion through outer membrane, correlation with activity, 1902
 nonspecific immunostimulation
 prevention of infection, 361
 outer membrane mutants
 tosufloxacin, 2030
 tosufloxacin uptake, 2030
 postantibiotic effect
 macromolecular biosynthesis, analysis of, 2118
 quinolones, 2118
 quinolone accumulation
 fluorometric assay, 1601
 quinolone resistance loci
 genetics and regulation, 1151
nfxB, *nfxC*, and *cfxB*, 1151
 quinolones

SOS-response and cell-division mutants, 819
 sparfloxacin
 renal infection in mice, 505
 tosufloxacin
 outer membrane mutants, 2030
 uptake, 2030
 trimethoprim resistant identification of new gene, 1720
 Ethambutol
 clarithromycin
M. paratuberculosis, enhancement of activity, 2843
 combinations
M. avium complex, 2408
 RU-40 555, 2408
 sparfloxacin, 2408
M. avium complex, 2408
 Ethanolamine
P. falciparum
 use of incorporation into phospholipids to measure activity, 50
 Ethionamide
Mycobacterium spp.
 mechanism of action, 1316
 mycolic acid synthesis inhibition, 1316
 5-Ethyl-1- β -D-ribofuranosylimidazole-4-carboxamide
 myxoviruses, 435
 orthoviruses, 435
[¹⁴C]FCE 22891
 pharmacokinetics
 healthy volunteers, 1958
 Feline leukemia virus
 3'-azido-3'-dideoxythymidine
 pre- and postexposure chemoprophylaxis, 2715
 Ferrous sulfate
 DR-3355
 pharmacokinetics, effect on, 2270
 pharmacokinetics
 DR-3355, effect on, 2270
 Flavonoids
 4',6-dicyanoflavan
 mechanism of action, 95
 rhinovirus, 95
 Fleroxacin
C. pneumoniae, 682
 cancer patients, bacterial isolates from comparative evaluation, 879
 comparative evaluation
 ciprofloxacin, ofloxacin, temafloxacin, sparfloxacin, 682
E. coli
 SOS-response and cell-division mutants, 819
L. pneumophila
 pneumonia in guinea pigs, 2387
Legionella spp., 2387
 penetration into blister fluid
 ciprofloxacin, comparative evaluation, 651
 pharmacokinetics
 aqueous and vitreous humors, 32
 guinea pigs, 2387
 patients with liver cirrhosis, 632
 positron emission tomography, 2286
 rabbits with *E. coli* infections, 2286
 sucralfate, effect of, 2758

Fluconazole
C. albicans, 64
 endothelial cells, interaction with, modulation of, 2239
 combinations
C. albicans, 1225
 candidiasis, 1225
 interleukin-1, human, 1225
 comparative evaluation
 SCH 39304 and ketoconazole, 64
 gas chromatography
 electron capture detection, 647
 high-performance liquid chromatography concentrations in plasma, serum, and cerebrospinal fluid, 603
 mixed-phase column, 603
 meningitis
 cryptococcal, 690
 patients with AIDS, 690
 susceptibility testing
 standardization, 1805
 systemic fungal infections, 64
 Flucytosine
 amphotericin B nephrotoxicity
 acute and chronic effects on, 2670
 3'-Fluoro-3'-deoxythymidine
 cellular transport
 comparative evaluation, 808
 human immunodeficiency virus
 comparative evaluation, 808
 pharmacokinetics
 comparative evaluation, 808
 penetration into brains, muscle tissue, and veins of monkeys, 2418
 relation to antiviral action, 2418
 2'-Fluoro-5-ethyl-1- β -D-arabinofuranosyluracil
 pharmacokinetics
 mice and rats, 1472
 preclinical pharmacology, 1472
cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 (-) and (+) enantiomers
 anabolic profiles, 2686
 cytotoxicities, 2686
 hepatitis B virus, 2686
 hepatitis B virus
 (-) and (+) enantiomers, 2686
 human immunodeficiency virus
 racemates and enantiomers, 2423
 Fluorometric assay
 quinolone accumulation
E. coli, 1601
P. aeruginosa, 1601
S. aureus, 1601
 5-Fluoroorotate
 malaria, 704
P. falciparum
 molecular targets, 704
 Fluoroquinolones
 antibacterial activity
 DNA gyrase inhibition and intracellular accumulation, relationship among, 2622
B. subtilis resistance
 multidrug efflux transporter Bmr, 484
 CI-960
 ciprofloxacin-susceptible and -resistant
S. aureus, 1192
 comparative evaluation, 851
Legionella spp., 2049
Staphylococcus spp., 851
 DNA gyrase

inhibition, relationship among antibacterial activity and intracellular accumulation, 2622
DU-6859
 antimicrobial activity, 1491
 inoculum size, media, pH, serum, and urine, effects on activity, 1491
E4695
Legionella spp., 2049
 intracellular accumulation
 DNA gyrase inhibition and antibacterial activity, relationship among, 2622
OPC-17116
 comparative evaluation, 1310
Enterobacteriaceae, 1310
 in vitro activity, 1310
P. aeruginosa supersusceptibility
OprH overexpression, 2365
P. carinii
 mice, 470
PD127,391
 gram-positive cocci, 1329
 pneumonia
 mice, 470
Q-35
 in vitro activity, comparative evaluation, 1708
 photostability and biological activity after UV irradiation, 1715
S. sonnei, 2346
T-3761
 in vitro activity, 2293
 topoisomerase II
 effects on catalytic activities, 751
 influence of C-8 fluorine group, 751
WIN 5723
 comparative evaluation, 851
Staphylococcus spp., 851
3'-Fluorothymidine
 simian immunodeficiency virus
 long-term tolerance and efficacy, 1770
Fluoxetine hydrochloride
P. faliciparum
 chloroquine resistant, enhancement of susceptibility, 2761
Foot rot
 anaerobic bacteria
 antimicrobial susceptibilities, 198
Foscarnet
 combinations
 pharmacokinetics, 1773
 zidovudine, 1773
 pharmacokinetics
 AIDS patients, 1821
 twice-daily administration, 1821
Foscarnet sodium
 U.S. FDA approval, 1584
Fungi
 amphotericin B
 colloidal dispersion, 486
 deoxycholate suspension, 486
Fusidic acid
M. leprae
 intracellular and extracellular, 92
Ganciclovir
 antagonism
 didanosine anti-human immunodeficiency virus activity, 1127
 zidovudine anti-human immunodeficiency virus activity, 1127
cytomegalovirus
 severe combined immunodeficient mice, 1837
Gas chromatography
 electron capture detection
 fluconazole, 647
Gentamicin
 combinations
 ampicillin, 1864
 cefuroxime, 801
 cephalothin, 801
 clarithromycin, 1695
 comparative evaluation, 801
E. faecium, vancomycin and ampicillin resistant, 1563
 endocarditis, 1864
Enterococcus spp., penicillin resistant, 1864
 febrile neutropenic patients, 801
K. pneumoniae, 1883
M. avium, 1695
 piperacillin, 1883
 piperacillin-tazobactam, 1883
 tazobactam, 1883
 vancomycin and ampicillin, 1563
Corynebacterium CDC group II, 1325
 endocarditis, 1325
 synergy with penicillin, 1325
E. coli
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
E. faecalis resistance
 β -lactamase-producing strain, intra-hospital spread, 230
 regions encoding, isolates from diverse geographic locations, 2259
 endocarditis, 1325
Enterococcus resistance
 ramoplanin, 2342
K. pneumoniae, 1883
M. avium, 1695
P. aeruginosa resistance
OprH, role in, 2566
 pharmacokinetics
 patients with end-stage renal disease, 1832
 patients with pleural effusions and hypoalbuminemia, 679
 tobramycin, comparative evaluation, 679
 piperacillin
 disposition, effect on, 1832
 resistance
E. faecium, *E. faecalis*, *S. agalactiae*, same structural gene, 1215
 resistance, adaptive
 dynamic in vitro model, 1951
 salmonellae
 ampicillin resistant, 1794
 toxicity
 polyaspartic acid, protection from, duration, 2556
Ginkgetin
 herpes simplex virus
 mechanism of action, 1890
Glycerol monolaurate
S. aureus, 626
 toxic shock syndrome toxin 1, 626
Glycopeptides
 decaplanin
 gram-positive organisms, 873
Gram-negative organisms
 amikacin resistance
 neonatal unit, 1596
 amoxicillin, 1140
 amoxicillin-BRL 42715, 1140
 amoxicillin-clavulanate, 1140
 clindamycin, 1140
 fluoroquinolones
 comparative evaluation, 1708
 Q-35, 1708
LJC 10,627
 comparative evaluation, 1418
Q-35
 comparative evaluation, 1708
 sparfloxacin
 comparative evaluation, 558
 temafloxacin, 1140
Tn21-specific structures, 1915
Gram-positive organisms
 daptomycin
 comparative evaluation, 1570
 decaplanin, 873
 fluoroquinolones
 comparative evaluation, 1708
 Q-35, 1708
LJC 10,627
 comparative evaluation, 1418
MDL 62208, 331
MDL 62211, 331
MDL 62873, 331
OPC-17116
 comparative evaluation, 2185
PD127,391
 comparative evaluation, 1329, 1570
Q-35
 comparative evaluation, 1708
 ramoplanin
 comparative evaluation, 1570
RP 59500
 pharmacodynamic interaction, 2211
 sparfloxacin
 comparative evaluation, 558
 teicoplanin
 comparative evaluation, 1570
 vancomycin
 comparative evaluation, 1570
Guanosine-3',5'-bis-pyrophosphate
 3,5-dihydroxy-4-ethyl-trans-stilbene activity
 role in mediating, 2645
gyrA
S. aureus, methicillin resistant
 analysis of mutations associated with ciprofloxacin resistance, 1166
Haemophilus ducreyi
 β -lactamase
 ROB-1, 467
 β -lactamase plasmid contents
 antimicrobial susceptibility, correlation with, 1639
Haemophilus influenzae
 azithromycin
 lung infection, 1412
 β -lactam resistance
 molecular basis, 1504
 non- β -lactamase mediated, 1504
 β -lactams
 peptidoglycan metabolism, effect on, 2147
cefaclor
 kill and growth rates, 46

molecular basis of efficacy, 2569
 cefdinir
 kill and growth rates, 46
 rifampin
 prophylaxis for contacts of infected patients, 545
 Ro 23-9424
 cancer patients, isolates from, 879
 6-Halo-dideoxypyrimidine nucleosides
 central nervous system
 uptake, 2156
 pharmacokinetics, 2156
 central nervous system uptake, 2156
 Head and neck surgery
 cancer patients
 clindamycin-ampicillin, 2014
 subbactam-ampicillin, 2014
Helicobacter pylori
 ampicillin, 1133
 azithromycin, 1133
 cefixime, 1133
 ciprofloxacin, 1133
 doxycycline, 1133
 erythromycin, 1133
 metronidazole, 1133
 metronidazole resistance
 metronidazole-amoxyillin-bismuth
 substrate, 163
 role in infection, 163
 omeprazole, 1133
 slowly growing
 antimicrobial agents, activity of, 185
 tinidazole, 1133
Hemodialysis
 vancomycin
 serum, removal from by high-flux hemodialysis membranes, 1424
Hepatitis B virus
 antiviral agents
 inhibition of replication, 2042
 mouse model, novel transgenic, 2042
 cis-5-fluoro-1-[2(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 (-) and (+) enantiomers, 2686
 mouse model, novel transgenic
 inhibition of replication, 2042
Hepatitis virus
 2'-fluoro-5-ethyl-1-β-D-arabinofuranosyluracil
 pharmacokinetics, 1472
Herpes simplex virus
 acyclovir, 2037
 dimethyl prostaglandin A₁
 replication, effect on, 2253
 ginkgetin
 mechanism of action, 1890
 L-653,180
 experimental genital herpes, 2020
 penciclovir, 2037
 ribonucleotide reductase inactivators
 acyclovir, in vivo potentiation, 934
 hematological profiles, 934
Herpes simplex virus type 1
 acyclovir, 2037
 penciclovir, 2037
 mechanism of action, 2747
 MRC-5 cells, 2747
Herpes simplex virus type 2
 acyclovir, 2037
 penciclovir, 2037
 mechanism of action, 2747
 MRC-5 cells, 2747

Herpesviruses
 minireview
 resistance, 1589
 resistance
 minireview, 1589
Hexadecylphosphocholine
L. donovani, 1630
L. infantum, 1630
 leishmaniasis
 visceral, 1630
High-performance liquid chromatography
 amoxycillin
 bovine plasma, determination in, 1859
 potency determination, 1272
 tandem solid-phase extraction method, 1859
 fluconazole
 concentrations in plasma, serum, and cerebrospinal fluid, 603
 mixed-phase column, 603
radioimmunoassay
 combined procedure for measuring intracellular zidovudine, 2473
 tandem solid-phase extraction method
 ampicillin, improved determination, 1606
Human immunodeficiency virus
 (-)-2'-deoxy-3'-thiacytidine 5' triphosphate
 DNA polymerase alpha, beta, and gamma, 1688
 reverse transcriptase inhibition, 1688
reverse transcriptase inhibition
 (-)-2'-deoxy-3'-thiacytidine 5' triphosphate, 1688
Human immunodeficiency virus type 1
 1-β-D-arabinofuranosyl-E-5-(2-bromo-5-vinyl)uracil
 anticancer nucleosides, 214
 anti-human immunodeficiency virus agents, 214
 3'-azido-3'-deoxythymidine
 comparative evaluation, 808
 3'-azido-3'-deoxythymidine resistance suppression by mutation conferring resistance to reverse transcriptase inhibitors, 2664
 2'-deoxy-3'-thiacytidine
 enantiomers, 202
 inhibition of virus replication, 202
 (-)-2'-deoxy-3'-thiacytidine
 inhibition of replication, 733
 3'-deoxythymidine diphosphate dimyristoylglycerol
 greatly enhanced inhibition, 2025
 didanosine
 antagonism by ganciclovir, 1127
 didanosine resistance
 replication endpoint concentration assay, 920
 2',3'-dideoxy-3'-thiacytidine (BCH-189)
 activities of the four optical isomers, 672
 2',3'-dideoxycytidine
pol gene mutations, decreased susceptibility, 153
 dimethyl prostaglandin A₁
 replication, effect on, 2253
 3'-fluoro-3'-deoxythymidine
 comparative evaluation, 808
 cis-5-fluoro-1-[2(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 racemates and enantiomers, 2423
 ganciclovir
 antagonism of zidovudine and didanosine, 1127
 inhibitors
 gp120-CD4 binding, 267
 screening assay, 267
 L-696,229, 1019
 inhibition of reverse transcriptase, 1019
 5-mercapto-substituted poly- and oligonucleotides
 mechanisms of action, 108
 structure-activity relationships, 108
polyethers
 inhibition of replication, 492
 [Tyr-5,12, Lys-7]polyphemusin II (T22), 1249
protease inhibitors, 982
protease inhibitors, C₂ symmetry based inhibition of replication, 926
purine nucleosides, TSAO derivatives
 potent and selective inhibitors, 1073
pyrimidine nucleosides, TSAO derivatives
 potent and selective inhibitors, 1073
reverse transcriptase
 nonnucleoside inhibitors, residues that contribute to the activity of, 1441
 Ro5-3335
 cell type-specific activity, 2628
zidovudine
 antagonism by ganciclovir, 1127
 zidovudine-2',3'-dideoxycytidine
 synergy, 1559
 zidovudine resistance
 replication endpoint concentration assay, 920
Human immunodeficiency virus type 2
 (-)-2'-deoxy-3'-thiacytidine
 inhibition of replication, 733
 (R)-9-(4-Hydroxy-2-(hydroxymethyl)butyl)guanine
 pharmacokinetics
 distribution over blood-brain barrier, 339
 rats, 339
 (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
 cytomegalovirus
 severe combined immunodeficient mice, 1837
Hydroxynaphthoquinones
 566C80
T. gondii cysts, 326
ICI 213,689
 pharmacokinetics
 healthy subjects, 2794
 renal impairment, patients with, 2794
 young and elderly healthy men, 1437
Imipenem
B. fragilis group, 2051
 bactericidal activity, serum
 comparative evaluation, 2085
 combinations
 cilastatin, 801, 2057, 2766
 comparative evaluation, 801, 2766
 effect of biliary obstruction on hepatic excretion, 2057
 febrile neutropenic patients, 801
 intra-abdominal infections, 2766
 pharmacokinetics, 2057

comparative evaluation
ceftriaxone, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole, 949

E. coli
diffusion through outer membrane, correlation with activity, 1902

meningitis, 949

P. aeruginosa resistance
β-lactamase and impermeability, association of, 2046

E1040, 684

protein D2, nucleotide sequence, 1791

pharmacokinetics
comparative evaluation, 2085

serum and skin window fluid of healthy adults, 1400

transplacental passage, 2652

R. equi, 1244

S. enteritidis, 949

Immunoglobulin G
amphotericin B
C. albicans infection in burned mice, 643

Immunomodulators
minireview, 1

nonspecific resistance to infection, 1

Impetigo
erythromycin-resistant *S. aureus*
erythromycin and mupirocin, comparative evaluation, 287

Influenza virus
pulse oximetry
measurement of antiviral activity in mice, 473

ribavirin
pulse oximetry, 473

Interferon
alpha
cytomegalovirus, 1837

cytomegalovirus
severe combined immunodeficient mice, 1837

Interleukin-1
amphotericin B-stimulated human mononuclear cells
expression, pharmacologic modulation of, 977

combinations
C. albicans, 1225
candidiasis, 1225
fluconazole, 1225

minireview, 1

nonspecific resistance to infection, 1

resistance to bacterial infection
glucocorticosteroids, not mediated by, 2785

Interleukin-6
combinations
interleukin-α, 68
L. monocytogenes, 68
tumor necrosis factor alpha, 68

L. monocytogenes
mice, 68

minireview, 1

nonspecific resistance to infection, 1

Interleukin-α
combinations
interleukin-6, 68
L. monocytogenes, 68

Intra-abdominal infections
imipenem-cilastatin
comparative evaluation, 2766

piperacillin-tazobactam
comparative evaluation, 2766

Iontophoresis
antimicrobial effect
chloroquine-containing medium, 2552

Isepamicin
pharmacokinetics
patients with end-stage renal disease, 1832

piperacillin
disposition, effect on, 1832

ISIS 1082
toxicology, in vitro, 527

Isoniazid
M. tuberculosis
pyrazinamide-rifampin, comparative evaluation, 548

pyrazinamide-rifampin
antagonism, 548

Isoprinosine
E. multilocularis
effect of multiple doses on metacercodes, 191

Isothiazoloquinolones
topoisomerase II
DNA breakage, 81

Itraconazole
synergy
B. dermatitidis, 2487

macrophages, 2487

Kanamycin
C. jejuni resistance
aphA-7 resistance determinant, plasmids carrying, 712

E. faecalis resistance plasmid
conjugal transfer to *E. coli*, 502

KB-5246
S. aureus, accumulation in carbonyl cyanide m-chlorophenylhydrazone, lack of effect on, 883

Ketamine
rabies virus
transcription, inhibition of, 1750

Ketoconazole
C. albicans, 64
comparative evaluation
SCH 39304 and fluconazole, 64

systemic fungal infections, 64

Klebsiella oxytoca
β-lactamase
transposition of gene encoding, 1981

Klebsiella pneumoniae
ceftazidime resistance
β-lactamase, extended spectrum, 1991

cancer patients, 1991

cephem antibiotics
effect of serum protein binding on efficacy, 17

gentamicin, 1883

piperacillin, 1883

piperacillin-gentamicin, 1883

piperacillin-tazobactam, 1883

piperacillin-tazobactam-gentamicin, 1883

romurtide-cefmenoxime
synergy, 167

tazobactam, 1883

tazobactam-gentamicin, 1883

Klebsiella rhinoscleromatis
amoxicillin-clavulanate, 1785

cefpodoxime, 1785

cefuroxime, 1785

cephalexin, 1785

chloramphenicol, 1785

ciprofloxacin, 1785

streptomycin, 1785

tetracycline, 1785

trimethoprim-sulfamethoxazole, 1785

Klebsiella spp.
bacteremia
combination versus monotherapy, 2639

β-lactamases
epidemiology, 989

relation to antimicrobial therapy, 989

KRM-1648

M. avium complex
mice, 387

L-627
in vitro activity
comparative evaluation, 1928

P. aeruginosa
comparative evaluation, 1928

L-646, 991
antifungal activity, 1648

1,3-β-D-glucan synthesis inhibition, 1648

L-653, 180
herpes simplex virus
experimental genital herpes, 2020

L-671, 329
antifungal activity, 1648

1,3-β-D-glucan synthesis inhibition, 1648

pharmacokinetics
rhesus monkeys and DBA/2 mice, 607

L-687, 781
antifungal activity, 1648

1,3-β-D-glucan synthesis inhibition, 1648

L-693, 989
P. carinii
rats, 1964

L-696, 229
human immunodeficiency virus type 1, 1019
inhibition of reverse transcriptase, 1019

Lactobacillus casei
YIT 9018
protection against infection induced by 5-fluorouracil, 361

Legionella pneumophila
floxacin, 2387

pneumonia
floxacin, 2387

Ro 23-9424, 2559

Legionella spp.
CI-960, 2049

E4695, 2049

floxacin
in vitro activity, 2387

fluoroquinolones
CI-960, 2049

E4695, 2049

Ro 23-9424, 2559

Leishmania donovani
drug targeting
polymers internalized by macrophages, 2228

hexadecylphosphocholine, 1630

leishmaniasis
hexadecylphosphocholine, 1630

Leishmania infantum
hexadecylphosphocholine, 1630

leishmaniasis

hexadecylphosphocholine, 1630

Leishmania spp.

- topoisomerase II inhibitors
- cytotoxicity for promastigotes, 495

Leishmaniasis

- amphotericin B
 - cholesterol dispersion, 1978
- hexadecylphosphocholine, 1630
- L. donovani*
 - hexadecylphosphocholine, 1630
- L. infantum*
 - hexadecylphosphocholine, 1630
- visceral
 - hexadecylphosphocholine, 1630

Letters to the editor

- amphotericin B
 - toxicity, effect of infusion rates, 2573
- Mediterranean spotted fever
 - trimethoprim-sulfamethoxazole, 1342
- rifampin
 - bioavailability in murine tuberculosis, 2066
- S. aureus*
 - methicillin resistance, detection by polymerase chain reaction, 1585
- ticarcillin-clavulanic acid
 - dosing ratio, 1585
 - interpretive criteria, new, 1343
 - S. aureus* endocarditis, 1585
 - zone size criteria, 2352
- trimethoprim-sulfamethoxazole
 - Mediterranean spotted fever, 1342

Levofloxacin

- antibacterial activities, in vitro and in vivo
 - comparative evaluation, 860

Lincosamides

- Peptostreptococcus* spp.
 - inducible and constitutive phenotypes, 662

Lipopeptides

- L-693,989
 - P. carinii*, 1964

Listeria monocytogenes

- ampicillin
 - comparative evaluation, 2375
 - hydrocortisone-treated mice, 2375
- ciprofloxacin
 - comparative evaluation, 2375
 - hydrocortisone-treated mice, 2375
- interleukin-6, 68
- interleukin-6-interleukin- α , 68
- interleukin-6-tumor necrosis factor alpha, 68
- tetracycline resistance
 - genetic basis, 463

LJC 10,627

- β -lactamase stability, 1418
- gram-negative organisms
 - comparative evaluation, 1418
- gram-positive organisms
 - comparative evaluation, 1418
- renal dehydropeptidase-I stability
 - imipenem, comparative evaluation, 481

Lomefloxacin

- pharmacokinetics
 - absorption, effect of antacid on, 1219
 - sputum penetration, 2458
 - steady state, 2458
 - transudative and exudative pleural effusion, penetration, 2774

Loperamide

- combinations
 - traveler's diarrhea, T426
 - trimethoprim-sulfamethoxazole, 2821

Loracarbef

- bactericidal titers and killing rates
 - patients receiving 200 versus 400 mg, 521
- U.S. FDA approval, 1584

lpxA2

- E. coli*
 - antibiotic supersusceptibility, 826

Lysophospholipids

- B669
 - mediators of antimicrobial activity, 2729
- clofazimine
 - mediators of antimicrobial activity, 2729

Macrolides

- inhibitory activity in presence of human serum, 10
 - M. genitalium*, 870
 - M. pneumoniae*, 870, 1322
- MC-352
 - in vitro activity, comparative evaluation, 1699
- Peptostreptococcus* resistance
 - inducible and constitutive phenotypes, 662
- S. lividans* resistance
 - MGT enzyme, 348
- serum protein binding, 10

Macrophages

- synergy
 - B. dermatitidis*, 2487
 - itraconazole, 2487

Magainins

- A. polylepha*
 - ameba and cyst stages, effects on, 1256
 - positive-charge chain extension
 - augmentation of activity, 313

Malaria

- 5-fluoroorotate
 - molecular targets, 704
- infected cells
 - cinnamic acid, effect on permeability, 1102

MC-352

- in vitro activity
 - comparative evaluation, 1699

MDL 62208

- comparative evaluation
 - MDL 62211, MDL 62873, teicoplanin, and vancomycin, 331
 - gram-positive organisms, 331

MDL 62211

- comparative evaluation
 - MDL 62208, MDL 62873, teicoplanin, and vancomycin, 331
 - gram-positive organisms, 331

MDL 62,873

- antimicrobial activity, 446
- comparative evaluation
 - MDL 62208, MDL 62211, teicoplanin, and vancomycin, 331
 - gram-positive organisms, 331

MDL 73811

- T. brucei rhodesiense*
 - S-adenosylmethionine decarboxylase inhibitor, 2736

mecA

- methicillin-resistant staphylococci distribution, 429

Mediterranean spotted fever

- trimethoprim-sulfamethoxazole
 - letter to the editor, 1342

Melioidosis

- ceftazidime-co-trimoxazole, 158
- chloramphenicol-doxycycline-co-trimoxazole, 158

Meningitis

- ceftriaxone
 - comparative evaluation, 949
 - coccidioidal
 - RR 42427, 217
 - SCH 39304, 217
 - SS 42426, 217
 - cryptococcal
 - fluconazole, 690
 - RR 42427, 217
 - SCH 39304, 217
 - SS 42426, 217
 - imipenem
 - comparative evaluation, 949
 - S. enteritidis*
 - ceftriaxone, 949
 - imipenem, 949
- Meropenem
 - E. coli*
 - diffusion through outer membrane, correlation with activity, 1902
 - metabolites
 - pharmacokinetics, 1437, 2794
 - P. aeruginosa* resistance
 - cephem and quinolone cross-resistance, 1847
 - outer membrane protein overproduction, association with, 1847
 - pharmacokinetics
 - healthy subjects, 2794
 - renal impairment, patients with, 2794
 - renal impairment, subjects with, 1532
 - young and elderly healthy men, 1437
 - renal dehydropeptidase I
 - β -methyl substitution, effect on stability, 1577
 - stability to, 1577
 - Meticillin
 - S. aureus* resistance
 - chromosomal factors, mapping and characterization of, 1367
 - mecA*, *mecR1-mecI*, and *femA-femB*, 2617
 - Staphylococcus* resistance
 - mecA* distribution, 429
 - mecA* transcription, correlation with, 25
 - 6-Methoxypurine arabinoside
 - transport into human erythrocytes, 283
 - 2'-O-valerate prodrug
 - transport into human erythrocytes, 283
 - 6'-(R)-6'-C-Methylneplanocin A
 - myxoviruses, 435
 - orthoviruses, 435
 - Methylobacterium* spp.
 - susceptibility testing, 1635
 - β -lactams, 1635

Metronidazole
B. fragilis group, 2051
 combinations
 amoxicillin and bismuth subcitrate, 163
 H. pylori, metronidazole resistant, 163
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, cefixime, and bismuth subcitrate, 185
H. pylori, 1133
 slowly growing, 185
H. pylori resistance, 163
 amoxicillin-metronidazole-bismuth subcitrate, 163

Minireviews
 active efflux mechanisms, 695
 antifungal agents
 toxicity, *in vitro* models for, 1799
 antimicrobial resistance
 active efflux mechanisms, 695
 antiviral agents
 retroviruses, 509
β-lactamases
 enterococci, 2355
β-lactams
 continuous infusion, 2577
 pharmacokinetics by continuous infusion, 2577
 biofilms, aging
 mechanism of resistance to antimicrobial therapy, 1347
 endocarditis
 pharmacokinetic and pharmacodynamic requirements, 2069
 herpesviruses
 resistance, 1589
 immunomodulators
 nonspecific resistance to infection, 1
 pulmonary disposition of antimicrobial agents
 clinical relevance and *in vivo* observations, 1176
 methodological considerations, 1171
 retrovirus
 reverse transcriptase inhibition, 245
 therapy, 245
 synergism, *in vivo*
 animal models, contribution of, 907
 toxicity
 antifungal agents, *in vitro* models for, 1799

Minocycline
 comparative evaluation
 erythromycin, ampicillin, amoxicillin, cefixime, metronidazole, and bismuth subcitrate, 185
H. pylori
 slowly growing, 185
M. avium complex
 human macrophages, 2104
R. equi, 1244
 synergy
 clarithromycin, 2852
 T. gondii, 2852

Monoclonal antibodies
 antipolysaccharide
 MAB-T88, phase I study, 2349
 MAB-T88
 phase I study, 2349
 MS-8209
 C. albicans, 2722
 C. neoformans, 2722

mycoses, experimental systemic, 2722
 toxicity
 renal tubular cells, 2722

Mupirocin
 comparative evaluation
 erythromycin, 287
 impetigo
 erythromycin-resistant *S. aureus*, 287

Mureidomycins
Pseudomonas spp., 1024
 imipenem resistant, 1024
 ofloxacin resistant, 1024

Mycobacterium avium
 azithromycin
 combinations, 1611
 comparative evaluation, 1611
 azithromycin-clarithromycin
 comparative evaluation, 1611
 clarithromycin resistance
 selection of mutants by monotherapy, 2839
 gentamicin, 1695
 gentamicin-clarithromycin, 1695

Mycobacterium avium complex
 clarithromycin
 beige mice, 2413
 comparative evaluation, 1163
 human macrophages, 2104
 J774 cells and alveolar macrophages, 1163
 clarithromycin-rifabutin
 beige mice, 2413
 erythromycin
 comparative evaluation, 1163
 J774 cells and alveolar macrophages, 1163
 ethambutol, 2408
 ethambutol-RU-40 555, 2408
 KRM-1648
 mice, 387
 minocycline
 human macrophages, 2104
 RU-40 555, 2408
 sparfloxacin, 2408
 sparfloxacin-ethambutol-RU-40 555, 2408
 WIN-57273
 human macrophages, 2104

Mycobacterium avium-M. intracellulare complex
 bacteremia
 clarithromycin-ciprofloxacin-amikacin, 1567

ciprofloxacin
 clarithromycin-ciprofloxacin-amikacin, 1567
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816

streptomycin
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816

Mycobacterium chelonae
 azithromycin, 180
 clarithromycin, 180
 erythromycin, 180
 roxithromycin, 180

Mycobacterium fortuitum
 azithromycin, 180
 β-lactam resistance
 β-lactamases, 1068
 penicillin-binding proteins, 1068

clarithromycin, 180
 erythromycin, 180
 roxithromycin, 180

Mycobacterium kansasi
 clarithromycin
 in vitro susceptibility, 2039

Mycobacterium leprae
 fusidic acid, 92
 quinolones
 comparative evaluation, 2544

Mycobacterium paratuberculosis
 clarithromycin
 comparative evaluation, 2843
 ethambutol, enhancement of activity, 2843

Mycobacterium spp.
 clarithromycin, 1987
 pH, effect on MICs, 2841
 ethionamide
 mechanism of action, 1316
 mycolic acid synthesis inhibition, 1316
 slowly growing, nontuberculous clarithromycin, 1987

Mycobacterium tuberculosis
 isoniazid
 antagonism with pyrazinamide-rifampin, 548
 pyrazinamide-rifampin
 antagonism with isoniazid, 548

Mycoplasma genitalium
 susceptibilities, *in vitro*, 870

Mycoplasma pneumoniae
 macrolides, 1322
 quinolones, 1322
 susceptibilities, *in vitro*, 870
 tetracyclines, 1322

Myocarditis
 coxsackievirus
 WIN 54954, 425
 WIN 54954, 425

Myxococcus xanthus
 antibiotic TA
 expression of genes required for production, 2322
 genes involved in production, mutation and mapping of, 2316

Myxovirus
 5-ethyl-1-β-D-ribofuranosylimidazole-4-carboxamide, 435
 6-(R)-6'-C-methylneplanocin A, 435
 ribavirin, 435

Myxoviruses
 protease inhibitors
 effects on replication, 1432

Naftifene
C. albicans
 squalene epoxidase inhibition, 1799

Nalidixic acid
E. coli
 SOS-response and cell-division mutants, 819

salmonellae
 ampicillin resistant, 1794

Naphthoquinones
 topoisomerase II
 DNA cleavage, induction of, 2589

Neisseria gonorrhoeae
 antibiotic susceptibilities
 isolates from the Philippines, 277
 antibiotic susceptibility survey, 1682

cefodoxime proxetil, 1764
ceftriaxone resistance, 1682
temafloxacin
comparative evaluation, 1131
urethritis
cefodoxime proxetil, 1764
Neisseria meningitidis
ampicillin susceptible
discrimination between moderately and fully susceptible isolates, 1028
penicillin susceptible
discrimination between moderately and fully susceptible isolates, 1028
Nephrotoxicity
amphotericin B
different formulations, comparative evaluation, 1525
Netilmicin
pyelonephritis
5 mg/kg once daily versus 3 mg/kg thrice daily, 1499
Neutrophils
pentoxifylline
modulation of activation, 408
Nifedipine
cefixime
bioavailability, effect on, 2462
Nikkomycin Z
C. albicans
chitin biosynthesis, inhibition of, 1909
Nikkomycins
combinations
azoles, 1284
C. albicans, 1284
synergy
azoles, 1284
C. albicans, 1284
Nonnucleoside reverse transcriptase inhibitors
human immunodeficiency virus resistance
suppression of resistance to 3'-azido-3'-deoxythymidine, 2664
Nonoxynol 9
C. trachomatis
infected HeLa 229 cells, 1478
infected primary monkey cervical epithelial cells, 1478
HeLa cells
toxicity to, 1478
primary monkey cervical epithelial cells
toxicity to, 1478
Norfloxacin
absorption
inhibition by dairy products, 489
E. coli
SOS-response and cell-division mutants, 819
E. coli colonization
porcine gut models, 401
P. aeruginosa resistance
nfxB type mutation, 2562
pharmacokinetics
effect of dairy products, 489
Ofloxacin
anaerobic bacteria
comparative evaluation, 1158
B. melitensis, 973
brucellosis, 973

C. burnetii, 2529
C. pneumoniae, 682
C. trachomatis
cervical infection, 1144
comparative evaluation, 1144
comparative evaluation
ciprofloxacin, fleroxacin, temafloxacin, sparfloxacin, 682
pharmacokinetics
multiple intravenous doses in healthy volunteers, 308
penetration into heart valves, myocardium, mediastinal fat, and bone marrow, 2493
R. conorii, 2529
R. rickettsii, 2529
safety
multiple intravenous doses, 308
traveler's diarrhea
three versus five days of therapy, 87
L-Ofloxacin
C. pneumoniae, 1573
Oligonucleotides
5-mercapto substituted
human immunodeficiency virus type 1, 108
Omeprazole
H. pylori, 1133
OPC-17116
comparative evaluation
ofloxacin, enoxacin, ciprofloxacin, and tosufloxacin, 573
Enterobacteriaceae
assay conditions, effect on activity, 1310
comparative evaluation, 1310
gram-positive organisms
comparative evaluation, 2185
in vitro activity
assay conditions, effect of, 1310
comparative evaluation, 1310
Orthovirus
5-ethyl-1-β-D-ribofuranosylimidazole-4-carboxamide, 435
6'-(R)-6'-C-methylneplanocin A, 435
ribavirin, 435
Osteomyelitis
staphylococcal
azithromycin, 2693
azithromycin-rifampin, 2693
Oxytetracycline
bacteria pathogenic to fish
temperature-dependent activity, 1738
Panipenem-betamipron
pharmacokinetics
prediction from animal data, 1810
Pasteurella multocida
penicillin G
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093
tetracycline
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093
trimethoprim-sulfamethoxazole
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093

PD 127,391
C. burnetii, 2529
gram-positive organisms
comparative evaluation, 1329
R. conorii, 2529
R. rickettsii, 2529
PD 131,628
C. burnetii, 2529
R. conorii, 2529
R. rickettsii, 2529
S. pneumoniae
comparative evaluation, 856
PD 127,391
gram-positive organisms
blood isolates, 1570
comparative evaluation, 1570
Pefloxacin
B. melitensis, 973
brucellosis, 973
C. burnetii, 2529
P. carinii
mice, 470
pneumonia
mice, 470
R. conorii, 2529
R. rickettsii, 2529
S. aureus
transport across cytoplasmic membrane, 2506
Penciclovir
herpes simplex virus
mechanism of action, 2747
MRC-5 cells, 2747
type 1, 2037
type 2, 2037
varicella-zoster virus
mechanism of action, 2747
MRC-5 cells, 2747
Penems
[¹⁴C]FCE 22891
pharmacokinetics, 1958
Penicillin
Corynebacterium CDC group II, 1325
endocarditis, 1325
synergy with gentamicin, 1325
E. faecalis
susceptibility changes following various exposure regimens, 121
E. faecium resistance
mechanisms of, 783
endocarditis, 1325
N. meningitidis susceptibility
discrimination between moderately and fully susceptible isolates, 1028
S. pneumoniae resistance
increased occurrence in a children's hospital, 1703
susceptibilities, in vitro, 1703
synergy
endocarditis, 2403
S. adjacens, 2403
tobramycin, optimal dosing regimen, 2403
Penicillin G
Enterococcus resistance
ramoplanin, 2342
P. multocida
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093

Penicillin-binding proteins
E. faecium
 analysis of, 783
M. fortuitum
 β -lactam resistance, 1068
S. aureus
 characterization, 656
 polymerase chain reaction, 6
S. aureus, methicillin resistant
 PBP 2a, construction of a water-soluble form, 533
S. pneumoniae
 multiply antimicrobial resistant, 2176
 Pentamidine
 pharmacokinetics
 metabolism in rats, primary and secondary, 1825
 Pentoxifylline
 human neutrophils
 modulation of activation by amphotericin B, 408
 Peptides
C. albicans
 effect on adherence, 132
 Peptidoglycan precursors
Enterococcus spp.
 vancomycin resistant, 1487
Peptostreptococcus spp.
 lincosamide resistance
 inducible and constitutive phenotypes, 662
 macrolide resistance
 inducible and constitutive phenotypes, 662
 Peritonitis
 complication of continuous ambulatory peritoneal dialysis
 susceptibility testing of isolated bacteria, 1097
 Pharmacokinetics
 acyclovir
 distribution over blood-brain barrier, 339
 rats, 339
 amikacin
 cefepime, lack of interaction with, 1382
 amoxicillin
 enzyme-linked immunosorbent assay, use to assess, 1545
 penetration into lung secretions, 1545
 amphotericin B
 colloidal dispersion, 299
 relationship to safety, 299
 ampicillin
 2085P, after oral administration of, 1002
 ampicillin-sulbactam
 serum and blister fluid, 2233
 antipyrine
 rifampin, 2- and 4-day regimens, effect of, 1553
 3'-azido-3'-deoxythymidine, 808
 2',3'-dideoxyinosine, lack of interaction with, 665
 azithromycin
 AIDS patients, 1013
 lung, 1412
 uptake by phagocytes, 1412
 azoles, oral
 effect of cyclodextrin, 477
 β -lactams
 continuous infusion, minireview, 2577
 BRL 42715
 rats, 1427
 brobactam
 2085P, after oral administration of, 1002
 cefazolin
 rats, 1427
 cefepime
 age and gender, effects of, 1181
 amikacin, lack of interaction with, 1382
 patients on continuous ambulatory peritoneal dialysis, 1387
 serum and blister fluid, 453
 single and multiple intravenous administrations, 552
 subjects with renal impairment, 2676
 cefixime
 bioavailability, effect of nifedipine on, 2462
 cefmenoxime
 concentrations in sera and peritoneal tissue, 1483
 patients undergoing gastrointestinal surgery, 1483
 cefonidic
 angiotensin II, effect of, 616
 cefoperazone
 serum and blister fluid, 453
 tissue penetration model, 295
 cefotetan
 patients undergoing colorectal surgery, 1115
 serum and blister fluid, 2233
 single dose, 1115
 cefoxitin
 serum and blister fluid, 2233
 cefpirome, 2085
 cefpodoxime proxetil, 796
 effect of antacid and H_2 -receptor antagonist on absorption, 796
 healthy volunteers, 126
 patients with impaired renal function, 126
 penetration into lung parenchyma and epithelial lining fluid, 2099
 cefprozil
 antacid, effect of, 962
 beagles, 687
 excretion in human breast milk, 938
 multiple dosing, 144
 ceftazidime, 2085
 patients with pneumonia, 1404
 serum and blister fluid, 453
 ceftizoxime
 serum and blister fluid, 2233
 ceftriaxone, 2085
 1,000 mg intravenously, 2804
 diclofenac, effects on, 2331
 prophylaxis in thoracic surgery, 2804
 tissue penetration, 2804
 transudative and exudative pleural effusion, penetration, 2774
 cephalosporin
 rats, rabbits, dogs, and monkeys, 966
 ciprofloxacin, 2085
 aluminum hydroxide, effect on bioavailability, 830
 bioavailability in cystic fibrosis patients, 2512
 calcium carbonate, effect on bioavailability, 830
 infants and small children, 1086
 penetration into blister fluid, 651
 single 750-mg dose, 677
 single intravenous and oral doses, 993
 clarithromycin
 infants and children, 2478
 metabolite, 14-(R) hydroxylated, 2478
 oral administration in humans, 1147
 single ascending oral doses, 2447
 CP-72, 2588, 2080
 CP-74, 667
 laboratory animals, 1671
 daptomycin
 healthy volunteers, 318
 intravenous drug abusers, 1109
 didanosine
 influence of hemodialysis, 1519
 patients with normal and impaired renal function, 1519
 ranitidine, interaction with, 2075
 2',3'-dideoxy-5-fluoro-3'-thiacytidine
 racemic, 2432
 rhesus monkeys, 2432
 2',3'-dideoxyinosine
 3'-azido-3'-deoxythymidine, lack of interaction with, 665
 bioavailability, impact on maximal tolerated dose, 1280
 6-dimethylaminopurine arabinoside, 353
 DQ-2556
 rats, rabbits, dogs, and monkeys, 966
 DR-3355
 antacids, effect of, 2270
 ferrous sulfate, effect of, 2270
 ranitidine, effect of, 2270
 epithelial cells
 intestinal transport of antimicrobial agents, use as a model for, 1374
 $[^{14}\text{C}]$ FCF 22891
 healthy volunteers, 1958
 fleroxacin
 aqueous and vitreous humors, 32
 guinea pigs, 2387
 patients with liver cirrhosis, 631
 penetration into blister fluid, 651
 positron emission tomography, 2286
 rabbits with *E. coli* infections, 2286
 sucralfate, effect of, 2758
 3'-fluoro-3'-deoxythymidine, 808
 penetration into brains, muscle tissue, and veins of monkeys, 2418
 relation to antiviral action, 2418
 2'-fluoro-5-ethyl-1- β -D-arabinofuranosyluracil
 mice and rats, 1472
 preclinical pharmacology, 1472
 fosfarnet
 AIDS patients, 1821
 twice-daily administrations, 1821
 foscarnet-zidovudine, 1773
 gentamicin
 patients with end-stage renal disease, 1832
 patients with pleural effusions and hypoalbuminemia, 679
 piperacillin, effect on gentamicin disposition, 1832
 tobramycin, comparative evaluation, 679
 6-halo-dideoxypyrimidine nucleosides, 2156
 central nervous system uptake, 2156
 (R) -9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
 distribution over blood-brain barrier,

339
 rats, 339
ICI 213,689
 healthy subjects, 2794
 renal impairment, patients with, 2794
 young and elderly healthy men, 1437
imipenem, 2085
 serum and skin window fluid of
 healthy adults, 1400
 transplacental passage, 2652
imipenem-cilastatin
 effect of biliary obstruction on hepatic
 excretion, 2057
isepamicin
 patients with end-stage renal disease,
 1832
 piperacillin, effect on isepamicin dis-
 position, 1832
L-671,329
 rhesus monkeys and DBA/2 mice, 607
lomefloxacin
 absorption, effect of antacid on, 1219
 sputum penetration, 2458
 steady state, 2458
 transudative and exudative pleural ef-
 fusion, penetration, 2774
loracarbef
 patients receiving 200 versus 400 mg,
 521
meropenem
 healthy subjects, 2794
 metabolite, 1437
 renal impairment, patients with, 2794
 renal impairment, subjects with, 1532
 young and elderly healthy men, 1437
norfloxacin
 effect of dairy products, 489
ofloxacin
 multiple intravenous doses in healthy
 volunteers, 308
 penetration into heart valves, myocardium,
 mediastinal fat, and bone
 marrow, 2493
panipenem-betamipron
 prediction from animal data, 1810
pentamidine
 metabolism in rats, primary and sec-
 ondary, 1825
piperacillin
 patients undergoing colorectal surgery,
 1997
 rats, 1427
pivalic acid
 S-1108, after administration of, 757
polymorphonuclear leukocytes
 delivery and transport of drugs, 2584
pulmonary disposition of antimicrobial
 agents
 minireviews, 1171, 1176
pyrimethamine
 infants with congenital toxoplasmosis,
 1040
R 82913
 AIDS patients, 2661
 intravenous versus oral administra-
 tion, 2661
ranitidine
 didanosine, interaction with, 2075
rifampin
 intraocular penetration, 1575
RP 59500
 fibrin clots, penetration into, 2211
rufoxacin

multiple dose, in healthy volunteers,
 1296
S-1108, 762
 carnitine body stores, 762
 healthy volunteers, 762
SCE-2787
 comparative evaluation, 2481
SCH-39304
 human immunodeficiency virus-in-
 fected patients, 2790
sparfloxacin, 2444
 human polymorphonuclear leukocytes,
 1053
 inflammatory fluid penetration, 2444
sucralfate
 fleroxacin, effect on, 2758
systemic antibiotics, perioperative
 liver transplant patients, 2125
tazobactam
 patients undergoing colorectal surgery,
 1997
teicoplanin
 healthy male volunteers, 115
 metabolism in humans, 1744
temafloxacin
 multiple oral doses, 378
ticarcillin-clavulanate
 serum and blister fluid, 2233
tobramycin
 patients with pleural effusions and hy-
 poalbuminemia, 679
 proximal tubular cells, subcellular lo-
 calization in, 2204
 tobramycin, comparative evaluation,
 679
vancomycin
 intravenous drug abusers, 1109
 proximal tubular cells, subcellular lo-
 calization in, 2204
 sternal bone, penetration into, 2539
zidovudine
 intravenous and oral, 2245
 penetration into brains, muscle tissue,
 and veins of monkeys, 2418
 relation to antiviral action, 2418
Phospholipids
amphotericin B
 influence of phospholipid/amphotericin
 B ratio on renal cell toxicity and
 fungicidal activity, 262
 influence of type on renal cell toxicity
 and fungicidal activity, 262
Piperacillin
B. fragilis group, 2051
 combinations
 amikacin, 2808
 BRL 42715, 1427
 comparative evaluation, 2766, 2808
E. coli, 1427
 febrile neutropenic patients with can-
 cer, 2808
 gentamicin, 1883
 intra-abdominal infections, 2766
K. pneumoniae, 1883
S. marcescens, 1427
 tazobactam, 1883, 2766
 tazobactam-gentamicin, 1883
gentamicin
 effect on gentamicin disposition, 1832
isepamicin
 effect on isepamicin disposition, 1832
K. pneumoniae, 1883
P. aeruginosa
 biofilms, dynamic interactions, 1208
P. aeruginosa resistance
 biofilm, barrier to diffusion, 2054
pharmacokinetics
 patients undergoing colorectal surgery,
 1997
 rats, 1427
Pirodavir
 comparative evaluation
 R 61837, 100
enterovirus, 100
rhinovirus, 100
 experimental infection, 727
 safety and efficacy, 727
Plasmids
 $aphA-7$ kanamycin resistance determi-
 nant
C. jejuni, 712
 characterization, 712
kanamycin resistance
 transfer from *E. faecalis* to *E. coli*,
 502
tetracycline resistance
S. hyicus, tet (L) sequence, 580
trimethoprim resistance
E. coli, 1720
Plasmodium falciparum
acridines
 anticancer, 1644
chloroquine resistant
 fluoxetin hydrochloride, enhancement
 of susceptibility, 2761
chloroquine-chlorpromazine, 209
chloroquine-prochlorperazine, 209
cinchona alkaloids
 stereochemical evaluation, 1538
cinnamic acid derivatives, 1102
 permeability of infected cells, effect
 on, 1102
ethanolamine, radioactive
 incorporation into phospholipids, 50
**microdilution technique, semiauto-
 mated, 50**
5-fluoroorotate
 molecular targets, 704
Platelet-activating factor antagonists
 CL 184,005
 animal models, evaluation in, 1971
 sepsis, bacterial, 1971
Plumbagin
 topoisomerase II
 DNA cleavage, induction of, 2589
Pneumocystis carinii
antifolate agents
 rat model, 1935
antimicrobial agents
 classification, new system for, 1943
antiviral agents
 rat model, 1935
benzimidazoles
 antimicrotubule activity, 779
fluoroquinolones
 mice, 470
L-693,989
 rats, 1964
pefloxacin
 mice, 470
trimethoprim-sulfamethoxazole
 pneumonia, 2328
**trimethoprim-sulfamethoxazole-zidovu-
 dine**
 pneumonia, 2328

Pneumocystosis
antimicrobial agents
classification, new system for, 1943

Pneumonia
amoxicillin
comparative evaluation, 833
efficacy and safety, 833

antifolate agents
rat model, 1935

antiviral agents
rat model, 1935

fluoroquinolones
mice, 470

P. carinii
antiviral and antifolate agents, 1935

pefloxacin
mice, 470

sparfloxacin
lipopolysaccharide-specific monoclonal antibodies, combination with, 1352

temafloxacin
comparative evaluation, 833
efficacy and safety, 833

trimethoprim-sulfamethoxazole, 2328

trimethoprim-sulfamethoxazole-zidovudine, 2328

pol
human immunodeficiency virus type 1, mutations in
2',3'-dideoxycytidine, decreased susceptibility, 153

Polyaspartic acid
toxicity
protection from, duration of, 2556

Polyethers
human immunodeficiency virus type 1
inhibition of replication, 492

Polymerase chain reaction
S. aureus
comparison with conventional microbiologic method of detection, 6
methicillin resistant, 6
penicillin-binding protein gene, 6

Polymixin B
P. aeruginosa resistance
OprH, role in, 2566

Polymorphonuclear leukocytes
drug delivery and transport, 2584

Polynucleotides
5-mercaptop substituted
human immunodeficiency virus type 1, 108

[Tyr-5,12, Lys-7]polyphemusin II
human immunodeficiency virus type 1, 1249

Polyphemusins
mechanisms of antibacterial action, 1460

Positron emission tomography
pharmacokinetics
fleroxacin, 2286

Postantibiotic effect
E. coli
macromolecular biosynthesis, analysis of, 2118
quinolones, 2118

platelet microbicidal protein
S. aureus, 1665

Pristinamycin
M. genitalium, 870

M. pneumoniae, 870

Prochlorperazine
combinations
chloroquine, 209

P. falciparum, 209

Protease inhibitors
human immunodeficiency virus, 982
human immunodeficiency virus type 1
C₂ symmetry based, 926
inhibition of replication, 926

myxoviruses
effects on replication, 1432

Proteus mirabilis
ceftazidime, 1580
E1040, 1580
outer membrane mutants
tosufloxacin, 2030
tosufloxacin uptake, 2030

tosufloxacin
outer membrane mutants, 2030
uptake, 2030

urinary tract infections
ceftazidime, 1580
E1040, 1580

Pseudomembranous colitis
C. difficile
effects of antibiotics on toxin production, 1322

teicoplanin
comparative evaluation, 2192
oral, 2192

vancomycin
comparative evaluation, 2192
oral, 2192

Pseudomonas aeruginosa
amikacin
postantibiotic sub-MIC effects, 1852

amikacin-aztreonam, 2741

amikacin-cefepime, 2741

amikacin-ceftazidime, 2741

bacteremia
erythromycin, 1198
rifampin-beta-lactam-aminoglycoside therapy, 620

β -lactamase
activity in sputum samples from cystic fibrosis patients, 71

biofilms
piperacillin, barrier to diffusion, 2054

piperacillin, dynamic interactions with, 1208

tobramycin, dynamic interactions with, 1208

ceftazidime, 1580

clindamycin
proinflammatory interactions, inhibition of, 1236

E1040, 1580

E1077
morphological changes, 1894

enoxacin resistance
mechanism of resistance, 1057

pleiotropic, posttherapy mutant, 1057

erythromycin, 1198
proinflammatory interactions, inhibition of, 1236

virulence, effect on, 1922

fluoroquinolone supersusceptibility
OprH overexpression, 2365

gentamicin resistance
adaptive, 1951
dynamic in vitro model, 1951

OprH, role in, 2566

imipenem resistance
protein D2, nucleotide sequence, 1791

imipenem resistant
 β -lactamase and impermeability, association of, 2046

E1040, 684

L-627
comparative evaluation, 1928

meropenem, cephem, and quinolone cross-resistance

outer membrane protein overproduction, association with, 1847

monoclonal antibodies, antiflagellar, 1290

antibiotic combinations, 1290

nfxB
norfloxacin resistance, 2562

norfloxacin resistant
nfxB type mutation, 2562

piperacillin resistance
biofilm as a diffusion barrier, 2054

polymixin resistance
OprH, role in, 2566

protein D2
nucleotide sequence, 1791

quinolone accumulation
fluorometric assay, 1601

rifampin-beta-lactam-aminoglycoside therapy, 620

Ro 23-9424
cancer patients, isolates from, 879

roxithromycin
proinflammatory interactions, inhibition of, 1236

sparfloxacin
lipopolysaccharide-specific monoclonal antibodies, combination with, 1352

sparfloxacin resistance, 255
ciprofloxacin, emergence of cross-resistance, 255

urinary tract infections
ceftazidime, 1580
E1040, 1580

Pseudomonas cepacia
resistance
pore-forming outer membrane protein, association with absence of, 2280

salicylate inducible, 2280

Pseudomonas spp.
imipenem resistant
mureidomycins, 1024

mureidomycins, 1024

ofloxacin resistant
mureidomycins, 1024

Pulse oximetry
influenza virus
measurement of antiviral activity in mice, 473

Pyelonephritis
netilmicin
5 mg/kg once daily versus 3 mg/kg thrice daily, 1499

Pyrazinamide
combinations
antagonism with isoniazid, 548
comparative activity, 548

M. tuberculosis, 548

rifampin, 548

Pyrimethamine
pharmacokinetics
infants with congenital toxoplasmosis, 1040

Q-35
 in vitro activity, comparative evaluation, 1708
 photostability and biological activity after UV irradiation, 1715

Quinolones
 AM-1155
 in vitro and in vivo activities, 2108
 CP-74,667
 pharmacokinetics, 1671
 cytochrome P450IA2
 inhibitory potency, 942
E. coli
 accumulation in, 1601
 SOS-response and cell-division mutants, 819
E. coli resistance loci
 genetics and regulation, 1151
nfxB, *nfxC*, and *cfxB*, 1151
M. leprae
 comparative evaluation, 2544
M. pneumoniae, 1322
 OPC-17116
 comparative evaluation, 573
 gram-positive organisms, 2185
P. aeruginosa
 accumulation in, 1601
P. aeruginosa resistance
 meropenem and cephem cross-resistance, 1847
 outer membrane protein overproduction, association with, 1847
 postantibiotic effect
E. coli, 2118
S. aureus
 accumulation in, 1601
X. maltophilia
 susceptibility, 669
X. maltophilia resistance
 outer membrane proteins, 669

4-Quinolones
 bacteria pathogenic to fish
 temperature-dependent activity, 1738

R 61837
 human rhinovirus 9
 capsid-stabilizing activity, 417
 parameters of binding, 417

R 82913
 pharmacokinetics
 AIDS patients, 2661
 intravenous versus oral administration, 2661

Rabies virus
 ketamine
 transcription, inhibition of, 1750

Radioimmunoassays
 high-pressure liquid chromatography
 combined procedure for measuring intracellular zidovudine, 2473

Ramoplanin
Enterococcus spp.
 gentamicin resistant, 2342
 penicillin G resistant, 2342
 vancomycin resistant, 2342

gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570

Ranitidine
 DR-3355
 pharmacokinetics, effect on, 2270

pharmacokinetics

didanosine, interaction with, 2075
 DR-3355, effect on, 2270

Red man syndrome
 teicoplanin, high dose
 absence in patients treated with, 1204

vancomycin
 absence in patients treated with, 1204

Renal dehydropeptidase I
 LJC 10,627
 stability, 481
 meropenem stability, 1577
 1 β -methyl substitution, effect on stability, 1577

Replication endpoint concentration assays
 didanosine resistance
 human immunodeficiency virus type 1, 920
 zidovudine resistance
 human immunodeficiency virus type 1, 920

Retroviruses
 antiviral agents
 minireview, 509
 reverse transcriptase inhibition
 minireview, 245

Rhinovirus
 4',6-dicyanoflavan
 mechanism of action, 95
 pirodavir, 100
 intranasal, 727
 safety and efficacy, 727

R 61837, 100
 capsid-stabilizing activity, 417
 parameters of binding, 417

reverse transcriptase inhibition
 minireview, 245

soluble intercellular adhesion molecule-1
 in vitro activity, 1186

Rhodococcus equi
 amikacin, 1244
 ciprofloxacin, 1244
 erythromycin, 1244
 imipenem, 1244
 minocycline, 1244
 rifampin, 1244
 vancomycin, 1244

Ribavirin
influenza virus
 pulse oximetry, measurement of activity in mice, 473

orthoviruses, 435

paramyxoviruses, 435

Rickettsia conorii
 ciprofloxacin, 2529
 ofloxacin, 2529
 PD 127,391, 2529
 PD 131,628, 2529
 pefloxacin, 2529

Rickettsia rickettsii
 ciprofloxacin, 2529
 ofloxacin, 2529
 PD 127,391, 2529
 PD 131,628, 2529
 pefloxacin, 2529

Rifabutin
 combinations
 clarithromycin, 2413
M. avium complex, 2413

Rifampin
 antipyrene metabolites, formation of
 2- and 4-day regimens, effect of, 1553
 antipyrene pharmacokinetics
 2- and 4-day regimens, effect of, 1553

B. meliensi, 973
 bioavailability
 letter to the editor, 2066
 murine tuberculosis, 2066

brucellosis, 973
 combinations
 antagonism with isoniazid, 548
 beta-lactam and aminoglycoside, 620
 comparative evaluation, 548
M. tuberculosis, 548
P. aeruginosa bacteremia, 620
 pyrazinamide, 548

H. influenzae
 prophylaxis for contacts of infected patients, 545

pharmacokinetics
 intraocular penetration, 1575

R. equi, 1244

Ro 09-1227
 comparative evaluation
 other cephalosporins, 233

Enterobacteriaceae, 233

Ro 23-9424
 cancer patients, bacterial isolates from comparative evaluation, 879

L. pneumophila, 2559

Legionella spp., 2559

Ro 40-6890
Enterobacteriaceae
 intestinal species, 2835
 in vitro and in vivo activities
 comparative evaluation, 2825

Vibronaceae
 intestinal species, 2835

Ro 41-3399
 in vitro and in vivo activities
 comparative evaluation, 2825

Ro 5-3335
 human immunodeficiency virus type 1
 cell type-specific activity, 2628

Romurtide
 combinations
 cefmenoxime, synergy, 167

K. pneumoniae, 167

Roxithromycin
 comparative evaluation
 erythromycin, azithromycin, and clarithromycin, 180
 inhibitory activity in presence of human serum, 10

M. chelonae, 180

M. chelonae-like organisms, 180

M. fortuitum, 180

P. aeruginosa
 proinflammatory interactions, inhibition of, 1236

S. pneumoniae
 postantibiotic sub-MIC effects, 1852

S. pyogenes
 postantibiotic sub-MIC effects, 1852

serum protein binding, 10

RP 59500
 gram-positive organisms
 pharmacodynamic interaction, 2211

pharmacokinetics
 fibrin clots, penetration into, 2211

Staphylococcus spp., 854
 testing methods, evaluation of, 854

RR 42427
C. immitis, 217

C. neoformans, 217

meningitis
 cryptococcal and coccidioidal, 217

RU-40 555
combinations
ethambutol, 2408
M. avium complex, 2408
sparfloxacin, 2408
M. avium complex, 2408
RU 29246
in vitro activity
comparative evaluation, 2360
RU44790
in vitro activity
comparative evaluation, 1756
Rufloxacin
pharmacokinetics
multiple dose, in healthy volunteers, 1296

S-1006
in vitro activity, 1336
susceptibility to hydrolysis, 1336
S-1108
metabolic profiles of metabolites, 757
metabolism, 757
pharmacokinetics, 762
carnitine body stores, 762
healthy volunteers, 762
Saccharomyces cerevisiae
[S-methyl-³H]bleomycin A₂
lesions and preferential initial localization on cell walls, 2497
Salmonella enteritidis
ceftriaxone
comparative evaluation, 949
imipenem
comparative evaluation, 949
meningitis
ceftriaxone, 949
imipenem, 949
Salmonella typhimurium
3'-azido-3'-deoxythymidine
intracellular activity, 1081
outer membrane mutants
tosufloxacin, 2030
tosufloxacin uptake, 2030
tosufloxacin
outer membrane mutants, 2030
uptake, 2030
zidovudine
intracellular activity, 1081
Salmonellae
ampicillin-resistant
amoxicillin-clavulanic acid, 1794
aztreonam, 1794
cefotaxime, 1794
ceftriaxone, 1794
chloramphenicol, 1794
ciprofloxacin, 1794
co-trimoxazole, 1794
gentamicin, 1794
nalidixic acid, 1794
tetracycline, 1794
Saperconazole
A. fumigatus
comparative evaluation, 2681
oral and intravenous, 2681
aspergillosis
comparative evaluation, 2681
oral and intravenous, 2681
SCE-2787
comparative evaluation, 1358
in vitro and in vivo activities, 1358
pharmacokinetics

comparative evaluation, 2481
SCH 39304
C. albicans, 64
C. immitis, 217
C. neoformans, 217
comparative evaluation
fluconazole and ketoconazole, 64
meningitis
cryptococcal and coccidioidal, 217
pharmacokinetics
human immunodeficiency virus-infected patients, 2790
systemic fungal infections, 64
SCH 42427
antifungal activity, 498
C. albicans, 498
in vitro and in vivo activity, 498
SDZ 87-469
C. albicans
squalene epoxidase inhibition, 1799
Seminal plasmin
13-residue peptide from
increased antibacterial activity without
increased hemolytic activity, 2468
Sepsis
CL 184,005
animal models, evaluation in, 1971
platelet-activating factor antagonist
animal models, evaluation in, 1971
Serratia marcescens
aac(6')-Ic
characterization of, 1447
aac(3)-Vb
cloning and sequence analysis, 2222
aminoglycoside resistance
aac(6')-Ic, characterization of, 1447
aac(3)-Vb, cloning and sequence analysis, 2222
aminoglycosides
factors affecting in vivo activity, 744
BRL-42715-cefazolin, 1427
BRL-42715-piperacillin, 1427
Shigella sonnei
fluoroquinolones
newer, 2346
Shikokin
topoisomerase II
DNA cleavage, induction of, 2589
Siderophores
β-lactams
E. coli, mechanism of action, 2166
β-lactam hypersusceptible, 840
growth promotion studies, 840
Simian immunodeficiency virus
3'-azido-3'-deoxythymidine
rhesus macaques, 2381
3'-azidothymidine
long-term tolerance and efficacy, 1770
3'-fluorothymidine
long-term tolerance and efficacy, 1770
Skin infections
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
Soluble intercellular adhesion molecule-1
rhinovirus
in vitro activity, 1186
Sparfloxacin
anaerobic organisms, 239
comparative evaluation, 1158
C. pneumoniae, 682
C. trachomatis, 188
combinations

ethambutol, 2408
lipopolysaccharide-specific monoclonal antibodies, 1352
M. avium complex, 2408
P. aeruginosa, 1352
RU-40 555, 2408
comparative evaluation
ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, 682
other quinolone derivatives, 255
other quinolones, 558
other quinolones and tetracyclines, 188
E. coli, 505
gram-negative organisms
comparative evaluation, 558
gram-positive organisms
comparative evaluation, 558
human polymorphonuclear leukocytes
uptake and intracellular activity, 1053
invasive isolates from pediatric patients, 255
M. avium complex, 2408
P. aeruginosa resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
pharmacokinetics, 2444
human polymorphonuclear leukocytes, 1053
inflammatory fluid penetration, 2444
renal infection
mice, 505
S. aureus, 505
S. aureus resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
S. pneumoniae
comparative evaluation, 856
penicillin susceptible and resistant, 2698
postantibiotic sub-MIC effects, 1852
S. pyogenes
postantibiotic sub-MIC effects, 1852
SS 42426
C. immitis, 217
C. neoformans, 217
meningitis
cryptococcal and coccidioidal, 217
Staphylococcus aureus
β-lactamase repressor
homology with enterococci, 2265
sequence analysis, 2265
β-lactamases
characterization, 440
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
cephalexin
interaction of biofilm cells in a chemostat system, 890
cephem antibiotics
effect of serum protein binding on efficacy, 17
CI-960, 1192
ciprofloxacin resistant
CI-960, 1192
daptomycin, 318
daptomycin early killing
in vitro pharmacodynamic model, investigation by, 2334
E1077
morphological changes, 1894
endocarditis
ticarcillin-clavulanic acid, 458

erythromycin resistant
 impetigo, 287
KB-5246 accumulation
 carbonyl cyanide *m*-chlorophenylhydrazone, lack of effect on, 883
MDL 62,873, 446
methicillin resistance
 chromosomal factors, mapping and characterization of, 1367
 letter to the editor, 1585
 polymerase chain reaction, detection by, 1585
methicillin resistant
 autolytic properties, 566
 $gyrA$ mutations associated with ciprofloxacin resistance, 1166
 $mecA$, $mecR1-mecI$, and $femA-femB$, 2617
 polymerase chain reaction, 6
methicillin susceptible
 autolytic properties, 566
NorA
 B. subtilis Bmr, structural and functional homolog, 484
pefloxacin
 transport across cytoplasmic membrane, 2506
penicillin-binding protein 2
 characterization, 656
penicillin-binding proteins
 construction of a water-soluble form, 533
postantibiotic effect
 platelet microbicidal protein, enhancement of, 1665
quinolone accumulation
 fluorometric assay, 1601
quinolone susceptible
 pefloxacin, transport across cytoplasmic membrane, 2506
skin infections
 cefadroxil suspension, 1614
 cefuroxime axetil suspension, 1614
sparfloxacin
 renal infection in mice, 505
sparfloxacin resistance, 255
 ciprofloxacin, emergence of cross-resistance, 255
ticarcillin-clavulanic acid
 dosing ratio, 1585
 endocarditis in rats, 458
 letter to the editor, 1585
tobramycin
 interaction of biofilm cells in a chemo-stat system, 890
toxic shock syndrome toxin 1
 glycerol monolaurate, effect on production, 626
WIN 57273
 β -lactamase- and transpeptidase-inhibitory activities, 894
Staphylococcus hyicus
pSTE1
 tet (L) sequence, 580
 tetracycline resistance, 580
Staphylococcus spp.
 β -lactamase-encoding fragments
 comparison with those from *Enterococcus* spp., 273
CI-960
 comparative evaluation, 851
mecA transcription
 methicillin resistance, correlation

with, 25
methicillin resistance
 mecA transcription, correlation with, 25
methicillin resistant
 mecA distribution, 429
Ro 23-9424
 cancer patients, isolates from, 879
RP 59500, 854
 testing methods, evaluation of, 854
time-kill studies
 concentration and pharmacodynamic response, relationship, 1766
vancomycin
 concentration and pharmacodynamic response, relationship, 1766
 time-kill studies, 1766
WIN 57273
 comparative evaluation, 851
Streptococcus adjacens
penicillin-tobramycin
 optimal tobramycin dosing regimen, 2403
 synergy, 2403
temafloxacin
 endocarditis, 2216
Streptococcus agalactiae
gentamicin resistance
 structural gene, identical to those of *E. faecalis* and *E. faecium*, 1215
Streptococcus pneumoniae
cefaclor
 kill and growth rates, 46
cefdinir
 kill and growth rates, 46
cefotaxime and ceftriaxone resistance, high level
 characterization of isolate, 886
ciprofloxacin
 comparative evaluation, 856
erythromycin
 comparative evaluation, 856
MDL 62,873, 446
multiply antimicrobial resistant
 multilocus enzyme electrophoresis profiles, 2176
penicillin-binding proteins, 2176
ribotypes, 2176
ofloxacin
 comparative evaluation, 856
PD 131628
 comparative evaluation, 856
penicillin resistant
 increased occurrence in a children's hospital, 1703
 susceptibilities, in vitro, 1703
penicillin susceptible and resistant
 sparfloxacin, 2698
roxithromycin
 postantibiotic sub-MIC effects, 1852
RP 59500
 comparative evaluation, 856
sparfloxacin
 comparative evaluation, 856
 postantibiotic sub-MIC effects, 1852
temafloxacin
 comparative evaluation, 856
vancomycin
 comparative evaluation, 856
 postantibiotic sub-MIC effects, 1852
Win 57273
 comparative evaluation, 856
Streptococcus pyogenes
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
MDL 62,873, 446
roxithromycin
 postantibiotic sub-MIC effects, 1852
skin infections
 cefadroxil suspension, 1614
 cefuroxime axetil suspension, 1614
sparfloxacin
 postantibiotic sub-MIC effects, 1852
vancomycin
 postantibiotic sub-MIC effects, 1852
Streptococcus spp.
endocarditis, native valve
 teicoplanin, 723
Ro 23-9424
 cancer patients, isolates from, 879
teicoplanin
 4-week treatment, 723
endocarditis, native valve, 723
tetracycline resistant
 occurrence of structures with homology to *Tn916*, 59
Streptogramins
RP 59500
 Staphylococcus spp., 854
Streptomyces lividans
MGT enzyme
 specificity of action, 348
substrate profile, 348
tetracycline resistance gene
 protein with similarities to translation elongation factors, *Tet*(M), and *Tet*(O), 1119
Streptomyces
B. melitensis, 973
brucellosis, 973
E. corrodens
 resistance gene, 740
K. rhinoscleromatis, 1785
M. avium-M. intracellulare complex
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816
Sucralfate
 floxacin
 pharmacokinetics, effect on, 2758
Sulbactam
 combinations
 ampicillin, 2014, 2233
 major head and neck surgery in cancer patients, prophylaxis for, 2014
 pharmacokinetics, 2233
Sulfones
 β -lactamases
 CO_2 and pH, effect on inhibition, 1870
Susceptibility patterns
 B. fragilis group
 Canada, 343
 Susceptibility testing
 antimycobacterial agents
 stability in, 2398
 B. wadsworthia
 endpoint determination, triphenyltetrazolium chloride, 1658
 bacteria from patients with peritonitis complicating continuous ambulatory peritoneal dialysis, 1097
Candida spp.
 relative growth measurement, 1727
 correlation with clinical outcome
 B. fragilis group infections treated

with cefoxitin, 540
 endpoint determination system
 yeasts, 1619
fluconazole
 standardization, 1805
Methylobacterium spp., 1635
 β -lactams, 1635
N. gonorrhoeae
 isolates from the Philippines, 277
 yeasts
 endpoint determination system, 1619
Synergy
 clarithromycin-minocycline
T. gondii, 2852
 minireview
 animal models, contribution of, 907
Syphilis
 cefotetan pivoxil
 rabbits, 598

T22
 human immunodeficiency virus type 1, 1249

T-3761
 in vitro activity
 comparative evaluation, 2293

TA
 genes required for production
 expression of, Tn5lac, use to study, 2322
 mutation and mapping of, 2316

Tachypleins
 mechanisms of antibacterial action, 1460

Tazobactam
 combinations
 comparative evaluation, 2766
 gentamicin, 1883
 intra-abdominal infections, 2766
K. pneumoniae, 1883
 piperacillin, 1883, 2766
 piperacillin-gentamicin, 1883
K. pneumoniae, 1883
 pharmacokinetics
 patients undergoing colorectal surgery, 1997

Teicoplanin
C. difficile
 comparative evaluation, 2192
 diarrhea, 2192
 diarrhea
C. difficile, 2192
 comparative evaluation, 2192

E. faecalis
 endocarditis, 1276

E. faecium
 glycopeptide resistant, 2611
 high versus low dose, 2611
 endocarditis, 1276
 high versus low dose, 2611
 endocarditis, native valve
 4-week treatment, 723
 streptococcal, 723

gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570

pharmacokinetics
 healthy male volunteers, 115
 metabolism in humans, 1744

pseudomembranous colitis
 comparative evaluation, 2192

red man syndrome
 absence in patients treated with high

doses, 1204
Streptococcus spp.
 endocarditis, 723

TEM-1
 sulfones
 CO_2 and pH, effect on inhibition, 1870

TEM-12
K. oxytoca
 transposition of gene encoding, 1981

Temafloxacin
 anaerobic organisms, 239
 comparative evaluation, 1158
 autoradiographic diffusion pattern
 cardiac vegetations, 2216

C. pneumoniae, 682
 comparative evaluation
 ciprofloxacin, ofloxacin, fleroxacin, sparfloxacin, 682
 penicillin, tetracycline, ceftriaxone, ciprofloxacin, and ofloxacin, 1131

endocarditis, 2216
 gram-negative organisms, 1140
N. gonorrhoeae, 1131

pharmacokinetics
 multiple oral doses, 378

pneumonia
 community acquired, 833
 comparative evaluation, 833
 efficacy and safety, 833

S. adjacens, 2216

S. pneumoniae
 comparative evaluation, 856

Terbinafine
C. albicans
 squalene epoxidase inhibition, 1799

Tet determinants
 tetracycline resistance
 evidence for division of tetracyclines into 2 classes, 876

tet(M)
 Tn916
 mechanism of regulation, 769
 nucleotide sequence analysis, 769
 regulation by transcription attenuation, 769

Tetracycline
 analogs whose primary target is not the ribosome
E. coli lysis, 913
 mechanisms of action, 913
 anticollagenase action
 relevance to anti-inflammatory potential, 227

Bacteroides resistance
 ribosome protection gene, 1005

C. pneumoniae, 291

C. trachomatis, 291

Enterococcus resistance
 occurrence of structures with homology to Tn916, 59

K. rhinoscleromatis, 1785

L. monocytogenes resistance
 genetic basis, 463

M. genitalium, 870

M. pneumoniae, 870, 1322

P. multocida
 cell surface characteristics, effect of sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093

S. hyicus resistance
 pSTE1, tet (L) sequence, 580

S. lividans resistance gene
 protein with similarities to translation

elongation factors, Tet(M), and Tet(O), 1119

salmonellae
 ampicillin resistant, 1794

Streptococcus resistance
 occurrence of structures with homology to Tn916, 59

Tet determinants
 evidence for division of tetracyclines into 2 classes, 876

tet(M)
 determinant of Tn916, characterization of, 769
 regulation by transcription attenuation, 769

V. salmonicida resistance determinant
 identification and cloning, 611

Tetrahydroechinocandin B
 antifungal activity, 1648
 1,3- β -D-glucan synthesis inhibition, 1648

Ticarcillin
B. fragilis group, 2051
 combinations
B. fragilis group, 2051
 clavulanate, 2233
 clavulanic acid, 137, 458, 2051, 2352
 letter to the editor, 2352
 pharmacokinetics, 2233
S. aureus endocarditis, 458
 susceptibility tests, error rates, 137
 zone size criteria, 2352
 susceptibility tests
Enterobacteriaceae, 137
 error rates, 137

Ticarcillin-clavulanic acid
S. aureus
 dosing ratio, 1585
 letter to the editor, 1585
 susceptibility testing
 interpretive criteria, 1343
 letter to the editor, 1343

Time-kill studies
Staphylococcus spp.
 concentration and pharmacodynamic response, relationship, 1766
 vancomycin, 1766

vancomycin
 concentration and pharmacodynamic response, relationship, 1766

Staphylococcus spp., 1766

Tinea pedis
 butenafine
 relapse rate reduction in guinea pigs, 2523

Tinidazole
H. pylori, 1133

Tn5lac
 antibiotic TA
 expression of genes required for production, 2322

Tn21
 gram-negative organisms
 Tn21-specific structures, 1915

Tobramycin
P. aeruginosa
 biofilms, dynamic interactions, 1208

pharmacokinetics
 gentamicin, comparative evaluation, 679
 patients with pleural effusions and hyaloproteinemia, 679
 proximal tubular cells, subcellular localization in, 2204

S. aureus biofilm cells
interaction in a chemostat system, 890

synergy
endocarditis, 2403
optimal dosing regimen, 2403
penicillin, 2403
S. adjacens, 2403

Tolcilate
C. albicans
squalene epoxidase inhibition, 1799

Tolnaftate
C. albicans
squalene epoxidase inhibition, 1799

Topoisomerase II
plumbagin
induction of DNA cleavage, 2589

shikonin
induction of DNA cleavage, 2589

Topoisomerase II inhibitors
Leishmania spp.
cytotoxicity for promastigotes, 495

Topoisomerasers
A. niger
targets for discovery of antifungal agents, 2778

C. albicans
drug discovery, target for, 2131
targets for discovery of antifungal agents, 2778

fluoroquinolones
effects of catalytic activities, 751
influence of C-8 fluorine group, 751

isothiazoloquinolones
DNA breakage, induction of, 81

Tosufloxacin
E. coli
outer membrane mutants, 2030
uptake, 2030

P. mirabilis
outer membrane mutants, 2030
uptake, 2030

S. typhimurium
outer membrane mutants, 2030
uptake, 2030

Toxic shock syndrome
S. aureus toxin 1
glycerol monolaurate, effect on production, 626

Toxicity
amphotericin B
aggregation and solvent, effects on, 2518
effect of infusion rates, 172
flucytosine, effects of, 2670
influence of phospholipid type, 262
influence of phospholipid/amphotericin B ratio, 262
infusion rates, effect of, 2573
letter to the editor, 2573
ventricular dysrhythmias with 1-hour infusion, 2542

antifungal agents
in vitro models, 1799
minireview, 1799

cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-) and (+) enantiomers, 2686

gentamicin
polyspartic acid, protection from, duration, 2556

MS-8209, 2722

zidovudine
fetal toxicity in pregnant mice, amelioration of, 2370

Toxicology
ISIS 1082
in vitro, 527

Toxoplasma gondii
566C80
cysts, 326
azithromycin, 997
pyrimethamine, synergy with, 997
sulfadiazine, synergy with, 997

clarithromycin
murine model, 2454

clarithromycin-minocycline
synergy, 2852

clarithromycin-pyrimethamine
murine model, 2454

clarithromycin-sulfadiazine
murine model, 2454

clindamycin
infected human fibroblasts, 1091
resistant mutant, selection of, 1091

hydroxynaphthoquinones
566C80, 326
cysts, 326

Toxoplasmosis
azithromycin, 997
pyrimethamine, synergy with, 997
sulfadiazine, synergy with, 997

clarithromycin
murine model, 2454

clarithromycin-minocycline
synergy, 2852

clarithromycin-pyrimethamine
murine model, 2454

clarithromycin-sulfadiazine
murine model, 2454

pyrimethamine
levels in cerebrospinal and ventricular fluids and sera of infants, 1040

Transpeptidases
S. aureus
WIN 57273, inhibitory activity, 894

Traveler's diarrhea
trimethoprim-sulfamethoxazole-loperamide, T426

Treponema pallidum
cefetamet pivoxil, 598

Trimethoprim
E. coli resistance
identification of new gene, 1720
resistance gene *dhfrIX*
spread among human and porcine pathogens, 2704

Trimethoprim-sulfamethoxazole combinations
loperamide, 2821

P. carinii, 2328
pneumonia, 2328
traveler's diarrhea, 2821
zidovudine, 2328

K. rhinoscleromatis, 1785
Mediterranean spotted fever
letter to the editor, 1342

P. carinii
pneumonia, 2328

P. multocida
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093

pneumonia, 2328

Trypanosoma brucei rhodesiense
MDL 73811
S-adenosylmethionine decarboxylase inhibitor, 2736

Trypanosoma lewisi
acridines
anticancer, 1644

TSAO derivatives
purine and pyrimidine
human immunodeficiency virus inhibitors, 1073

Tumor necrosis factor alpha
combinations
interleukin-6, 68
L. monocytogenes, 68
minireview, 1
nonspecific resistance to infection, 1

Urethritis
cefdodoxime proxetil, 1764

N. gonorrhoeae
cefdodoxime proxetil, 1764

Urinary tract infections
ceftazidime, 1580
E1040, 1580

P. aeruginosa
ceftazidime, 1580
E1040, 1580

P. mirabilis
ceftazidime, 1580
E1040, 1580

Vaccines
U.S. FDA approvals, 1584

vanC
E. gallinarum
species specificity, 2005
vancomycin resistance
E. gallinarum, species specificity, 2005

Vancomycin
bacteremia, 1109

C. difficile
comparative evaluation, 2192
diarrhea, 2192
carboxypeptidase activity
induction in *Enterococcus* spp., 77

combinations
ampicillin and gentamicin, 1563

Corynebacterium CDC group II, 1325

E. faecium, *vancomycin* and ampicillin resistant, 1563
gentamicin, 1325

Corynebacterium CDC group II, 1325
diarrhea
C. difficile, 2192
comparative evaluation, 2192

E. faecalis
endocarditis, 1276

E. faecium resistance
VanY, characterization of, 1514

E. gallinarum resistance, 1392
penicillin-binding protein 6, possible role in, 1392

vanC, species specificity, 2005

endocarditis, 1276, 1325
comparative evaluation, 1854

enterococci, penicillin resistant, 1864

endocarditis, gram positive, 1109

Enterococcus resistance
carboxypeptidase activity, 77
effects of amino acids on expression, 902

D-lactate, incorporation into pepti-

doglycan precursors, 867
peptidoglycan precursors, analysis of, 1487
ramoplanin, 2342
Enterococcus spp.
comparative evaluation, 1864
endocarditis, 1864
penicillin resistant, 1864
Enterococcus spp., highly vancomycin resistant
ampicillin, absence of synergy, 2201
Enterococcus susceptibility
gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
febrile neutropenic patients receiving ceftazidime
initial treatment, not necessary for, 1062
gram-positive organisms
blood isolates, 1570
comparative evaluation, 1570
hemodialysis
serum, removal from by high-flux hemodialysis membranes, 1424
pharmacokinetics
intravenous drug abusers, 1109
proximal tubular cells, subcellular localization in, 2204
sternal bone, penetration into, 2539
pseudomembranous colitis
comparative evaluation, 2192
R. equi, 1244
red man syndrome
absence in patients treated with, 1204
S. pneumoniae
postantibiotic sub-MIC effects, 1852
S. pyogenes
postantibiotic sub-MIC effects, 1852
serum bactericidal activity
concentration, pH, and growth phase, effects on, 2709
Staphylococcus spp.
concentration and pharmacodynamic response, relationship, 1766
time-kill studies
concentration and pharmacodynamic response, relationship, 1766
Staphylococcus spp., 1766

Varicella-zoster virus
penciclovir
mechanism of action, 2747
MRC-5 cells, 2747
Vibrio anguillarum
oxytetracycline
temperature-dependent activity, 1738
4-quinolones
temperature-dependent activity, 1738
Vibrio cholerae
β-lactam resistance, 788
β-lactams
interaction, novel features of, 788
Vibrio salmonicida
oxytetracycline
temperature-dependent activity, 1738
4-quinolones
temperature-dependent activity, 1738
tetracycline resistance determinant
identification and cloning, 611
Vibrionaceae
Ro 40-6890
intestinal species, 2835

WIN 54954
coxsackievirus
mice, 425
myocarditis
mice, 425

WIN 57273
anaerobic bacteria
comparative evaluation, 1158
anaerobic organisms, 239
M. avium complex
human macrophages, 2104
S. aureus
β-lactamase- and transpeptidase-inhibitory activities, 894
S. pneumoniae
comparative evaluation, 856
Staphylococcus spp.
comparative evaluation, 851

Xanthomonas maltophilia
quinolone resistant
outer membrane proteins, 669
quinolone susceptibility, 669

Yeast
susceptibility testing
endpoint determination system, 1619
Yersinia enterocolitica
ampC-ampR
nucleotide sequence, 1049
β-lactamases
nucleotide sequence of structural gene, 1049
Yersinia ruckeri
oxytetracycline
temperature-dependent activity, 1738
4-quinolones
temperature-dependent activity, 1738

Zidovudine
azithromycin
effect on disposition in AIDS patients, 1013
coagulation effects
human immunodeficiency virus-infected hemophiliacs, 2245
combinations
2',3'-dideoxycytidine, 1559
foscarnet, 1773
human immunodeficiency virus type 1, 1559
P. carinii, 2328
pharmacokinetics, 1773
pneumonia, 2328
trimethoprim-sulfamethoxazole, 2328
human immunodeficiency virus type 1
ganciclovir antagonism, 1127
human immunodeficiency virus type 1
resistance
replication endpoint concentration assay, 920
pharmacokinetics
human immunodeficiency virus-infected hemophiliacs, 2245
intravenous and oral, 2245
penetration into brains, muscle tissue, and veins of monkeys, 2418
relation to antiviral action, 2418
S. typhimurium
intracellular activity, 1081
toxicity
fetal, amelioration in pregnant mice, 2370